
<html lang="en"     class="pb-page"  data-request-id="504fc83a-87aa-48b8-b165-377505f43743"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2015.58.issue-9;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.5b00270;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Structure–Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer" /></meta><meta name="dc.Creator" content="Chun-Hui  Zhang" /></meta><meta name="dc.Creator" content="Ming-Wu  Zheng" /></meta><meta name="dc.Creator" content="Ya-Ping  Li" /></meta><meta name="dc.Creator" content="Xing-Dong  Lin" /></meta><meta name="dc.Creator" content="Mei  Huang" /></meta><meta name="dc.Creator" content="Lei  Zhong" /></meta><meta name="dc.Creator" content="Guo-Bo  Li" /></meta><meta name="dc.Creator" content="Rong-Jie  Zhang" /></meta><meta name="dc.Creator" content="Wan-Ting  Lin" /></meta><meta name="dc.Creator" content="Yan  Jiao" /></meta><meta name="dc.Creator" content="Xiao-Ai  Wu" /></meta><meta name="dc.Creator" content="Jiao  Yang" /></meta><meta name="dc.Creator" content="Rong  Xiang" /></meta><meta name="dc.Creator" content="Li-Juan  Chen" /></meta><meta name="dc.Creator" content="Ying-Lan  Zhao" /></meta><meta name="dc.Creator" content="Wei  Cheng" /></meta><meta name="dc.Creator" content="Yu-Quan  Wei" /></meta><meta name="dc.Creator" content="Sheng-Yong  Yang" /></meta><meta name="dc.Description" content="A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were designed and synthesized. Structure–activity relationship (SAR) analysis of these compounds led to the discovery o..." /></meta><meta name="Description" content="A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were designed and synthesized. Structure–activity relationship (SAR) analysis of these compounds led to the discovery o..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 16, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00270" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00270" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00270" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00270" /></link>
        
    
    

<title>Design, Synthesis, and Structure–Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00270" /></meta><meta property="og:title" content="Design, Synthesis, and Structure–Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0001.jpeg" /></meta><meta property="og:description" content="A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were designed and synthesized. Structure–activity relationship (SAR) analysis of these compounds led to the discovery of compound 1j, which showed the highest inhibitory potency against the Src kinase and the most potent antiviability activity against the typical TNBC cell line MDA-MB-231 among all the synthesized compounds. Further kinase inhibition assays showed that compound 1j was a multikinase inhibitor and potently inhibited Src (IC50 = 0.0009 μM) and MAPK signaling protein kinases B-RAF and C-RAF. In an MDA-MB-231 xenograft mouse model, a once-daily dose of compound 1j at 30 mg/kg for 18 days completely suppressed the tumor growth with a tumor inhibition rate larger than 100% without obvious toxicity. It also displayed good pharmacokinetic properties in a preliminary pharmacokinetic assay. Western blot and immunohistochemical assays revealed that compound 1j significantly inhibited Src and MAPK signaling and markedly induced apoptosis in tumor tissues." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00270"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00270">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00270&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00270&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00270&amp;href=/doi/10.1021/acs.jmedchem.5b00270" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 3957-3974</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b00208" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b00523" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Structure–Activity Relationship Studies of 3-(Phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun-Hui++Zhang">Chun-Hui Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ming-Wu++Zheng">Ming-Wu Zheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ya-Ping++Li">Ya-Ping Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xing-Dong++Lin">Xing-Dong Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mei++Huang">Mei Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Zhong">Lei Zhong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guo-Bo++Li">Guo-Bo Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rong-Jie++Zhang">Rong-Jie Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wan-Ting++Lin">Wan-Ting Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Jiao">Yan Jiao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-Ai++Wu">Xiao-Ai Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiao++Yang">Jiao Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rong++Xiang">Rong Xiang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li-Juan++Chen">Li-Juan Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ying-Lan++Zhao">Ying-Lan Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Cheng">Wei Cheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Quan++Wei">Yu-Quan Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheng-Yong++Yang">Sheng-Yong Yang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Clinical Medicine, School of Medicine, Nankai University, Tianjin 300071, China</span></div><div class="corresp-info"><strong>*</strong>Phone: +86-28-85164063. Fax: +86-28-85164060. E-mail: <a href="/cdn-cgi/l/email-protection#87fee6e9e0f4fec7f4e4f2a9e2e3f2a9e4e9"><span class="__cf_email__" data-cfemail="5c253d323b2f251c2f3f2972393829723f32">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00270&amp;href=/doi/10.1021%2Facs.jmedchem.5b00270" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 3957–3974</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 2, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 February 2015</li><li><span class="item_label"><b>Published</b> online</span>16 April 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 May 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00270" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00270</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3957%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChun-Hui%2BZhang%252C%2BMing-Wu%2BZheng%252C%2BYa-Ping%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D9%26contentID%3Dacs.jmedchem.5b00270%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BStructure%25E2%2580%2593Activity%2BRelationship%2BStudies%2Bof%2B3-%2528Phenylethynyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2BDerivatives%2Bas%2Ba%2BNew%2BClass%2Bof%2BSrc%2BInhibitors%2Bwith%2BPotent%2BActivities%2Bin%2BModels%2Bof%2BTriple%2BNegative%2BBreast%2BCancer%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3974%26publicationDate%3DMay%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00270"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3534</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">29</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00270" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Structure–Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chun-Hui&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ming-Wu&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Ya-Ping&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xing-Dong&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Mei&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Guo-Bo&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Rong-Jie&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Wan-Ting&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Jiao&quot;},{&quot;first_name&quot;:&quot;Xiao-Ai&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Jiao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Rong&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Li-Juan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Ying-Lan&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Yu-Quan&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Sheng-Yong&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;3957-3974&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00270&quot;},&quot;abstract&quot;:&quot;A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were designed and synthesized. Structure–activity relationship (SAR) analysis of these compounds led to the discovery of compound 1j, which showed the highest inhibitory potency against the Src kinase and the most potent antiviability activity against the typical TNBC cell line MDA-MB-231 among all the synthesized compounds. Further kinase inhibition assays showed that compound 1j was a multikinase inhibitor and potently inhibited Src (IC50 = 0.0009 μM) and MAPK signaling protein kinases B-RAF and C-RAF. In an MDA-MB-231 xenograft mouse model, a once-daily dose of compound 1j at 30 mg/kg for 18 days completely suppressed the tumor growth with a tumor inhibition rate larger than 100% without obvious toxicity. It also displayed good pharmacokinetic properties in a preliminary pharmacokinetic assay. Western blot and immunohistochemical assays revealed that compound 1j significantly inhibited Src and MAPK signaling and markedly induced &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00270&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00270" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00270&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00270" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00270&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00270" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00270&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00270&amp;href=/doi/10.1021/acs.jmedchem.5b00270" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00270" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00270" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00270%26sid%3Dliteratum%253Aachs%26pmid%3D25835317%26genre%3Darticle%26aulast%3DZhang%26date%3D2015%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BStructure%25E2%2580%2593Activity%2BRelationship%2BStudies%2Bof%2B3-%2528Phenylethynyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2BDerivatives%2Bas%2Ba%2BNew%2BClass%2Bof%2BSrc%2BInhibitors%2Bwith%2BPotent%2BActivities%2Bin%2BModels%2Bof%2BTriple%2BNegative%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D9%26spage%3D3957%26epage%3D3974%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/jmcmar.2015.58.issue-9/20150514/jmcmar.2015.58.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of 3-(phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine derivatives were designed and synthesized. Structure–activity relationship (SAR) analysis of these compounds led to the discovery of compound <b>1j</b>, which showed the highest inhibitory potency against the Src kinase and the most potent antiviability activity against the typical TNBC cell line MDA-MB-231 among all the synthesized compounds. Further kinase inhibition assays showed that compound <b>1j</b> was a multikinase inhibitor and potently inhibited Src (IC<sub>50</sub> = 0.0009 μM) and MAPK signaling protein kinases B-RAF and C-RAF. In an MDA-MB-231 xenograft mouse model, a once-daily dose of compound <b>1j</b> at 30 mg/kg for 18 days completely suppressed the tumor growth with a tumor inhibition rate larger than 100% without obvious toxicity. It also displayed good pharmacokinetic properties in a preliminary pharmacokinetic assay. Western blot and immunohistochemical assays revealed that compound <b>1j</b> significantly inhibited Src and MAPK signaling and markedly induced apoptosis in tumor tissues.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer is one of the most common cancer types in women worldwide. Within breast cancer, the “triple-negative” subtype (triple-negative breast cancer, TNBC), which lacks the expression of estrogen and progesterone receptor (ER/PR) and HER2, is the most aggressive and also the most deadly.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> TNBC has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against HER2.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Currently, chemotherapy is the only systemic therapy and prognosis remains poor.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a></div><div class="NLM_p">Compared with chemotherapy, targeted therapies have the advantage of maximizing efficacy while often reducing toxicity. However, unlike other molecular subtypes of breast cancer, there is no validated specific biomarker for TNBC.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a> Preclinical studies have identified several potential targets, and Src is one of the targets that have recently received increasing interest.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Src is a nonreceptor tyrosine kinase and has been revealed to be a critical regulator of a large number of intracellular signaling pathways.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> Abnormal activation or amplification of Src has been detected in TNBC and demonstrated to play a role in proliferation, migration, and invasion of breast cancer cell lines.<a onclick="showRef(event, 'ref10 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref10 ref15 ref16">(10, 15, 16)</a> Furthermore, a number of recent studies have shown that dysregulation of Src is strongly associated with tumor metastasis and a poor prognosis of TNBC.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> Src therefore represents a rational molecular target for TNBC.<a onclick="showRef(event, 'ref10 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref10 ref19 ref20 ref21 ref22">(10, 19-22)</a> Several agents (see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) are currently available for inhibiting Src,<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27 ref28">(23-28)</a> and dasatinib is the only one that is in clinical trials for treating TNBC. Dasatinib is an orally active tyrosine kinase inhibitor that targets Src and BCR-ABL as well as several other kinases and has been approved for the treatment of imatinib-resistant BCR-ABL-positive leukemia.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Though dasatinib has a good potency against Src kinase (IC<sub>50</sub> = 0.0003 μM), it just showed moderate anti-TNBC activity. For example, the IC<sub>50</sub> value of dasatinib against the typical TNBC cell line MDA-MB-231 is just 0.178 μM. The updated reports from clinical trial studies of dasatinib in the treatment of TNBC indicated that single-agent dasatinib just showed limited efficacy in TNBC.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Reasons causing the limited efficacy of the Src inhibitor in treating TNBC could be complicated but should be mainly due to the refractory of TNBC and certain unknown imperfect properties of this compound. Therefore, discovery of new Src inhibitors with potent anti-TNBC activity is now strongly demanded for drug research and development (R&D) against TNBC.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative Src inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an effort to discover Src inhibitors with high potency against TNBC tumor, we recently performed a rational drug design in which scaffold hopping was applied on ponatinib (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A). Ponatinib was selected, since we are interested in the 1,2-diarylethyne structure motif; in addition to that it can potently inhibit Src (IC<sub>50</sub> = 0.003 μM).<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> Before the scaffold hopping, we collected a total of 209 potential “hinge-binder” fragments derived from known kinase inhibitors; a hinge-binder fragment indicates a moiety in a kinase inhibitor that can form one to three hydrogen bonds with the hinge region of kinase domain.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The collected hinge-binder fragments were used to replace the imidazo[1,2-<i>b</i>]pyridazine moiety in ponatinib; the imidazo[1,2-<i>b</i>]pyridazine moiety corresponds to the hinge-binder of ponatinib. Molecular docking was then used to evaluate the binding affinities of constructed molecules with Src, and GoldScore<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> was adopted to rank these compounds (for details, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Chemical structures of the top 100 compounds are given in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> (see Table S1). Interestingly, the second ranked compound happened to be a known potent Src inhibitor.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Encouraged by this result, we decided to choose one from the top of these compounds to synthesize; a compound was selected if it is a new compound and synthetically accessible and can potentially form at least two hydrogen bonds with the hinge region of kinase domain (for details, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). The finally obtained compound is 3-((4-amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1a</b>; Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A), which showed a slightly improved kinase inhibitory potency (IC<sub>50</sub> = 0.002 μM) against Src compared with ponatinib. More importantly, it exhibited an IC<sub>50</sub> value of 0.069 μM against the TNBC MDA-MB-231 cells in antiviability assays, which is approximately 2.5 times more potent than dasatinib and ponatinib (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). This result indicated that improving the anti-TNBC potency of Src inhibitors was feasible and encouraged us to carry out a further structural optimization to compound <b>1a</b>.</div><div class="NLM_p">In this investigation, we shall perform structural modifications to compound <b>1a</b>. A series of 3-(phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine derivatives are synthesized, and the structure–activity relationship (SAR) of this series of compounds is discussed. To the most active compound in enzymatic and cellular assays, an in depth anti-TNBC activities both in vitro and in vivo are evaluated. The mechanism of action of this compound is also investigated.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Structures of ponatinib and compound <b>1a</b>. (B) Schematic showing regions that are the focus of structural modifications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All the target compounds in this investigation were readily prepared using palladium-catalyzed Sonogashira coupling as a key step (Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Synthetic routes of compound <b>1a</b>–<b>h</b> are schematically illustrated in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. First, intermediate 3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>2</b>), which was prepared through NIS iodination of commercially available 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine, reacted with commercially available haloalkanes or self-prepared methanesulfonates to produce the key intermediates <b>3a</b>–<b>i</b>. Second, commercially available 3-iodo-4-methylbenzoic acid was esterificated and subsequently coupled with ethynyltrimethylsilane under Sonogashira coupling conditions, followed by deprotection to yield 3-ethynyl-4-methylbenzoic acid <b>6</b>. Third, reduction of benzonitrile <b>7a</b>–<b>c</b> with DIBAL cleanly afforded aldehyde <b>8a</b>–<b>c</b> in excellent yield. <b>8a</b>–<b>c</b> were then coupled with amine through a classical Borch reductive amination to produce <b>9a</b>,<b>c</b>,<b>d</b>,<b>f</b>–<b>h</b>. Fourthly, <b>9a</b>,<b>c</b>,<b>d</b>,<b>f</b>–<b>h</b> together with 4-((4-methylpiperazin-1-yl)methyl)aniline (<b>9b</b>) and 3-(trifluoromethyl)aniline (<b>9e</b>), which were purchased from market, reacted with <b>6</b> under basic conditions to give the key intermediates <b>10a</b>–<b>h</b>. Finally, target compounds <b>1a</b>–<b>h</b> were obtained through a palladium-catalyzed Sonogashira coupling reaction between <b>10a</b>–<b>h</b> and <b>3a</b>. Similarly, target compounds <b>1i</b>–<b>r</b>, which contain various substituents at the N-1 position of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (R<sub>3</sub>) (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>), were prepared again through a Sonogashira coupling reaction between <b>3b</b>–<b>i</b> and <b>10a</b>. Among them, <b>1q</b> was produced by deprotection of <b>1p</b>, and amidation of <b>1q</b> led to <b>1r</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes for Compounds <b>1a</b>–<b>h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NIS, DMF, 80 °C, N<sub>2</sub>; (b) R<sub>3</sub>-X(Br, I) or R<sub>3</sub>-OMs, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, N<sub>2</sub>; (c) MeOH, conc H<sub>2</sub>SO<sub>4 cat</sub>, reflux; (d) ethynyltrimethylsilane, CuI, Pd(PPh<sub>3</sub>)<sub>4</sub>, triethylamine, THF, rt, N<sub>2</sub>; (e) (i) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, (ii) NaOH, H<sub>2</sub>O, rt; (f) diisobutylaluminum hydride, anhydrous THF, N<sub>2</sub>, rt; (g) pyridinium <i>p</i>-toluenesulfonate, amine, sodium triacetoxyborohydride, EA, N<sub>2</sub>, 110–50 °C; (h) (i) SOCl<sub>2</sub>, 80 °C, (ii) DIPEA, EA, 0 °C to rt ((iii) this step only for <b>10h</b>, LiOH, THF/H<sub>2</sub>O, rt); (j) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes for Compounds <b>1i</b>–<b>r</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>; (b) TFA, DCM, 0 °C to rt; (c) acrylyl chloride, triethylamine, DCM, −10 °C to rt.</p></p></figure><div class="NLM_p">The synthetic routes for compounds <b>14a</b>–<b>g</b> are outlined in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Terminal-alkyne-containing intermediates <b>11</b> was first prepared through a Sonogashira coupling reaction of <b>3b</b> with ethynyltrimethylsilane and a succeeding deprotection. Then commercially available or self-prepared benzoic acids <b>12a</b>–<b>f</b> were coupled with 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (<b>9a</b>) to produce iodobenzamides <b>13a</b>–<b>f</b>, which underwent Sonogashira coupling to yield final compounds <b>14a</b>–<b>f</b>, and hydrolysis of <b>14f</b> with BBr<sub>3</sub> led to compound <b>14g</b>. Self-prepared iodobenzoic acids <b>12c</b>,<b>d</b> were synthesized by esterification of corresponding benzoic acids <b>15a</b>,<b>b</b>, followed by iodination and hydrolysis.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes for Compounds <b>14a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, ethynyltrimethylsilane, triethylamine, DMF, 80 °C, N<sub>2</sub>; (b) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (c) (i) SOCl<sub>2</sub>, 80 °C, (ii) 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (<b>7a</b>), DIPEA, EA, 0 °C to rt; (d) CuI, (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, DIPEA, DMF, 80 °C, N<sub>2</sub>; (e) BBr<sub>3</sub>, DCM, −78 °C to rt; (f) MeOH, conc H<sub>2</sub>SO<sub>4 cat</sub>, reflux; (g) NaIO<sub>4,</sub> I<sub>2</sub>, conc H<sub>2</sub>SO<sub>4</sub>, acetic anhydride, acetic acid, 5–40 °C; (h) EtOH/H<sub>2</sub>O, NaOH, rt.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3 Results and Discussions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57582" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57582" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1 SAR Analyses of 3-(Phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine Derivatives</h3><div class="NLM_p">Since our goal here is to discover Src inhibitors with high potency against TNBC, both enzymatic and cellular assays were utilized to evaluate the bioactivity of synthesized compounds in the SAR studies. For the cellular assays, two tumor cell lines, MDA-MB-231 and HepG2, were chosen. MDA-MB-231 is a typical human TNBC cell line and expresses a high level of Src. HepG2 is a human liver cancer cell line that expresses very low level of Src; HepG2 was used here for ruling out the possible off-target effects and cellular toxic effects.</div><div class="NLM_p">The SAR analyses below will mainly focus on discussing the influences of various substituents at the following three regions (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B) on the bioactivities: the phenyl ring of the amino terminal of amide (Ring A; R<sub>1</sub>, R<sub>2</sub>), the N-1 position of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (R<sub>3</sub>), and the phenyl ring of the carboxyl terminal of amide (Ring B; R<sub>4</sub>).</div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">3.1.1 Substitution Effects of the Phenyl Ring of the Amino Terminal of Amide (Ring A; R<sub>1</sub>, R<sub>2</sub>)</h4><div class="NLM_p">In this section, we shall explore the effects of different substituents at the meta-position (R<sub>1</sub>) or para-position (R<sub>2</sub>) of ring A. In the first step, we fixed R<sub>2</sub> as its original group, namely, (4-methylpiperazin-1-yl)methyl, and varied R<sub>1</sub>. Bioactivities of the resulting compounds (<b>1a</b>–<b>d</b>) are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Obviously, replacement of trifluoromethyl group by hydrogen led to a slight drop in bioactivities in both enzymatic and cellular assays (<b>1b</b>). Introduction of chloride or bromide at R<sub>1</sub> did not improve the biochemical and cellular potencies too much, rather likely increased the antiviability activity against HepG2, implying a possible increase in toxicity. In the second step, we thus fixed R<sub>1</sub> as trifluoromethyl group and changed R<sub>2</sub> with different substituents. Compared with <b>1a</b>, substitution of R<sub>2</sub> by hydrogen (<b>1e</b>) or 4-methylmorpholine (<b>1f</b>) decreased the enzymatic activity and the antiviability potency against MDA-MB-231 cells. For replacement of R<sub>2</sub> with 1-ethyl-4-methylpiperidine (<b>1g</b>), its enzymatic and cellular potencies remained. However, introduction of 2-(4-methylpiperazin-1-yl)ethanol (<b>1h</b>) at R<sub>2</sub> slightly increased the antiviability against HepG2, implying an increase in toxicity. Obviously, the results indicated that modifications of <b>1a</b> on R<sub>1</sub> and R<sub>2</sub> had almost no effect on the improvement of bioactivity. Therefore, in subsequent structural modification processes, R<sub>1</sub> and R<sub>2</sub> will be kept as their original trifluoromethyl and (4-methylpiperazin-1-yl)methyl, respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Kinase Inhibitory Potency against Src and Antiviability Activities against MDA-MB-231 and HepG2 Cells of Compounds <b>1a</b>–<b>h</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values were determined from KinaseProfiler of Eurofins. The data represent the mean values of two independent experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.1.2 Influences of Various Substituents at the N-1 Position of 1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidine Moiety (R<sub>3</sub>)</h4><div class="NLM_p">To examine the possible influences of substituents at the N-1 position of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine moiety, various alkyl groups with different size were first used to replace the original isopropyl. Bioactivities of the synthesized derivatives (<b>1a</b>, <b>1i</b>–<b>r</b>) are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. From Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, we can see that all the derivatives have good bioactivities in both enzymatic and cellular levels. The most active compound corresponds to <b>1j</b> (Src, IC<sub>50</sub> = 0.0009 μM; MDA-MB-231, IC<sub>50</sub> = 0.011 μM), which contains an ethyl group at R<sub>3</sub>. Compared with <b>1j</b>, compounds with a smaller size hydrophobic group (methyl, <b>1i</b>), or a larger size hydrophobic group (isopropyl (<b>1a</b>), cyclobutyl (<b>1k</b>), and cyclopentyl (<b>1l</b>)), at the R<sub>3</sub> position afforded a slightly lower bioactivity, implying that ethyl represents the most suitable size of alkyl substituent. Then, various polar substituents including methoxymethyl (<b>1m</b>), (<i>S</i>)-tetrahydrofuran-3-yl (<b>1n</b>), (<i>R</i>)-tetrahydrofuran-3-yl (<b>1o</b>), 1-(Boc)piperidin-4-yl) (<b>1p</b>), piperidin-4-yl (<b>1q</b>), and 1-acryloylpiperidin-4-yl (<b>1r</b>) were used to replace the ethyl group. However, bioactivities of these compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) still did not exceed that of compound <b>1j</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Kinase Inhibitory Potency against Src and Antiviability Activities against MDA-MB-231 and HepG2 Cells of Compounds <b>1i</b>–<b>r</b> and <b>1a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0016.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values were determined from KinaseProfiler of Eurofins. The data represent the mean values of two independent experiments.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">nd means not determined.</p></div></div><div></div></div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">3.1.3 Possible Impacts of Various Substituents at the C-4 Position of Phenyl Ring B (R<sub>4</sub>)</h4><div class="NLM_p">To explore the possible impact of different substituents at the C-4 position (R<sub>4</sub>) of phenyl ring B, we synthesized compounds <b>14a</b>–<b>g</b>, which contain varied substituents at R<sub>4</sub> and fixed groups at R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> as their optimal forms. Bioactivities of compounds <b>14a</b>–<b>g</b> are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. From Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, we can see that replacement of methyl group by hydrogen slightly decreased the biochemical and cellular anti-TNBC activities. A bulky alkyl substituent at R<sub>4</sub>, such as ethyl or <i>i</i>-Pr, remarkably decreased its bioactivities. Further, a halide (Cl, F) or a polar group (methoxyl and hydroxyl) also considerably decreased the bioactivity. These results indicated that methyl is the best substituent group at R<sub>4</sub>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Kinase Inhibitory Potency against Src and Antiviability Activities against MDA-MB-231 and HepG2 Cells of Compounds <b>14a</b>–<b>g</b> and <b>1j</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0017.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">anti-cell viability (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center">kinase inhibition (IC<sub>50</sub>, μM),<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> Src</th><th class="colsep0 rowsep0" align="center">MDA-MB-231</th><th class="colsep0 rowsep0" align="center">HepG2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1j</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">0.0009</td><td class="colsep0 rowsep0" align="left">0.011 ± 0.001</td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.005</td><td class="colsep0 rowsep0" align="left">0.024 ± 0.002</td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14b</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">0.011</td><td class="colsep0 rowsep0" align="left">0.052 ± 0.004</td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14c</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">0.418 ± 0.029</td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14d</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">1.409</td><td class="colsep0 rowsep0" align="left">1.225 ± 0.090</td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14e</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.743 ± 0.222</td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14f</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">0.059</td><td class="colsep0 rowsep0" align="left">0.321 ± 0.041</td><td class="colsep0 rowsep0" align="left">4.640 ± 0.387</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14g</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">3.191</td><td class="colsep0 rowsep0" align="left">>5</td><td class="colsep0 rowsep0" align="left">>5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were determined from KinaseProfiler of Eurofins. The data represent the mean values of two independent experiments.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">nd means not determined.</p></div></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">3.2 Preliminary in Vivo Antitumor Assays for Screening Compounds with the Most Potent Anti-TNBC Activity</h3><div class="NLM_p">The SAR analyses above led to the discovery of a number of Src inhibitors that exhibited higher potency than dasatinib and ponatinib in in vitro antiviability assays against human TNBC MDA-MB-231 cells. To screen compounds with potent anti-TNBC activity in vivo, we chose three compounds, namely, <b>1n</b>, <b>1i</b>, and <b>1j</b>, to carry out a preliminary in vivo anti-TNBC study in a MDA-MB-231 xenograft mouse model. The three compounds were chosen because they are potent Src inhibitors with an IC<sub>50</sub> value less than 10 nM and ranked as the top three most active ones among all the compounds in the in vitro antiviability assay against the TNBC MDA-MB-231 cells. In the preliminary in vivo assays, compound <b>1j</b> was still the most active one (see Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Therefore, further in-depth studies including in vitro and in vivo anti-TNBC activities, and the mechanism of action, were subsequently carried out with compound <b>1j</b>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Preliminary in vivo anti-TNBC assays of compounds <b>1n</b>, <b>1i</b>, and <b>1j</b>. Daily oral administration of compounds <b>1n</b>, <b>1i</b>, and <b>1j</b> at concentrations of 40 mg kg<sup>–1</sup> d<sup>–1</sup>, respectively, was initiated when the MDA-MB-231 tumors reached approximately 200 mm<sup>3</sup> in volume (three mice per group). Points indicate mean tumor volume (mm<sup>3</sup>); bars indicate SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.3 Biochemical Activities of Compound <b>1j</b> against Various Recombinant Human Protein Kinases</h3><div class="NLM_p">The kinase inhibition profile of compound <b>1j</b> against a panel of selected recombinant human protein kinases is presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Compound <b>1j</b> potently inhibited Src (IC<sub>50</sub> = 0.0009 μM), Yes (IC<sub>50</sub> = 0.0008 μM), Fyn (IC<sub>50</sub> = 0.005 μM), and Blk (IC<sub>50</sub> = 0.019 μM), which all belong to the Src family kinases (SFKs). Compound <b>1j</b> also exhibited considerable potency against several other kinases, including B-RAF<sub>V600E</sub> (IC<sub>50</sub> = 0.015 μM), B-RAF (IC<sub>50</sub> = 0.092 μM), C-RAF (IC<sub>50</sub> = 0.027 μM), BCR-ABL (IC<sub>50</sub> = 0.001 μM), EphA2 (IC<sub>50</sub> = 0.016 μM), EphB2 (IC<sub>50</sub> = 0.026 μM), TrkA (IC<sub>50</sub> = 0.027 μM), DDR2 (IC<sub>50</sub> = 0.128 μM), TAK1 (IC<sub>50</sub> = 0.061 μM), Btk (IC<sub>50</sub> = 0.067 μM), IKKα (IC<sub>50</sub> = 0.353 μM), IKKβ (IC<sub>50</sub> = 0.164 μM), Axl (IC<sub>50</sub> = 0.578 μM), PDGFRα (IC<sub>50</sub> = 0.890 μM), JAK2 (IC<sub>50</sub> = 2.911 μM), and EGFR(IC<sub>50</sub> = 3.518 μM). Compound <b>1j</b> displayed almost no inhibitory activity against 18 other tested protein kinases (IC<sub>50</sub> > 10 μM). These data demonstrate that compound <b>1j</b> is a multikinase inhibitor with high potencies against Src family kinases (SFKs) and several other kinases including MAPK signaling protein kinases B-RAF and C-RAF.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinase Inhibition Profile of Compound <b>1j</b> against Human Src and a Panel of Other Selected Protein Kinases<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">0.0009</td><td class="colsep0 rowsep0" align="left">TAK1</td><td class="colsep0 rowsep0" align="left">0.061</td><td class="colsep0 rowsep0" align="left">CHK1</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Src (T341M)</td><td class="colsep0 rowsep0" align="left">0.030</td><td class="colsep0 rowsep0" align="left">Btk</td><td class="colsep0 rowsep0" align="left">0.067</td><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">0.0008</td><td class="colsep0 rowsep0" align="left">IKKα</td><td class="colsep0 rowsep0" align="left">0.353</td><td class="colsep0 rowsep0" align="left">GSK3β</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fyn</td><td class="colsep0 rowsep0" align="left">0.005</td><td class="colsep0 rowsep0" align="left">IKKβ</td><td class="colsep0 rowsep0" align="left">0.164</td><td class="colsep0 rowsep0" align="left">JNK1α1</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Blk</td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">Axl</td><td class="colsep0 rowsep0" align="left">0.578</td><td class="colsep0 rowsep0" align="left">MAPK1</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B-RAF (V600E)</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">PDGFRα</td><td class="colsep0 rowsep0" align="left">0.890</td><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B-RAF</td><td class="colsep0 rowsep0" align="left">0.092</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">2.911</td><td class="colsep0 rowsep0" align="left">mTOR</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C-RAF</td><td class="colsep0 rowsep0" align="left">0.027</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">3.518</td><td class="colsep0 rowsep0" align="left">PAK1</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCR-ABL</td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left">Aurora A</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">Pim-1</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EphA2</td><td class="colsep0 rowsep0" align="left">0.016</td><td class="colsep0 rowsep0" align="left">Ark5</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">PKBα</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EphB2</td><td class="colsep0 rowsep0" align="left">0.026</td><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">PKBβ</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TrkA</td><td class="colsep0 rowsep0" align="left">0.027</td><td class="colsep0 rowsep0" align="left">CDK7</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">PKCα</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR2</td><td class="colsep0 rowsep0" align="left">0.128</td><td class="colsep0 rowsep0" align="left">TBK1</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">PI3Kα</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were determined from KinaseProfiler of Eurofins. The data represent the mean values of two independent experiments.</p></div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3.4 Antiviability Activities of Compound <b>1j</b> against Various Cancer Cell Lines</h3><div class="NLM_p">The antiviability potencies of compound <b>1j</b> against various tumor cell lines including TNBC, and other breast cancer subtypes, as well as other selected cancer types, were measured using the MTT assay method. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, compound <b>1j</b> displayed potent activities against TNBC cell lines MDA-MB-231 and MDA-MB-435 with IC<sub>50</sub> values of 0.011 and 0.005 μM, respectively. It also exhibited considerable potencies against several other cell lines, including MDA-MB-436 (TNBC, IC<sub>50</sub> = 0.316 μM), MDA-MB-453 (TNBC, IC<sub>50</sub> = 0.325 μM), MM.1S (myeloma, IC<sub>50</sub> = 0.872 μM), U-87 MG (glioblastoma, IC<sub>50</sub> = 0.742 μM). For other 12 cell lines including BT474 (breast cancer), MCF-7 (breast cancer), SKBR-3 (breast cancer), HBL-1 (lymphadenoma), OCI-LY10 (lymphadenoma), RAMOS (lymphadenoma), THP-1 (leukemia), HepG2 (hepatocarcinoma), Hela (cervical cancer), H358 (lung cancer), A2058 (melanoma), PANC-1 (pancreatic cancer), compound <b>1j</b> just showed very weak activity or no activity (IC<sub>50</sub> > 10 μM).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antiviability Activities of Compound <b>1j</b> against Various Cancer Cell Lines<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231</td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-435</td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-436</td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">0.316</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-453</td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">0.325</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT474</td><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCF-7</td><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">7.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SKBR-3</td><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">4.523</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HBL-1</td><td class="colsep0 rowsep0" align="left">lymphadenoma</td><td class="colsep0 rowsep0" align="left">∼10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">OCI-LY10</td><td class="colsep0 rowsep0" align="left">lymphadenoma</td><td class="colsep0 rowsep0" align="left">2.168</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RAMOS</td><td class="colsep0 rowsep0" align="left">lymphadenoma</td><td class="colsep0 rowsep0" align="left">∼10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MM.1S</td><td class="colsep0 rowsep0" align="left">myeloma</td><td class="colsep0 rowsep0" align="left">0.872</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">THP-1</td><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="left">5.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U-87 MG</td><td class="colsep0 rowsep0" align="left">glioblastoma</td><td class="colsep0 rowsep0" align="left">0.742</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="left">hepatocarcinoma</td><td class="colsep0 rowsep0" align="left">8.672</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hela</td><td class="colsep0 rowsep0" align="left">cervical cancer</td><td class="colsep0 rowsep0" align="left">5.410</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H358</td><td class="colsep0 rowsep0" align="left">lung cancer</td><td class="colsep0 rowsep0" align="left">1.665</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A2058</td><td class="colsep0 rowsep0" align="left">melanoma</td><td class="colsep0 rowsep0" align="left">1.908</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PANC-1</td><td class="colsep0 rowsep0" align="left">pancreatic cancer</td><td class="colsep0 rowsep0" align="left">6.556</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div></div><div class="NLM_p">Colony-forming assays were then used to examine the antiproliferation activity of compound <b>1j</b>. It was found that compound <b>1j</b> at concentrations larger than 0.01 μM significantly inhibited the colony formation of MDA-MB-231 cells (see Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A). Dasatinib also considerably decreased the formation of colonies of MDA-MB-231 cells at concentrations of >0.01 μM. Nevertheless, in terms of the potency in inhibiting the formation of colonies, compound <b>1j</b> is obviously more potent than dasatinib.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) <b>1j</b> inhibited colony formation of MDA-MB-231 cells. MDA-MB-231 cells were seeded in six-well plates and treated with <b>1j</b> or dasatinib for 12 days. Colonies were stained with crystal violet and pictures taken. (B, C) <b>1j</b> induced apoptosis and G<sub>0</sub>/G<sub>1</sub> cell cycle arrest of MDA-MB-231 cells. MDA-MB-231 cells were harvested after treatment with various concentrations of <b>1j</b> and dasatinib for 24 and 48 h. Cells were stained with an annexin V-FITC apoptosis detection kit or cell cycle and apoptosis analysis kit, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">3.5 Effects of Compound <b>1j</b> on Cell Apoptosis and Cell Cycle Progression</h3><div class="NLM_p last">A flow cytometry assay was performed to examine cell apoptosis upon treatment with compound <b>1j</b>. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B, compound <b>1j</b> induced apoptosis in MDA-MB-231 cells in a concentration-dependent manner. At a concentration of 0.3 μM, an apoptosis rate of 34.4% was observed after 48 h. We further examined the influence of compound <b>1j</b> treatment on the cell cycle of MDA-MB-231 cells using flow cytometry. The results indicated that compound <b>1j</b> could induce cell cycle arrest in G<sub>0</sub>/G<sub>1</sub> phase (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>C). As a positive control, dasatinib also showed the same effects in both flow cytometry assays but was relatively weaker than compound <b>1j</b> in terms of the potency. Taken together, these data demonstrated that compound <b>1j</b> could effectively lead to cell apoptosis and G<sub>0</sub>/G<sub>1</sub> phase arrest in MDA-MB-231.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">3.6 Effects of Compound <b>1j</b> on Tumor Cell Migration and Invasion</h3><div class="NLM_p">The effects of compound <b>1j</b> on tumor cell migration and invasion were assessed using wound healing assays and transwell assays, respectively. As displayed in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A, after treatment of compound <b>1j</b> in concentrations of >0.03 μM for 20 h, the migration of MDA-MB-231 cells was significantly inhibited. Results from the transwell assays showed that 0.1 μM compound <b>1j</b> potently blocked the invasion ability of MDA-MB-231 (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). Again, dasatinib also exhibited the same effects but was relatively weaker than compound <b>1j</b> in terms of the potency. These results demonstrated that <b>1j</b> could efficiently inhibit the migration and invasion of tumor cells.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) <b>1j</b> inhibited MDA-MB-231 cell migration in wound healing assay. Cells were wounded by the pipet and then treated with various concentrations of compounds for 20 h. Scale bar, 100 μm. (B) <b>1j</b> inhibited MDA-MB-231 cells invasion in transwell invasion assay. The bottom chambers of the transwells were filled with 600 μL of DMEM with 10% FBS, while the top chambers were seeded with 1 × 10<sup>5</sup> MDA-MB-231 cells in 200 μL of DMEM and treated with different concentrations of compounds for 24 h. Scale bar, 50 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">3.7 Inactivation of Key Signaling Proteins in Intact Cells</h3><div class="NLM_p">The ability of compound <b>1j</b> to inhibit the activation of key signaling proteins in intact cells was assessed using Western blot. After a 5 h treatment with increasing concentrations of compound <b>1j</b>, MDA-MB-231 cells were harvested and lysed for an IP/wt assay. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, compound <b>1j</b> inhibited Src phosphorylation in a dose-dependent manner with an estimated IC<sub>50</sub> value of 0.03 μM. Consistent with the inhibition of Src activation, the phosphorylation of its downstream signaling protein FAK was significantly inhibited at concentrations of >0.03 μM. Additionally, phosphorylation of the MAPK signaling proteins, MEK and ERK, was also strongly inhibited, which could be due to the inactivation of B-RAF and C-RAF (see Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), upstream signaling proteins of MAPK, by compound <b>1j</b>. It is also noteworthy that compound <b>1j</b> has no impact on the phosphorylation of AKT, indicating no effect on the AKT signaling. Similar to compound <b>1j</b>, dasatinib also efficiently inhibited Src and FAK and showed no effect on AKT signaling. However, different from compound <b>1j</b>, dasatinib just displayed very weak inhibitory potency against the ERK phosphorylation, suggesting less influence on the MAPK signal pathway. From here, it is reasonable to conclude that one of the main causes that compound <b>1j</b> showed a higher antiproliferation activity against TNBC cells than dasatinib could be due to it being able to inhibit MAPK signaling more efficiently than dasatinib, in addition to the potent inhibition of Src signaling.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>1j</b> inhibited the phosphorylation of Src and its downstream signaling proteins and the activation of MAPK signaling proteins in cell cultures. MDA-MB-231 cells were treated with <b>1j</b> or dasatinib for 20 h. Cells were lysed, and the proteins were analyzed by Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">3.8 In Vivo Effects of Compound <b>1j</b></h3><div class="NLM_p">The in vivo anti-TNBC activities of compound <b>1j</b> were evaluated using an MDA-MB-231 xenograft model. When the tumor grew to a volume of 150–200 mm<sup>3</sup>, the mice were grouped and treated orally once daily with 7.5, 15, or 30 mg kg<sup>–1</sup> d<sup>–1</sup><b>1j</b> for 18 days. The tumor volumes were measured every 3 days. At all doses given, compound <b>1j</b> markedly inhibited the tumor growth. Notably, a 30 mg kg<sup>–1</sup> d<sup>–1</sup> dose of compound <b>1j</b> completely stopped the tumor growth with a tumor inhibitory rate of >100% (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>A) without obvious toxicity. On the contrary, dasatinib (40 mg kg<sup>–1</sup> d<sup>–1</sup>) and paclitaxel (10 mg kg<sup>–1</sup> week<sup>–1</sup>), a clinically used TNBC drug, just showed moderate anti-TNBC effects in the same model (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>A).</div><div class="NLM_p">To better understand the mechanism of antitumor activities in vivo, the abilities of compound <b>1j</b> to inhibit Src and MAPK signaling, and cell proliferation (Ki67), as well as its effect on apoptosis in tumor tissues were also evaluated using tumor tissues isolated from MDA-MB-231 tumor xenograft models at the end of the treatment with histological and immunohistochemical techniques. A significant decrease in the phosphorylation of Src and MEK/ERK was observed in the compound <b>1j</b> treated groups compared with the control groups (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>B), indicating inhibition of Src and MAPK signal pathways. These tumors exhibited reduced staining of Ki67, implying a reduction in the number of proliferating cells in the tumor tissues. Further, more TUNEL-positive cells with AP-Red staining were observed, indicating a significant increased apoptosis in the treatment group when compared with the control group.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) In vivo antitumor efficacy of <b>1j</b> against MDA-MB-231 tumor xenograft models. Daily oral administration of <b>1j</b> at concentrations of 7.5, 15, 30 mg kg<sup>–1</sup> d<sup>–1</sup> and paclitaxel at a dose of 10 mg kg<sup>–1</sup> week<sup>–1</sup> though tail vein injection were initiated when the MDA-MB-231 tumors reached appoximately 200 mm<sup>3</sup> in volume (6 mice per group). Points indicate mean tumor volume (mm<sup>3</sup>); bars indicate SD; iv, intravenous. (B) Mechanism of action of <b>1j</b> in human tumor xenograft models. Mice bearing MDA-MB-231 tumor xenograft which was treated with <b>1j</b> at 30 mg/kg were humanly euthanized at the end of the experiment, and the tumor tissues were removed for further immunohistochemistry analysis and TUNEL detection. Scale bar, 50 μm. (C) Plasma concentration–time curve of <b>1j</b> in SD rats after a single oral dose of 10 mg/kg. Blood was collected at the indicated times, and the plasma concentrations were determined by LC/MS. Points, mean; bars, SD; <i>n</i> = 5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">3.9 Pharmacokinetic Characteristics of Compound <b>1j</b></h3><div class="NLM_p">A preliminary pharmacokinetic property assessment of compound <b>1j</b> was carried out on rats. The plasma concentration versus time profile is presented in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>C, and the key pharmacokinetic parameters of compound <b>1j</b> are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. After per os administration of 10 mg/kg compound <b>1j</b>, the area under the concentration–time curve (AUC<sub>0–∞</sub>) was about 4772.5 μg L<sup>–1</sup> h and the half-life (<i>t</i><sub>1/2</sub>) was about 12.76 h. In addition, compound <b>1j</b> achieved a maximum plasma concentration (<i>C</i><sub>max</sub>) of 214.63 μg/L within about 12 h and showed a clearance rate (CL) of 2.1 L h<sup>–1</sup> kg<sup>–1</sup> and apparent distribution volume (<i>V</i><sub>ss</sub>) of 38.57 L/kg. All of these indicated that compound <b>1j</b> has good pharmacokinetic properties.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters of Compound <b>1j</b> after Oral Administration to SD Rats (<i>n</i> = 5)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">po (10 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (μg L<sup>–1</sup> h)</td><td class="colsep0 rowsep0" align="left">4772.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (h)</td><td class="colsep0 rowsep0" align="left">12.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (μg/L)</td><td class="colsep0 rowsep0" align="left">214.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (h)</td><td class="colsep0 rowsep0" align="left">12.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> (L h<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">2.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a> (L/kg)</td><td class="colsep0 rowsep0" align="left">38.57</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Mean area under the plasma concentration–time curve.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Mean half-life associated with the terminal slope.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Mean peak plasma concentration.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Mean time to reach maximum plasma concentration.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">Mean body clearance.</p></div><div class="footnote" id="t6fn6"><sup>f</sup><p class="last">Mean volume of distribution at steady state.</p></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">4 Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, a series of new Src inhibitors bearing a 3-(phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine scaffold were designed and synthesized. Structure–activity relationships of these compounds were discussed based on enzymatic and cellular activities. A number of compounds showed high potencies in both biochemical and cell functional assays. Three most active compounds were selected to conduct a preliminary in vivo anti-TNBC assay, and <b>1j</b> exhibited the most potent in vivo anti-TNBC activity. Then, further in depth studies were carried out on <b>1j</b> for its in vitro and in vivo anti-TNBC activities. The results showed that compound <b>1j</b> was a multikinase inhibitor with high potencies against Src and several other kinases including MAPK signaling protein kinases B-RAF and C-RAF. In cellular assays, compound <b>1j</b> significantly inhibited the proliferation of TNBC MDA-MB-231 and MDA-MB-435 cells and displayed good selectivity for these TNBC cells against other cancer cells. This compound could effectively block the migration and invasion of MDA-MB-231 cells and lead to apoptosis and G<sub>0</sub>/G<sub>1</sub> phase arrest. In an MDA-MB-231 xenograft mouse model, a once-daily dose of compound <b>1j</b> at 30 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analyses indicated that compound <b>1j</b> potently inhibited Src and MAPK signal pathways. Finally, it is also important to mention that although dasatinib has a comparable potency with compound <b>1j</b> in Src inhibition, it has a relatively weaker activity than compound <b>1j</b> in inhibiting MAPK signaling; dysregulation of MAPK signaling has been demonstrated to be associated with tumor development and drug resistance of TNBC.<a onclick="showRef(event, 'ref21 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref21 ref36 ref37">(21, 36, 37)</a> This could be one of the most important reasons that compound <b>1j</b> showed more potent anti-TNBC activity than dasatinib.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">5 Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Kinase Inhibition Assays</h3><div class="NLM_p last">Kinase inhibition profiles were obtained using KinaseProfiler services provided by Eurofins, and ATP concentrations used are the ATP <i>K</i><sub>m</sub> of corresponding kinases.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Cell Lines and Cell Culture Conditions</h3><div class="NLM_p last">All of the cell lines used were obtained from the American Type Culture Collection (Manassas, VA, USA). These cell lines were cultured in the designated medium containing 10% fetal bovine serum (FBS) (v/v) at 37 °C in a humidified 5% CO<sub>2</sub> incubator according to ATCC guidelines.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Cell Viability Assays</h3><div class="NLM_p last">The viability of cells was determined using the MTT assay method. The cell lines were seeded (1500–30 000 cells per well, depending on the cell type) in 96-well plates. After incubation for 24 h in serum-containing media, the cells were treated with inhibitors (0–10 μg/mL) diluted with culture medium for 72 h at 37 °C under a 5% CO<sub>2</sub> atmosphere. Then 20 μL of the MTT reagent (5 mg/mL) was added to each well, and the plates were incubated for 2–4 h at 37 °C. For the adherent cells, the media and MTT were carefully aspirated from each well, and the formazan crystals were dissolved in 150 μL of 100% DMSO. For the suspended cells, 50 μL of 20% acidified SDS (w/v) was used to dissolve the oxidative product, and the cells were incubated overnight. Finally, the absorbance at 570 nm was read using a Multiskan MK3 ELISA photometer (Thermo Scientific). All experiments were performed in triplicate. The IC<sub>50</sub> values were calculated using GraphPad Prism software.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Colony Formation Assay</h3><div class="NLM_p last">Cells were seeded in six-well plates at a density of 5000 per well and treated with vehicle, dasatinib, or <b>1j</b> the next day. The medium containing vehicle or <b>1j</b> was replaced every 4 days. Cells were fixed with methanol and stained with crystal violet after treatment for 12 days.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Wound Healing Assay</h3><div class="NLM_p last">MDA-MB-231 cells were cultured to confluence in 24-well plates and wounded using a sterilized pipet tip to make a straight scratch. Cells were rinsed with physiological saline gently, and then PBS was replaced with DMEM medium containing vehicle, dasatinib, or <b>1j</b>. Pictures were taken by an OLYMPUS digital camera and analyzed by AxioVision Rel 4.8 (Carl Zeiss) after 20 h.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Transwell Invasion Assay</h3><div class="NLM_p last">The cell invasion assay was performed as described previously.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The cells were photographed with Leica DM2500.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Cell Cycle Progression and Apoptosis Assays</h3><div class="NLM_p last">A total of 2 × 10<sup>5</sup> MDA-MB-231 cells were plated in a six-well plate and treated with <b>1j</b> and dasatinib for 24 and 48 h at 37 °C. After incubation, the cells were harvested and washed with ice-cold PBS. The cell cycle progression was analyzed using a cell cycle and apoptosis analysis kit (Beyotime), and the apoptosis ratio was performed with an annexin V-FITC Apoptosis Detection Kit (keygentec).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Western Blot Analysis</h3><div class="NLM_p last">After treatment with a series of concentrations of <b>1j</b> for 20 h at 37 °C, MDA-MB-231 cells were harvested, washed with ice-cold physiological saline, and lysed with RIPA lysis buffer (Beyotime) including 1% cocktail (Sigma-Aldrich). Whole-cell protein lysates were prepared and centrifuged for 10 min at 12 000 rpm and 4 °C to remove any insoluble material. The total proteins were determined using the Bradford method, and an equivalent quantity of protein was combined with an SDS–PAGE loading buffer (Beyotime) in boiled water for 5 min. Cell lysates were separated by SDS–PAGE and electrotransferred onto PVDF membranes (Millipore). The PVDF membranes were incubated with each antibody and detected according to the immunoblot analysis principle. The antibodies were purchased from Cell Signaling Technology, and the dilutions of the antibodies were according to the instruction from Cell Signaling Technology.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> In Vivo Models</h3><div class="NLM_p last">The animal studies were conducted under the approval of the Experimental Animal Management Committee of Sichuan University. MDA-MB-231 cells were harvested during the exponential-growth phase, washed 3 times with serum-free medium, followed by resuspension at a concentration of 5 × 10<sup>7</sup> per mL. A total of 100 μL of cell suspension was injected into SCID mice (5–6 weeks) subcutaneously. After the tumors had grown to 150–200 mm<sup>3</sup>, all the mice were randomized into 6 groups (6 mice for each group) and dosed with <b>1j</b> (7.5, 15, or 30 mg kg<sup>–1</sup> d<sup>–1</sup>), dasatinib, paclitaxel (10 mg/kg/week), or vehicle. The compounds were dissolved in sterilization water with 25% (v/v) PEG400 plus 5% DMSO and administered orally. Mice were monitored for side effects every day, and tumor growth was measured every 3 days. The volume was calculated as follows: tumor size = <i>ab</i><sup>2</sup>/2 (<i>a</i>, long diameter; <i>b</i>, short diameter).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Histopathology and IHC</h3><div class="NLM_p last">SCID mice bearing tumors were treated with control or <b>1j</b> as described before. At the indicated time after dosing, individual mice were humanely euthanized. The tumors were fixed with formalin and embedded in paraffin. Sections measuring 4–8 μm in thickness were prepared for histological and immunostaining with the Ki67 antibody (Thermo Fisher Scientific, Fremont, CA). Apoptosis was determined using transferase-mediated dUTP nick-end labeling (TUNEL) and AP-Red staining (Roche Applied Science). The tissues of heart, liver, spleen, lung, and kidney were stained with hematoxylin and eosin (H&E). Finally, images were acquired on an Olympus digital camera attached to a light microscope.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Pharmacokinetic Assessments</h3><div class="NLM_p last">The pharmacokinetics analysis of <b>1j</b> was conducted in male Sprague–Dawley rats (Chinese Academy of Medical Science, Beijing, China). Briefly, catheters were surgically placed into the jugular veins of the rats to collect serial blood samples. The animals were administered a single dose of 10 mg/kg <b>1j</b> by oral gavage after fasting overnight. Blood was collected at the indicated time and centrifuged immediately to isolate plasma. The plasma concentrations were determined using high performance liquid chromatography with tandem mass spectrometric detection (3200 QTRAP system, Applied Biosystems). Noncompartmental pharmacokinetic parameters were fitted using DAS software (Enterprise, version 2.0, Mathematical Pharmacology Professional Committee of China).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Chemistry Methods</h3><div class="NLM_p last">All reagents and solvents were obtained from commercial suppliers and used without further purification unless otherwise indicated. Anhydrous solvents were dried and purified by conventional methods prior use. Column chromatography was carried out on silica gel (300–400 mesh). All reactions were monitored by thin-layer chromatography (TLC), and silica gel plates with fluorescence F-254 were used and visualized with UV light. All of the final compounds were purified to >95% purity, as determined by high-performance liquid chromatography (HPLC). HPLC analysis was performed on a Waters 2695 HPLC system with the use of a Kromasil C18 reversed-column (4.6 mm × 250 mm, 5 μm). The binary solvent system (A/B) was as follows: 10 mmol of ammonium acetate in water (pH 9) (A) and acetonitrile (B), A/B = 32/68. The absorbance was detected at 254 nm, and the flow rate was 1 mL/min. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 and 100 MHz, respectively. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Spin multiplicities are described as s (singlet), br s (broad singlet), t (triplet), q (quartet), and m (multiplet). Chemical shifts (δ) are listed in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. Mass spectral (MS) data were acquired on a Waters Q-TOF Premier mass spectrometer (Micromass, Manchester, U.K.).</div></div><div id="sec5_12_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3-Iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>2</b>)</h3><div class="NLM_p last">A solution of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (20 g, 148 mmol) and <i>N</i>-iodosuccinimide (50 g, 222 mmol) in DMF (150 mL) was stirred at 80 °C for 10–12 h under an N<sub>2</sub> atmosphere. A second batch of <i>N</i>-iodosuccinimide (3.92 g, 2 mmol) was added and the solution stirred for additional 12 h. Upon standing at room temperature, a precipitate was formed which was separated by filtration and washed with dimethylformamide and ethanol to afford 15.1 g of the title compound. The filtrate was concentrated in vacuo to about one-half of the original volume, and 500 mL of water was added. The precipitated product was separated by filtration and washed with ethanol to afford a second batch of the product (18.8 g, combined yield 33.9 g, 87.8% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.06 (br s, 1H), 8.17 (s, 1H), 7.91 (br s, 1H), 6.76 (br s, 1H). MS <i>m</i>/<i>z</i> (ESI): 262.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-Iodo-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3a</b>)</h3><div class="NLM_p last">To a suspension of <b>2</b> (5.0 g, 19.2 mmol) in anhydrous <i>N</i>,<i>N</i>-dimethylformamide (40 mL) under an N<sub>2</sub> atmosphere, potassium carbonate (5.3 g, 38.4 mmol) and 2-bromopropane (1.9 mL, 20.1 mmol) were added sequentially. The resulting mixture was stirred at 80 °C for 5 h and then was allowed to cool to room temperature. The mixture was filtered. The filtrate was concentrated in vacuo and then partitioned between water and DCM. The organic layer was dried with sodium sulfate and concentrated in vacuo. The crude product was purified using silica gel chromatography with a methanol/dichloromethane gradient to afford the desired product as a yellow solid (5.4 g, 92.8% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (s, 1H), 7.72 (br s, 1H), 6.72 (br s, 1H), 4.99–4.93 (m, 1H), 1.42 (d, <i>J</i> = 6.7 Hz, 6H). MS <i>m</i>/<i>z</i> (ESI): 304.0 [M + H]<sup>+</sup>. Compounds <b>3b</b>–<b>i</b> were synthesized by using a similar procedure; yield 51.1–92.0%.</div></div><div id="sec5_12_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 1-Ethyl-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.20 (s, 1H), 7.82 (br s, 1H), 6.67 (br s, 1H), 4.30 (q, <i>J</i> = 7.2 Hz, 2H), 1.35 (t, <i>J</i> = 7.2 Hz, 3H). MS <i>m</i>/<i>z</i> (ESI): 290.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 3-Iodo-1-methyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.21 (s, 1H), 7.87 (br s, 1H), 6.67 (br s, 1H), 3.88 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 275.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-Cyclobutyl-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (s, 1H), 7.69 (br s, 1H), 6.64 (br s, 1H), 5.32–5.13 (m, 1H), 2.71–2.54 (m, 2H), 2.36 (d, <i>J</i> = 4.7 Hz, 2H), 1.93–1.76 (m, 2H). MS <i>m</i>/<i>z</i> (ESI): 316.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 1-Cyclopentyl-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (s, 1H), 7.78 (br s, 1H), 6.70 (br s, 1H), 5.28–4.97 (m, 1H), 2.05 (dt, <i>J</i> = 12.1, 7.9 Hz, 2H), 1.99–1.88 (m, 2H), 1.88–1.78 (m, 2H), 1.72–1.59 (m, 2H). MS <i>m</i>/<i>z</i> (ESI): 330.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-Iodo-1-(methoxymethyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.87 (br s, 1H), 6.70 (br s, 1H), 5.54 (s, 2H), 3.26 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 306.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>S</i>)-3-Iodo-1-(tetrahydrofuran-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.21 (s, 1H), 7.89 (br s, 1H), 6.62 (br s, 1H), 5.50–5.28 (m, 1H), 4.10–3.96 (m, 2H), 3.92–3.80 (m, 2H), 2.43–2.23 (m, 2H). MS <i>m</i>/<i>z</i> (ESI): 332.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>R</i>)-3-Iodo-1-(tetrahydrofuran-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3h</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.21 (s, 1H), 7.89 (br s, 1H), 6.63 (br s, 1H), 5.60–5.28 (m, 1H), 4.15–3.96 (m, 2H), 3.94–3.76 (m, 2H), 2.44–2.22 (m, 2H). MS <i>m</i>/<i>z</i> (ESI): 332.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>tert</i>-Butyl 4-(4-Amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>3i</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.20(s, 1H), 7.79 (br s, 1H), 6.72 (br s, 1H), 4.87–4.75 (m, 1H), 4.06 (d, <i>J</i> = 10.8 Hz, 2H), 2.95 (br s, 2H), 1.99–1.81 (m, 4H), 1.43 (s, 9H). MS <i>m</i>/<i>z</i> (ESI): 445.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-Ethynyl-4-methylbenzoic Acid (<b>6</b>)</h3><div class="NLM_p"><i>3-Iodo-4-methylbenzoate (<b>4</b>).</i> A solution of 3-iodo-4-methylbenzoic acid (15 g, 57.14 mmol) and conc H<sub>2</sub>SO<sub>4</sub> (cat., 3 mL) in MeOH (100 mL) was heated at 65 °C for 24 h. The reaction mixture was cooled, and the solvent was evaporated. The residue was dissolved in Et<sub>2</sub>O, washed with saturated aqueous NaHCO<sub>3</sub> (3×), H<sub>2</sub>O, brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated to give the methyl 3-iodo-4-methylbenzoate <b>4</b> (14.8 g, 94.0%) as an orange liquid.</div><div class="NLM_p"><i>Methyl 4-Methyl-3-((trimethylsilyl)ethynyl)benzoate (<b>5</b>).</i><b>4</b> (14.8 g, 53.6 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (3.3 g, 2.86 mmol), and CuI (1.1 g, 5.74 mmol) were in suspended absolute THF (100 mL). The mixture underwent three cycles of vacuum/filling with N<sub>2</sub>. Triethylamine (5 mL, 35.6 mmol) and trimethylsilylacetylene (2.65 mL, 18.7 mmol) were then added. The mixture was stirred at room temperature overnight. Then the mixture was filtered, filtrate concentrated in vacuo, and the residue was diluted with EA (3×) and 0.5 M ammonia solution for extraction. The combined organic phases were dried over sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified using silica gel chromatography with a petroleum ether/ethyl acetate gradient to afford the methyl 4-methyl-3-((trimethylsilyl)ethynyl)benzoate (<b>5</b>) as a yellow liquid.</div><div class="NLM_p last"><b>5</b> was dissolved in methanol (80 mL). K<sub>2</sub>CO<sub>3</sub> (7.4 g, 53.6 mmol) was added and stirred for 10 min at rt. Then to the mixture were added NaOH (2.1 g, 53.6 mmol) and water (20 mL), and the mixture was stirred for another 3 h. The mixture was acidified with hydrochloric acid (pH 4) and extracted with DCM (3×). The combined organic phases were washed with saturated sodium chloride solution and concentrated under reduced pressure. Chromatographic purification through a short silica gel frit with a petroleum ether/ethyl acetate gradient yields <b>6</b> (6.8 g, 74.1% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.04 (br s, 1H), 7.93 (s, 1H), 7.85 (d, <i>J</i> = 8.0 Hz, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 4.48 (s, 1H), 2.45 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 159.0 [M – H]<sup>−</sup>.</div></div><div id="sec5_12_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (<b>9a</b>)</h3><div class="NLM_p"><i>4-Amino-2-trifluoromethylbenzaldehyde (<b>8a</b>).</i> 4-Amino-2-(trifluoromethyl)benzonitrile (<b>7a</b>) (11.2 g, 60 mmol) was charged into a 500 mL three-necked, round-bottomed flask and underwent three cycles of vacuum/filling with N<sub>2</sub>. Dry THF (100 mL) was then added and a solution of diisobutylaluminum hydride (100 mL, 1.5 M in toluene) was added at 23–30 °C over 20 min. Upon complete addition, the resulting solution was stirred for an additional 30 min. After the reaction was complete, the mixture was cooled to −10 °C and methanol (18 mL) was carefully added. Then the mixture was stirred for an additional 2 h at rt and an aqueous saturated Rochelle salt solution was added dropwise. After the quench was complete, the mixture was stirred at 45–50 °C for 10 min. <i>tert</i>-Butyl methyl ether (150 mL) was added and stirred for 10 min. Organic layers were separated, and more <i>tert</i>-butyl methyl ether was added for extraction. The combined organic phases were dried over MgSO<sub>4</sub> and concentrated under vacuum. The residue was used directly in the next step. MS <i>m</i>/<i>z</i> (ESI): 188.0 [M – H]<sup>−</sup>.</div><div class="NLM_p last">4-Amino-2-trifluoromethylbenzaldehyde (<b>8a</b>) (1.13 g, 6 mmol) was dissolved in ethyl acetate (35 mL), and aqueous 1 M HCl solution (20 mL) was added. The mixture was stirred rapidly at 20–35 °C for 5 min. A solution of aqueous 1 M NaOH (15 mL) was charged to the mixture and stirred for an additional 5 min. The organic layer was separated, washed with 10% (w/w) aqueous NaCl solution (20 mL), and charged to a 100 mL reactor. 1-Methylpiperazine (3.0 g, 30 mmol), pyridinium <i>p</i>-toluenesulfonate (150.8 mg, 0.6 mmol), and toluene (15 mL) were charged. The mixture underwent azeotropic distillation under Dean–Stark conditions with a final vessel temperature of 102–110 °C. After each 15 mL portion of distillate had been collected, fresh ethyl acetate (15 mL) was charged to the reaction mixture. This distillation–addition operation was repeated until a total of 45 mL of ethyl acetate was collected. The mixture was cooled to 50 °C, and sodium triacetoxyborohydride (2.54 g, 12 mmol) was added in portions at 50–60 °C. The reaction mixture was cooled to 10–15 °C and quenched with water (25 mL) over 10 min while maintaining the batch temperature below 20 °C. The organic layer was separated, washed with water (2 × 25 mL), dried over MgSO<sub>4</sub>, and concentrated in vacuo. The residue was washed with petroleum ether/ethyl acetate (v/v = 5), and the title compound <b>9a</b> was obtained as a white solid (1.26 g, 76.1% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.47 (d, <i>J</i> = 8.4 Hz, 1H), 6.91 (d, <i>J</i> = 2.4 Hz, 1H), 6.79 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 3.76 (br s, 2H), 3.52 (s, 2H), 2.70–2.35 (m, 8H), 2.28 (s, 3H); MS (ESI) <i>m</i>/<i>z</i> 274.2 [M + H]<sup>+</sup>. Compounds <b>9c</b>–<b>d</b> and <b>9f</b>–<b>h</b> were synthesized by using a similar procedure; yield 51.1–85.0%.</div></div><div id="sec5_12_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 4-(Morpholinomethyl)-3-(trifluoromethyl)aniline (<b>9f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 6.85 (d, <i>J</i> = 2.1 Hz, 1H), 6.72–6.75 (m, 1H), 5.45 (s, 2H), 3.60–3.50 (m, 4H), 3.39 (s, 2H), 2.40–2.30 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 261.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (<b>9g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.29 (d, <i>J</i> = 8.2 Hz, 1H), 6.87 (d, <i>J</i> = 2.2 Hz, 1H), 6.76 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H,), 5.42 (s, 2H), 3.39 (s, 2H), 2.34–2.26 (m, 10H), 0.97 (t, <i>J</i> = 5 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 288.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 2-(4-(4-Amino-2-(trifluoromethyl)benzyl)piperazin-1-yl)ethan-1-ol (<b>9h</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.47 (d, <i>J</i> = 8.3 Hz, 1H), 6.92 (d, <i>J</i> = 2.0 Hz, 1H), 6.79 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 3.77 (br s, 2H), 3.60 (t, <i>J</i> = 5.4 Hz, 2H), 3.53 (s, 2H), 2.76 (br s, 1H), 2.56–2.49 (m, 10H). MS (ESI) <i>m</i>/<i>z</i> 304.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 3-Ethynyl-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>10a</b>)</h3><div class="NLM_p">3-Ethynyl-4-methylbenzoic acid <b>6</b> (571 mg, 3.56 mmol) was refluxed in SOCl<sub>2</sub> for 2 h, concentrated in vacuo, and redissolved in ethyl acetate (8 mL) to afford 3-ethynyl-4-methylbenzoyl chloride solution.</div><div class="NLM_p last">3-((4-Methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)aniline <b>9a</b> (812 mg, 2.97 mmol) and DIPEA (806 mg, 6.24 mmol) were dissolved in ethyl acetate (10 mL) and cooled to 0 °C. Then 3-ethynyl-4-methylbenzoyl chloride ethyl acetate solution was dropwise added, resulting in an off-white suspension. The suspension was allowed to stir for 1 h at rt. To the reaction mixture was added 30 mL of water, and the aqueous phase was extracted with ethyl acetate (3 × 20 mL). The combined organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness under reduced pressure to give a solid residue. The solid was purified by flash column chromatography using MeOH in dichloromethane to give <b>10a</b> as an off-white solid (1.1 g, 88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.33 (s, 1H), 7.91 (s, 1H), 7.86 (d, <i>J</i> = 13.7 Hz, 2H), 7.73 (t, <i>J</i> = 7.1 Hz, 2H), 7.28 (s, 1H), 3.60 (s, 2H), 3.32 (s, 1H), 2.48 (br s, 11H), 2.30 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 416.3 [M + H]<sup>+</sup>. Compounds <b>10b</b>–<b>g</b> were synthesized by using a similar procedure; yield 79.1–88.2%.</div></div><div id="sec5_12_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 3-Ethynyl-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)benzamide (<b>10b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.91 (d, <i>J</i> = 10.3 Hz, 2H), 7.76 (d, <i>J</i> = 7.8 Hz, 1H), 7.57 (d, <i>J</i> = 7.7 Hz, 2H), 7.31 (d, <i>J</i> = 7.7 Hz, 3H), 3.49 (s, 2H), 3.35 (s, 1H), 2.51 (s, 3H), 2.48 (br s, 8H), 2.32 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 348.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(3-Chloro-4-((4-methylpiperazin-1-yl)methyl)phenyl)-3-ethynyl-4-methylbenzamide (<b>10c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.86 (s, 1H), 7.99 (s, 1H), 7.89 (s, 1H), 7.81 (d, <i>J</i> = 7.9 Hz, 1H), 7.49 (d, <i>J</i> = 8.3 Hz, 1H), 7.35–7.29 (m, 2H), 3.64 (s, 2H), 3.33 (s, 1H), 3.03–2.78 (m, 11H), 2.47 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 382.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-(3-Bromo-4-((4-methylpiperazin-1-yl)methyl)phenyl)-3-ethynyl-4-methylbenzamide (<b>10d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.30 (s, 1H), 8.10 (s, 1H), 8.03 (s, 1H), 7.86 (d, <i>J</i> = 7.9 Hz, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 7.27 (d, <i>J</i> = 7.9 Hz, 1H), 3.63 (s, 2H), 3.32 (s, 1H), 3.04–2.94 (m, 8H), 2.82 (s, 3H), 2.48 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 426.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 3-Ethynyl-4-methyl-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide (<b>10e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.55 (s, 1H), 8.25 (s, 1H), 8.11 (s, 1H), 8.07 (d, <i>J</i> = 8.4 Hz, 1H), 7.92 (d, <i>J</i> = 8.0 Hz, 1H), 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.47 (t, <i>J</i> = 8.8 Hz, 2H), 4.54 (s, 1H), 2.47 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 304.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 3-Ethynyl-4-methyl-<i>N</i>-(4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)benzamide (<b>10f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 1H), 7.95 (s, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.87 (s, 1H), 7.82–7.75 (m, 2H), 7.34 (d, <i>J</i> = 8.0 Hz, 1H), 3.81–3.66 (m, 4H), 3.63 (s, 2H), 3.36 (s, 1H), 2.52 (s, 3H), 2.51–2.41 (m, 4H). MS <i>m</i>/<i>z</i> (ESI): 403.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>N</i>-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-ethynyl-4-methylbenzamide Hydrochloride Salt (<b>10g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.57 (s, 1H), 10.24 (br s, 1H), 8.22 (s, 1H), 8.11 (d, <i>J</i> = 8.9 Hz, 2H), 7.92 (d, <i>J</i> = 8.2 Hz, 1H), 7.72 (d, <i>J</i> = 8.5 Hz, 1H), 7.48 (d, <i>J</i> = 8.2 Hz, 1H), 4.55 (s, 1H), 3.67 (s, 2H), 3.43 (d, <i>J</i> = 12.1 Hz, 2H), 3.18–3.04 (m, 2H), 3.03–2.81 (m, 6H), 2.47 (s, 3H), 1.24 (t, <i>J</i> = 7.2 Hz, 3H). MS <i>m</i>/<i>z</i> (ESI): 430.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 3-Ethynyl-<i>N</i>-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide (<b>10h</b>)</h3><div class="NLM_p">3-Ethynyl-4-methylbenzoic acid <b>6</b> (1.04 g, 6.5 mmol) was refluxed in SOCl<sub>2</sub> for 2 h, concentrated in vacuo, and redissolved in ethyl acetate (15 mL) to afford 3-ethynyl-4-methylbenzoyl chloride solution.</div><div class="NLM_p last">2-(4-(4-Amino-2-(trifluoromethyl)benzyl)piperazin-1-yl)ethan-1-ol <b>9h</b> (910 mg, 3 mmol) and DIPEA (840 mg, 6.5 mmol) were dissolved in ethyl acetate (20 mL) and cooled to 0 °C. Then 3-ethynyl-4-methylbenzoyl chloride–ethyl acetate solution was dropwise added, resulting in an off-white suspension. The suspension was allowed to stir for 1 h at rt. To the reaction mixture was added 40 mL of water, and the aqueous phase was extracted with ethyl acetate (3× 30 mL). The combined organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness under reduced pressure to give a solid residue. The solid combined with LiOH (500 mg) was dissolved in THF/H<sub>2</sub>O (v/v = 3, 16 mL) and was stirred at 25 °C overnight. The mixture was diluted with EA (3× 30 mL) and brine (30 mL) for extraction. Combined organic phases were dried over MgSO<sub>4</sub>, concentrated in vacuo. The residue was purified by flash column chromatography using MeOH in dichloromethane to give <b>10h</b> as a solid (1.65 g, 61.7% yield).</div></div><div id="sec5_12_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3-((4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1a</b>)</h3><div class="NLM_p last"><b>3a</b> (151.6 mg, 0.5 mmol), <b>10a</b> (207.7 mg, 0.5 mmol), CuI (9.5 mg, 0.05 mmol), and (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub> (17.5 mg, 0.025 mmol) were suspended in anhydrous DMF (3 mL). The mixture underwent three cycles of vacuum/filling with N<sub>2</sub>. Then DIPEA (165 μL, 1 mmol) was added with syringe. The mixture was stirred at 80 °C for 8 h and then quenched with water. DCM and 5% ammonia were added for extraction. The combined organic layer was concentrated in vacuo and the crude product was purified using silica gel chromatography with a methanol/dichloromethane gradient to afford the title compound <b>1a</b> as a white solid (136 mg, 46.0% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (s, 1H), 8.29 (s, 1H), 8.18 (s, 2H), 8.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.64 (d, <i>J</i> = 8.3 Hz, 1H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 5.01–4.95 (m, 1H), 3.58 (s, 2H), 3.04 (br s, 4H), 2.62 (s, 3H), 2.56 (br s, 4H), 2.43 (s, 3H), 1.40 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.72, 157.80, 156.29, 152.32, 144.14, 138.53, 132.03, 131.46, 131.37, 131.09, 129.97, 128.75, 127.55 (d, <i>J</i> = 29.5 Hz), 124.89, 123.57, 122.93, 121.57, 117.42, 100.77, 91.09, 85.55, 56.65, 52.79, 49.54, 48.89, 42.71, 42.36, 21.76, 20.54. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>31</sub>H<sub>34</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 591.2808; found, 591.2806. Compounds <b>1b</b>–<b>p</b> were synthesized by using a similar procedure; yield 39.0–58.1%.</div></div><div id="sec5_12_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 3-((4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)benzamide (<b>1b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H), 8.28–8.25 (m, 3H), 8.09 (s, 1H), 7.94 (d, <i>J</i> = 7.9 Hz, 1H), 7.87 (br s, 1H), 7.75 (d, <i>J</i> = 8.2 Hz, 1H), 7.36 (d, <i>J</i> = 8.2 Hz, 1H), 5.09–5.03 (m, 1H), 3.70 (s, 2H), 2.49 (s, 3H), 2.46 (br s, 8H), 2.24 (s, 3H), 1.49 (d, <i>J</i> = 6.4 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.00, 157.87, 156.26, 152.28, 141.15, 136.75, 135.52, 133.62, 131.61, 130.74, 130.01, 127.29 (d, <i>J</i> = 30.1 Hz), 125.10, 125.02, 123.80, 121.76, 121.32, 100.80, 91.76, 84.76, 57.40, 54.47, 52.40, 48.87, 45.33, 21.74, 19.89. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>30</sub>H<sub>35</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 523.2934; found, 523.2928.</div></div><div id="sec5_12_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 3-((4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-<i>N</i>-(3-chloro-4-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methylbenzamide (<b>1c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 7.98 (s, 1H), 7.94 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.4 Hz, 1H), 7.54 (d, <i>J</i> = 8.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.4 Hz, 1H), 5.13–4.99 (m, 1H), 3.53 (s, 2H), 2.58 (s, 3H), 2.43 (br s, 8H), 2.20 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>30</sub>H<sub>34</sub>ClN<sub>8</sub>O [M + H]<sup>+</sup> 557.2544; found, 557.2538.</div></div><div id="sec5_12_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 3-((4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-<i>N</i>-(3-bromo-4-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methylbenzamide (<b>1d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.44 (s, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.16 (s, 1H), 7.95 (d, <i>J</i> = 8.0 Hz, 1H), 7.80 (d, <i>J</i> = 8.2 Hz, 1H), 7.54 (d, <i>J</i> = 8.2 Hz, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 5.19–4.94 (m, 1H), 3.56 (s, 2H), 2.73 (br s, 11H), 2.58 (s, 3H), 1.49 (d, <i>J</i> = 6.0 Hz, 6H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>30</sub>H<sub>34</sub>BrN<sub>8</sub>O [M + H]<sup>+</sup> 601.2039; found, 601.2040.</div></div><div id="sec5_12_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 3-((4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide (<b>1e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 8.36 (s, 1H), 8.26 (s, 2H), 8.09 (d, <i>J</i> = 7.9 Hz, 1H), 7.97 (d, <i>J</i> = 7.7 Hz, 1H), 7.88 (br s, 1H), 7.61 (t, <i>J</i> = 7.9 Hz, 1H), 7.54 (d, <i>J</i> = 7.9 Hz, 1H), 7.46 (d, <i>J</i> = 7.5 Hz, 1H), 6.74 (br s, 1H), 5.20–4.92 (m, 1H), 2.58 (s, 3H), 1.48 (d, <i>J</i> = 6.4 Hz, 6H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>25</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 479.1807; found, 479.1813.</div></div><div id="sec5_12_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 3-((4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 8.34 (s, 1H), 8.27 (s, 1H), 8.23 (s, 1H), 8.09 (d, <i>J</i> = 8.3 Hz, 1H), 7.97 (d, <i>J</i> = 7.9 Hz, 1H), 7.75 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (d, <i>J</i> = 7.9 Hz, 1H), 5.12–5.03 (m, 1H), 3.59 (s, 6H), 2.59 (s, 3H), 2.39 (s, 4H), 1.49 (d, <i>J</i> = 6.8 Hz, 6H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>30</sub>H<sub>31</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 578.2491; found, 578.2488.</div></div><div id="sec5_12_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 3-((4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-<i>N</i>-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide (<b>1g</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.35 (s, 1H), 8.27 (s, 1H), 8.24 (s, 1H), 8.10 (d, <i>J</i> = 8.2 Hz, 1H), 7.98 (dd, <i>J</i> = 7.9, 1.1 Hz, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.55 (d, <i>J</i> = 8.2 Hz, 1H), 5.10–5.03 (m, 1H), 3.62 (s, 2H), 2.59 (s, 3H), 2.55 (br s, 10H), 1.49 (d, <i>J</i> = 6.7 Hz, 6H), 1.10 (t, <i>J</i> = 6.9 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 605.2964; found, 605.2962.</div></div><div id="sec5_12_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 3-((4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-<i>N</i>-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide (<b>1h</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 8.34 (s, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 8.07 (d, <i>J</i> = 8.2 Hz, 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.55 (d, <i>J</i> = 8.0 Hz, 1H), 5.19–4.94 (m, 1H), 4.37 (s, 1H), 3.56 (s, 2H), 3.48 (d, <i>J</i> = 5.4 Hz, 2H), 2.58 (s, 3H), 2.38 (br s, <i>J</i> = 6.1 Hz, 10H), 1.49 (d, <i>J</i> = 6.3 Hz, 6H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup> 621.2913; found, 621.2917.</div></div><div id="sec5_12_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 3-((4-Amino-1-methyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1i</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 8.1 Hz, 1H), 7.69 (d, <i>J</i> = 8.5 Hz, 1H), 7.52 (d, <i>J</i> = 8.1 Hz, 1H), 3.93 (s, 3H), 3.62 (s, 2H), 2.92 (br s, 4H), 2.58 (br s, 7H), 2.48 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.79, 157.79, 156.57, 153.26, 144.19, 138.48, 132.12, 131.46, 131.38, 131.30, 129.96, 128.69, 127.53 (d, <i>J</i> = 31.0 Hz), 125.04, 123.52, 121.61, 117.36, 117.30, 99.55, 91.12, 85.41, 56.82, 53.27, 50.27, 33.97, 20.50, 17.33. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>30</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 563.2495; found, 563.2497.</div></div><div id="sec5_12_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1j</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 8.34 (s, 1H), 8.27 (s, 1H), 8.22 (d, <i>J</i> = 1.7 Hz, 1H), 8.07 (d, <i>J</i> = 8.5 Hz, 1H), 7.97 (d, <i>J</i> = 8.1 Hz, 1H), 7.72 (d, <i>J</i> = 8.5 Hz, 1H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 4.38 (q, <i>J</i> = 7.2 Hz, 2H), 3.57 (s, 2H), 2.58 (s, 3H), 2.39 (br s, 8H), 2.16 (s, 3H), 1.42 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.77, 157.86, 156.52, 152.75, 144.17, 138.19, 132.23, 132.20, 131.38, 131.32, 129.99, 128.72, 127.75 (d, <i>J</i> = 30.0 Hz), 125.11, 123.56, 123.02, 121.62, 117.31, 100.19, 91.18, 85.47, 57.50, 54.78, 52.75, 45.78, 41.99, 20.55, 14.68. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>30</sub>H<sub>32</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 577.2651; found, 577.2652.</div></div><div id="sec5_12_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 3-((4-Amino-1-cyclobutyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1k</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 8.35 (s, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 8.08 (d, <i>J</i> = 8.5 Hz, 1H), 7.97 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.5 Hz, 1H), 7.55 (d, <i>J</i> = 8.0 Hz, 1H), 5.38–5.29 (m, 1H), 3.57 (s, 2H), 2.76–2.62 (m, 2H), 2.59 (s, 3H), 2.41 (br s, 10H), 2.18 (s, 3H), 1.95–1.80 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.66, 157.82, 156.43, 152.71, 144.14, 138.18, 132.13, 132.10, 131.33, 131.26, 129.95, 128.74, 127.42 (d, <i>J</i> = 30.0 Hz), 125.30, 123.51, 122.98, 121.54, 117.27, 100.77, 91.25, 85.45, 57.43, 54.68, 52.61, 50.39, 45.62, 29.36, 20.53, 14.41. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>32</sub>H<sub>34</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 603.2808; found, 603.2808.</div></div><div id="sec5_12_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 3-((4-Amino-1-cyclopentyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1l</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.33 (s, 1H), 8.25 (s, 1H), 8.22 (s, 1H), 8.11 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 7.9 Hz, 1H), 7.70 (d, <i>J</i> = 8.5 Hz, 1H), 7.54 (d, <i>J</i> = 7.9 Hz, 1H), 5.29–5.14 (m, 1H), 3.65 (s, 2H), 3.03–2.87 (m, 4H), 2.75 (s, 3H), 2.57 (s, 3H), 2.45–2.26 (m, 4H), 2.14–2.07 (m, 2H), 2.05–1.93 (m, 2H), 1.93–1.78 (m, 2H), 1.74–1.61 (m, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>33</sub>H<sub>36</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 617.2964; found, 617.2968.</div></div><div id="sec5_12_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 3-((4-Amino-1-(methoxymethyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1m</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.57 (s, 1H), 8.36 (s, 1H), 8.32 (s, 1H), 8.22 (s, 1H), 8.07 (d, <i>J</i> = 8.3 Hz, 1H), 7.98 (d, <i>J</i> = 7.9 Hz, 1H), 7.72 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (d, <i>J</i> = 7.9 Hz, 1H), 5.63 (s, 2H), 3.58 (s, 2H), 3.31 (s, 3H), 2.59 (s, 3H), 2.40 (br s, 8H), 2.19 (s, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>30</sub>H<sub>32</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup> 593.2600; found, 593.2597.</div></div><div id="sec5_12_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (<i>S</i>)-3-((4-Amino-1-(tetrahydrofuran-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1n</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.36 (s, 1H), 8.28 (s, 1H), 8.23 (s, 1H), 8.10 (d, <i>J</i> = 8.0 Hz, 1H), 7.97 (d, <i>J</i> = 7.6 Hz, 1H), 7.72 (d, <i>J</i> = 8.0 Hz, 1H), 7.55 (d, <i>J</i> = 7.6 Hz, 1H), 5.58–5.41 (m, 1H), 4.18–3.98 (m, 2H), 3.91 (dd, <i>J</i> = 13.4, 9.1 Hz, 2H), 3.62 (s, 2H), 2.59 (s, 3H), 2.54 (s, 3H), 2.44 (br s, 8H), 2.38–2.29 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.63, 157.85, 156.51, 153.17, 144.19, 138.18, 132.12, 131.34, 131.25, 129.98, 129.94, 128.80, 127.42 (d, <i>J</i> = 29.3 Hz), 125.45, 123.52, 123.01, 121.52, 117.27, 100.83, 91.37, 85.36, 71.57, 67.39, 57.48, 54.76, 52.73, 45.75, 31.82, 20.56, 14.66. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>32</sub>H<sub>34</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup> 619.2757; found, 619.2756.</div></div><div id="sec5_12_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>R</i>)-3-((4-Amino-1-(tetrahydrofuran-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1o</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 9.98 (br s, 1H), 9.44 (br s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 8.12 (d, <i>J</i> = 8.2 Hz, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.55 (d, <i>J</i> = 8.0 Hz, 1H), 5.61–5.36 (m, 1H), 4.19–3.98 (m, 2H), 3.91 (dd, <i>J</i> = 12.3, 7.6 Hz, 2H), 3.67 (s, 2H), 3.08 (s, 6H), 2.91 (br s, 2H), 2.74 (s, 3H), 2.59 (s, 3H), 2.43–2.33 (m, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>32</sub>H<sub>34</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup> 619.2757; found, 619.2761.</div></div><div id="sec5_12_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>tert</i>-Butyl 4-(4-Amino-3-((2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)ethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>1p</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 8.33 (s, 1H), 8.24 (s, 1H), 8.22 (s, 1H), 8.09 (d, <i>J</i> = 8.0 Hz, 1H), 7.95 (d, <i>J</i> = 7.7 Hz, 1H), 7.69 (d, <i>J</i> = 8.0 Hz, 1H), 7.52 (d, <i>J</i> = 7.7 Hz, 1H), 4.98–4.78 (m, 1H), 4.10–4.01 (m, 2H), 3.61 (s, 2H), 3.03–2.81 (m, 6H), 2.55 (br s, 7H), 2.48 (s, 3H), 1.99–1.90 (m, 4H), 1.41 (s, 9H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>38</sub>H<sub>45</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 732.3597; found, 732.3598.</div></div><div id="sec5_12_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 3-((4-Amino-1-(piperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1q</b>)</h3><div class="NLM_p last"><b>1p</b> (1.46 g, 2 mmol) was dissolved in DCM (20 mL) and cooled to 0 °C. Then 10 mL of CF<sub>3</sub>COOH was slowly added and stirred at rt for 2 h. The mixture was concentrated and suspended in water. Aqueous sodium hydrogen carbonate was added and adjusted to pH 8. Then the mixture was filtered and washed with water. The solid was dried in vacuo and recrystallized in acetone. Then the mixture was filtered to afford <b>1q</b> as a light yellow solid (1.07 g, 84.9% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.22 (s, 1H), 8.08 (d, <i>J</i> = 7.9 Hz, 1H), 7.98 (d, <i>J</i> = 7.9 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.55 (d, <i>J</i> = 8.2 Hz, 1H), 5.09–4.98 (m, 1H), 4.36–4.32 (m, 1H), 3.58 (s, 2H), 3.21–3.08 (m, 2H), 2.99 (d, <i>J</i> = 7.0 Hz, 2H), 2.58 (s, 3H), 2.42 (br s, 8H), 2.31 (d, <i>J</i> = 11.7 Hz, 2H), 2.22 (s, 3H), 2.12 (d, <i>J</i> = 11.6 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>33</sub>H<sub>37</sub>F<sub>3</sub>N<sub>9</sub>O [M + H]<sup>+</sup> 632.3073; found, 632.3071.</div></div><div id="sec5_12_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 3-((1-(1-Acryloylpiperidin-4-yl)-4-amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>1r</b>)</h3><div class="NLM_p last"><b>1q</b> (510 mg, 0.807 mmol) and triethylamine (223 μL, 1.6 mmol) were dissolved in 10 mL of DCM. Then the mixture was cooled to −10 °C, and to it was dropped a solution of acrylyl chloride (72 μL, 0.888 mmol) in dichloromethane (2 mL) within 0.5 h. Then the mixture was stirred at rt for an additional 0.5 h and quenched with water. DCM and more water were added for extraction. The combined organic layer was dried with sodium sulfate, filtered, concentrated, and the crude product was purified using silica gel chromatography with a methanol/dichloromethane gradient to afford the <b>1r</b> as a yellow solid (440 mg, 72.3%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.21 (s, 1H), 8.06 (d, <i>J</i> = 7.7 Hz, 1H), 7.96 (d, <i>J</i> = 7.7 Hz, 1H), 7.71 (d, <i>J</i> = 7.8 Hz, 1H), 7.54 (d, <i>J</i> = 7.8 Hz, 1H), 6.88 (dd, <i>J</i> = 17.7, 10.2 Hz, 1H), 6.14 (d, <i>J</i> = 17.7 Hz, 1H), 5.71 (d, <i>J</i> = 10.2 Hz, 1H), 5.08–4.94 (m, 1H), 4.56 (d, <i>J</i> = 10.5 Hz, 1H), 4.21 (d, <i>J</i> = 10.9 Hz, 1H), 3.57 (s, 2H), 2.97–2.84 (m, 1H), 2.73–2.62 (m, 1H), 2.57 (s, 3H), 2.39 (br s, 8H), 2.19 (s, 3H), 2.01 (br s, 4H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>36</sub>H<sub>39</sub>F<sub>3</sub>N<sub>9</sub>O<sub>2</sub> [M + H]<sup>+</sup> 686.3179; found, 686.3181.</div></div><div id="sec5_12_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 1-Ethyl-3-ethynyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>11</b>)</h3><div class="NLM_p"><i>1-Ethyl-3-((trimethylsilyl)ethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine.</i><b>3b</b> (5.15 g, 17.8 mmol), CuI (339 mg, 1.78 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (1 g, 0.89 mmol) were suspended in anhydrous DMF (25 mL). The mixture underwent three cycles of vacuum/filling with N<sub>2</sub>. Triethylamine (5 mL, 35.6 mmol) and trimethylsilylacetylene (2.65 mL, 18.7 mmol) were then added. The mixture was stirred at 80 °C for 5 h and then quenched with water. EA and more water were added for extraction. The combined organic layer was dried with sodium sulfate, filtered, concentrated, and the crude product was purified using silica gel chromatography with a methanol/dichloromethane gradient to afford the 1-ethyl-3-((trimethylsilyl)ethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine as a yellow solid.</div><div class="NLM_p last">1-Ethyl-3-((trimethylsilyl)ethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine was dissolved in methanol. Then K<sub>2</sub>CO<sub>3</sub> (4.9 g, 35.6 mmol) was added, and the mixture was stirred for 10 min at room temperature. The mixture was filtered, and the filtrate was concentrated in vacuo and then partitioned between water and DCM. The organic layer was dried with sodium sulfate and concentrated in vacuo. The crude product was purified using silica gel chromatography with a methanol/dichloromethane gradient to afford the title compound <b>11</b> as a white solid (1.49 g, 44.7% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.20 (s, 1H), 7.82 (br s, 1H), 6.67 (br s, 1H), 4.30 (q, <i>J</i> = 7.2 Hz, 2H), 1.35 (t, <i>J</i> = 7.2 Hz, 3H). MS <i>m</i>/<i>z</i> (ESI): 188.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 3-Iodo-4-isopropylbenzoic Acid (<b>12d</b>)</h3><div class="NLM_p last">Methyl 4-isopropylbenzoate (<b>16b</b>). A solution of 4-isopropylbenzoic acid <b>15b</b> (1 g, 6.1 mmol), and conc H<sub>2</sub>SO<sub>4</sub> (cat., 1 mL) in MeOH (10 mL) was heated at 65 °C for 20 h. The reaction mixture was cooled, and the solvent was evaporated. The residue was dissolved in Et<sub>2</sub>O, washed with saturated aqueous NaHCO<sub>3</sub> (3×), brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated to give the <b>16b</b> (998 mg, 92.0%) as an orange liquid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.89 (d, <i>J</i> = 8.3 Hz, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 3.84 (s, 3H), 3.07–2.86 (m, 1H), 1.22 (d, <i>J</i> = 6.9 Hz, 6H). MS <i>m</i>/<i>z</i> (ESI): 179.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Methyl 3-Iodo-4-isopropylbenzoate (<b>17b</b>)</h3><div class="NLM_p last">To 8 mL of acetic acid and 4 mL of acetic anhydride in a 50 mL round-bottom flask were added NaIO<sub>4</sub> (599 mg, 2.8 mmol) and powdered I<sub>2</sub> (507.62 mg, 2 mmol) at 5–10 °C with stirring. Then conc H<sub>2</sub>SO<sub>4</sub> (1 mL) was slowly added dropwise while keeping the temperature at 5–10 °C followed with methyl 4-isopropylbenzoate (998 mg, 5.6 mmol) at the same temperature. A brown suspension was stirred for 1 h at room temperature and 4 h at 40 °C (during this time a brown-violet solution almost decolorized). After cooling, water (30 mL) was added at 0 °C and product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3× 20 mL). Extracts were washed with 20% NaOH (approximately 3 mL; water layer was strongly alkaline after extraction), dried over MgSO<sub>4</sub>, and evaporated to afford a yellow oil. Crude product was purified using silica gel chromatography with a petroleum ether gradient to afford the desired product as a light yellow solid (1.56 g, 91.5% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 1.7 Hz, 1H), 7.94 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 7.49 (d, <i>J</i> = 8.1 Hz, 1H), 3.85 (s, 3H), 3.24–3.06 (m, 1H), 1.21 (d, <i>J</i> = 6.8 Hz, 6H). MS <i>m</i>/<i>z</i> (ESI): 305.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 3-Iodo-4-isopropylbenzoic Acid (<b>12d</b>)</h3><div class="NLM_p last">To a solution of <b>17b</b> (1.56 g, 5.1 mmol) in ethanol (20 mL) was added 1 M NaOH (6 mL). After stirring for 2 h at room temperature a clear pale yellow solution was obtained. The mixture was concentrated in vacuo and suspended in water. Then the solution was adjusted to pH 2 by addition of 1 M HCl and the solvent was stripped off. The residue was washed with water and taken up three times in toluene (30 mL) and evaporated to afford <b>12d</b> as a beige powder (1.33 g, 89.9% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.10 (s, 1H), 8.32 (d, <i>J</i> = 1.6 Hz, 1H), 7.92 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.46 (d, <i>J</i> = 8.1 Hz, 1H), 3.22–3.07 (m, 1H), 1.21 (d, <i>J</i> = 6.8 Hz, 6H). MS <i>m</i>/<i>z</i> (ESI): 289.0 [M – H]<sup>−</sup>. Compound <b>12c</b> was prepared by using a similar procedure; yield 78.1%.</div></div><div id="sec5_12_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 4-Ethyl-3-iodobenzoic Acid (<b>12c</b>)</h3><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.31 (s, 1H), 7.89 (d, <i>J</i> = 7.8 Hz, 1H), 7.44 (d, <i>J</i> = 7.8 Hz, 1H), 2.73 (q, <i>J</i> = 7.2 Hz, 2H), 1.16 (t, <i>J</i> = 7.2 Hz, 3H). MS <i>m</i>/<i>z</i> (ESI): 275.0 [M – H]<sup>−</sup>.</div><div class="NLM_p last">Compounds <b>13a</b>–<b>f</b> were prepared in a similar manner to that described for <b>10a</b> from 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline and different benzoic acid; yield 67.9–85.0%.</div></div><div id="sec5_12_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 3-Iodo-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>13a</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ10.57 (s, 1H), 8.32 (s, 1H), 8.18 (s, 1H), 8.04 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (d, <i>J</i> = 7.8 Hz, 2H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.36 (t, <i>J</i> = 7.9 Hz, 1H), 3.57 (s, 2H), 2.40 (br s, 8H), 2.17 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 504.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 4-Chloro-3-iodo-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide Hydrochloride Salt (<b>13b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (s, 1H), 8.54 (s, 1H), 8.24 (s, 1H), 8.13 (d, <i>J</i> = 8.3 Hz, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 1H), 7.89 (br s, 1H), 7.77 (d, <i>J</i> = 8.4 Hz, 1H), 3.90 (br s, 2H), 3.47 (br s, 2H), 3.16 (br s, 4H), 2.78 (s, 3H), 2.71 (br s, 2H). MS <i>m</i>/<i>z</i> (ESI): 538.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 4-Ethyl-3-iodo-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>13c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl3), δ 8.29(s, 1H), 8.16 (s, 1H), 7.88–7.85 (m, 2H), 7.78 (d, <i>J</i> = 8.0 Hz, 1H), 7.74 (d, <i>J</i> = 8.4 Hz, 1H), 7.29 (d, <i>J</i> = 8.0 Hz, 1H), 3.62 (s, 2H), 2.77 (q, <i>J</i> = 7.6 Hz, 2H), 2.51 (br s, 8H), 2.41 (s, 3H), 1.22 (t, <i>J</i> = 7.6 Hz, 3H). MS <i>m</i>/<i>z</i> (ESI): 532.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 3-Iodo-4-isopropyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>13d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (s, 1H), 8.31 (s, 1H), 7.95 (d, J = 10.1 Hz, 2H), 7.90 (d, <i>J</i> = 7.6 Hz, 1H), 7.57 (d, <i>J</i> = 6.4 Hz, 1H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 3.73 (s, 2H), 3.27–3.23 (m, 1H), 3.04 (br s, 4H), 2.87 (s, 4H), 2.74 (s, 3H), 1.26 (d, <i>J</i> = 6.8 Hz, 6H). MS <i>m</i>/<i>z</i> (ESI): 546.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 4-Fluoro-3-iodo-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>13e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 8.46 (d, <i>J</i> = 5.7 Hz, 1H), 8.17 (s, 1H), 8.03 (d, <i>J</i> = 8.3 Hz, 2H), 7.71 (d, <i>J</i> = 8.6 Hz, 1H), 7.45 (t, <i>J</i> = 8.2 Hz, 1H), 3.58 (s, 2H), 2.43 (br s, 8H), 2.24 (s, 3H). MS <i>m</i>/<i>z</i> (ESI): 522.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 3-Iodo-4-methoxy-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide Hydrochloride Salt (<b>13f</b>)</h3><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 9.62 (br s, 1H), 8.43 (d, <i>J</i> = 1.9 Hz, 1H), 8.19 (s, 1H), 8.14–7.97 (m, 2H), 7.69 (d, <i>J</i> = 8.5 Hz, 1H), 7.16 (d, <i>J</i> = 8.7 Hz, 1H), 3.92 (s, 3H), 3.65 (s, 2H), 3.15 (br s, 4H), 2.75 (s, 3H), 2.67 (br s, 4H). MS <i>m</i>/<i>z</i> (ESI): 534.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>14a</b>–<b>f</b> were prepared in a similar manner to that described for <b>1a</b> from 1-ethyl-3-ethynyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine <b>11</b> and different iodobenzamide (<b>13a</b>–<b>f</b>); yield 37.9–51.6%.</div></div><div id="sec5_12_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>14a</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.65 (s, 1H), 8.36 (s, 1H), 8.27 (s, 1H), 8.23 (s, 1H), 8.13–8.01 (m, 2H), 7.97 (s, 1H), 7.73 (d, <i>J</i> = 7.6 Hz, 1H),7.65 (s, 1H), 4.37 (q, <i>J</i> = 7.2 Hz, 2H), 3.58 (s, 2H), 2.43 (br s, 8H), 2.23 (s, 3H), 1.42 (t, <i>J</i> = 7.2 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>30</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 563.2495; found, 563.2499.</div></div><div id="sec5_12_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-chloro-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>14b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.67 (s, 1H), 8.48 (s, 1H), 8.29 (s, 1H), 8.20 (s, 1H), 8.05 (s, 2H), 7.83 (d, <i>J</i> = 8.2 Hz, 1H), 7.73 (d, <i>J</i> = 8.2 Hz, 1H), 4.39 (d, <i>J</i> = 6.9 Hz, 2H), 3.57 (s, 2H), 2.40 (br s, 8H), 2.19 (s, 3H), 1.42 (t, <i>J</i> = 6.9 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>29</sub>ClF<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 597.2105; found, 597.2107.</div></div><div id="sec5_12_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-ethyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>14c</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.62 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 8.09 (d, <i>J</i> = 8.3 Hz, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.3 Hz, 1H), 7.56 (d, <i>J</i> = 8.0 Hz, 1H), 4.38 (q, <i>J</i> = 7.6 Hz, 2H), 3.60 (s, 2H), 2.95 (q, <i>J</i> = 7.2 Hz, 2H), 2.51 (br s, 8H), 2.34 (s, 3H), 1.42 (t, <i>J</i> = 7.6 Hz, 3H), 1.29 (t, <i>J</i> = 7.2 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>31</sub>H<sub>34</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 591.2808; found, 591.2805.</div></div><div id="sec5_12_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-isopropyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>14d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (s, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 8.23 (s, 1H), 8.08 (d, <i>J</i> = 8.1 Hz, 1H), 8.02 (d, <i>J</i> = 8.1 Hz, 1H), 7.72 (d, <i>J</i> = 8.4 Hz, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 1H), 4.39 (q, <i>J</i> = 7.2 Hz, 2H), 3.61 (s, 2H), 3.59–3.50 (m, 1H), 2.39 (s, 8H), 2.33 (s, 3H), 1.42 (t, <i>J</i> = 7.2 Hz, 3H), 1.32 (d, <i>J</i> = 6.9 Hz, 6H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 605.2964; found, 605.2970.</div></div><div id="sec5_12_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-fluoro-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>14e</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.64 (s, 1H), 8.47 (d, <i>J</i> = 8.1 Hz, 1H), 8.28 (s, 1H), 8.20 (s, 1H), 8.15–8.08 (m, 1H), 8.05 (d, <i>J</i> = 8.1 Hz, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.59 (t, <i>J</i> = 9.0 Hz, 1H), 4.38 (q, <i>J</i> = 7.2 Hz, 2H), 3.57 (s, 2H), 2.39 (br s, 8H), 2.16 (s, 3H), 1.42 (t, <i>J</i> = 7.2 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>29</sub>F<sub>4</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 581.2400; found, 581.2405.</div></div><div id="sec5_12_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methoxy-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>14f</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H), 8.40 (s, 1H), 8.29 (s, 2H), 8.22 (s, 1H), 8.16–8.02 (m, 2H), 7.71 (d, <i>J</i> = 7.9 Hz, 1H), 7.34 (d, <i>J</i> = 8.8 Hz, 1H), 6.73 (br s, 1H), 4.36 (d, <i>J</i> = 6.7 Hz, 2H), 4.04 (s, 3H), 3.60 (s, 2H), 2.39 (br s, 8H), 2.34 (s, 3H), 1.42 (t, <i>J</i> = 6.7 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>30</sub>H<sub>32</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup> 593.2600; found, 593.2598.</div></div><div id="sec5_12_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-hydroxy-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (<b>14g</b>)</h3><div class="NLM_p last">To a stirred suspension of 3-((4-amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methoxy-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <b>14f</b> (296 mg, 0.5 mmol) in dry DCM (10 mL) at −78 °C was added dropwise BBr<sub>3</sub> (1.0 M solution in DCM, 6 mL, 6 mmol) under an N<sub>2</sub> atmosphere. Then the reaction mixture was stirred at this temperature for 20 min and moved to rt for another 8 h. The reaction was then quenched by the dropwise addition of water. The reaction mixture was poured into ammonia solution (30 mL, pH 8), and more DCM was added for extraction. The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent was removed under reduced pressure to give a solid which was purified by flash chromatography to afford the title compound as a yellow solid (173.5 mg, 60.1% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (s, 1H), 8.41 (s, 1H), 8.31 (s, 1H), 8.28 (s, 1H), 8.14 (d, <i>J</i> = 8.6 Hz, 1H), 8.04 (d, <i>J</i> = 8.7 Hz, 1H), 7.98 (d, <i>J</i> = 8.7 Hz, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 1H), 7.58 (s, 1H), 4.44 (q, <i>J</i> = 7.2 Hz, 2H), 3.67 (s, 2H), 3.11 (br s, 4H), 2.70 (s, 3H), 2.65 (br s, 4H), 1.46 (t, <i>J</i> = 7.2 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>30</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup> 579.2444; found, 579.2446.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00270">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Chemical structures of top 100 compounds, a full description of the scaffold hopping and molecular docking, and a csv file of molecular formula strings. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00270/suppl_file/jm5b00270_si_001.pdf">jm5b00270_si_001.pdf (591.4 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00270/suppl_file/jm5b00270_si_002.csv">jm5b00270_si_002.csv (3.13 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00270" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng-Yong Yang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#186179767f6b61586b7b6d367d7c6d367b76"><span class="__cf_email__" data-cfemail="433a222d24303a033020366d2627366d202d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun-Hui Zhang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming-Wu Zheng</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-Ping Li</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xing-Dong Lin</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mei Huang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Zhong</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guo-Bo Li</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong-Jie Zhang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wan-Ting Lin</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Jiao</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-Ai Wu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiao Yang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong Xiang</span> - <span class="hlFld-Affiliation affiliation">Department of Clinical
Medicine, School of Medicine, Nankai University, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li-Juan Chen</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying-Lan Zhao</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Cheng</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Quan Wei</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative
Innovation Center for Biotherapy, Sichuan
University, Sichuan 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.-H.Z., M.-W.Z., and Y.-P.L. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2364e6004-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the 973 Program (Grant 2013CB967204), the National Natural Science Foundation (Grant 81325021, 81172987, and 81473140), and the Program for Changjiang Scholars and Innovative Research Team in University (Grant IRT13031).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i101" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i101"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i102" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i102"> Abbreviations Used</h2><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">sarcoma</p></td></tr><tr><td class="NLM_term">B-RAF</td><td class="NLM_def"><p class="first last">serine/threonine protein kinase B-RAF</p></td></tr><tr><td class="NLM_term">C-RAF</td><td class="NLM_def"><p class="first last">RAF proto-oncogene serine/threonine protein kinase</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular regulated protein kinases</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">SFK</td><td class="NLM_def"><p class="first last">Src family kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">R&D</td><td class="NLM_def"><p class="first last">research and development</p></td></tr><tr><td class="NLM_term"><i>i</i>-Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last">1-iodopyrrolidine-2,5-dione</p></td></tr><tr><td class="NLM_term">DIBAL</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Foulkes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1948</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&issue=20&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0ljXZyIYN-qhsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D20%26spage%3D1938%26epage%3D1948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Carey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer: disease entity or title of convenience?</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">692</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnrclinonc.2010.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=20877296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252Fgt1Kjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=683-692&issue=12&author=L.+Careyauthor=E.+Winerauthor=G.+Vialeauthor=D.+Cameronauthor=L.+Gianni&title=Triple-negative+breast+cancer%3A+disease+entity+or+title+of+convenience%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer: disease entity or title of convenience?</span></div><div class="casAuthors">Carey Lisa; Winer Eric; Viale Giuseppe; Cameron David; Gianni Luca</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">683-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This Review outlines the understanding and management of triple-negative breast cancer (TNBC).  TNBC shares morphological and genetic abnormalities with basal-like breast cancer (BLBC), a subgroup of breast cancer defined by gene-expression profiling.  However, TNBC and BLBC tumors are heterogeneous and overlap is incomplete.  Breast cancers found in BRCA1 mutation carriers are also frequently triple negative and basal like.  TNBC and BLBC occur most frequently in young women, especially African Americans, and tend to exhibit aggressive, metastatic behavior.  These tumors respond to conventional chemotherapy but relapse more frequently than hormone receptor-positive, luminal subtypes and have a worse prognosis.  New systemic therapies are urgently needed as most patients with TNBC and/or BLBC relapse with distant metastases, and hormonal therapies and HER2-targeted agents are ineffective in this group of tumors.  Poly (ADP-ribose) polymerase inhibitors, angiogenesis inhibitors, EGFR-targeted agents, and src kinase and mTOR inhibitors are among the therapeutic agents being actively investigated in clinical trials in patients with TNBC and/or BRCA1-associated tumors.  Increased understanding of the genetic abnormalities involved in the pathogenesis of TNBC, BLBC and BRCA1-associated tumors is opening up new therapeutic possibilities for these hard-to-treat breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlqlWDxtx3xkewzGPswiWOfW6udTcc2eaMWiL1Ib7mB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252Fgt1Kjsg%253D%253D&md5=8136a61a205486e4613c63fd7ac9a39b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.154%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DL.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520disease%2520entity%2520or%2520title%2520of%2520convenience%253F%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D7%26issue%3D12%26spage%3D683%26epage%3D692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Cleator, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombes, R. C.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer: therapeutic options</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1016%2FS1470-2045%2807%2970074-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=17329194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A280%3ADC%252BD2s7ivFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=235-244&issue=3&author=S.+Cleatorauthor=W.+Hellerauthor=R.+C.+Coombes&title=Triple-negative+breast+cancer%3A+therapeutic+options"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer: therapeutic options</span></div><div class="casAuthors">Cleator Susan; Heller Wolfgang; Coombes R Charles</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-44</span>
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    </div><div class="casAbstract">Triple-negative breast cancers are defined by a lack of expression of oestrogen, progesterone, and ERBB2 receptors.  This subgroup accounts for 15% of all types of breast cancer and for a higher percentage of breast cancer arising in African and African-American women who are premenopausal.  Because of the absence of specific treatment guidelines for this subgroup, triple-negative breast cancers are managed with standard treatment; however, such treatment leaves them associated with a high rate of local and systemic relapse.  Histologically, such cancers are poorly differentiated, and most fall into the basal subgroup of breast cancers, characterised by staining for basal markers (ie, cytokeratin 5/6).  Analyses of microarray gene-expression profiling data show that they form a homogeneous group (or so-called cluster) in transcriptional terms and, increasingly, research studies are identifying basal cancers on the basis of exhibiting this distinctive transcriptional profile.  Histologically and transcriptionally, triple-negative breast cancers have many similarities to BRCA1-associated breast cancers, which suggests that dysfunction in BRCA1 or related pathways occurs in this subset of sporadic cancers.  In this review, we discuss the molecular features of triple-negative breast cancers and consider how the use of existing cytotoxic agents can be optimised for this patient group.  We discuss the implications of a possible underlying BRCA1-pathway dysfunction in this subgroup in terms of treatment and we also investigate the predominant proliferative signals and the on-going research addressing the suitability of these signals as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkJlxHGuTx0Xl8icjszYl0fW6udTcc2eaMWiL1Ib7mB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7ivFKjsA%253D%253D&md5=d51518f923eb499081a8aca8f651357e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2807%2970074-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252807%252970074-8%26sid%3Dliteratum%253Aachs%26aulast%3DCleator%26aufirst%3DS.%26aulast%3DHeller%26aufirst%3DW.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520therapeutic%2520options%26jtitle%3DLancet%2520Oncol.%26date%3D2007%26volume%3D8%26issue%3D3%26spage%3D235%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Higgins, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Targeted therapies for breast cancer</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">3797</span><span class="NLM_x">–</span> <span class="NLM_lpage">3803</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=3797-3803&issue=10&author=M.+J.+Higginsauthor=J.+Baselga&title=Targeted+therapies+for+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHiggins%26aufirst%3DM.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DTargeted%2520therapies%2520for%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26issue%3D10%26spage%3D3797%26epage%3D3803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">von Minckwitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span> </span><span class="NLM_article-title">Neoadjuvant treatments for triple-negative breast cancer (TNBC)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">vi35</span><span class="NLM_x">–</span> <span class="NLM_lpage">vi39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1093%2Fannonc%2Fmds193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=23012300" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=vi35-vi39&issue=Suppl.+6&author=G.+von+Minckwitzauthor=M.+Martin&title=Neoadjuvant+treatments+for+triple-negative+breast+cancer+%28TNBC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds193%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DNeoadjuvant%2520treatments%2520for%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26issue%3DSuppl.%25206%26spage%3Dvi35%26epage%3Dvi39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Mayer, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">New strategies for triple-negative breast cancer—deciphering the heterogeneity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">782</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1078-0432.CCR-13-0583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=24536073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=782-790&issue=4&author=I.+A.+Mayerauthor=V.+G.+Abramsonauthor=B.+D.+Lehmannauthor=J.+A.+Pietenpol&title=New+strategies+for+triple-negative+breast+cancer%E2%80%94deciphering+the+heterogeneity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity</span></div><div class="casAuthors">Mayer, Ingrid A.; Abramson, Vandana G.; Lehmann, Brian D.; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">782-790</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biol.  Exploring novel approaches to treatment of these subtypes is crit. because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy.  To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the std. treatment.  We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.  Clin Cancer Res; 20(4); 782-90. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdvsR_JjXMyLVg90H21EOLACvtfcHk0lgIayI9iSXk9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D&md5=4ce0876cb914096f913a7a637d7b63d5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0583%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DNew%2520strategies%2520for%2520triple-negative%2520breast%2520cancer%25E2%2580%2594deciphering%2520the%2520heterogeneity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D4%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Craig, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shaughnessy, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moses, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christoforides, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aitelli, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izatt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurdoglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacioru, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakarya, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De La Vega, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billings, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salhia, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mousses, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpten, J. D.</span><span> </span><span class="NLM_article-title">Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1535-7163.MCT-12-0781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=23171949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVamug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=104-116&issue=1&author=D.+W.+Craigauthor=J.+A.+O%E2%80%99Shaughnessyauthor=J.+A.+Kieferauthor=J.+Aldrichauthor=S.+Sinariauthor=T.+M.+Mosesauthor=S.+Wongauthor=J.+Dinhauthor=A.+Christoforidesauthor=J.+L.+Blumauthor=C.+L.+Aitelliauthor=C.+R.+Osborneauthor=T.+Izattauthor=A.+Kurdogluauthor=A.+Bakerauthor=J.+Koemanauthor=C.+Barbacioruauthor=O.+Sakaryaauthor=F.+M.+De+La+Vegaauthor=A.+Siddiquiauthor=L.+Hoangauthor=P.+R.+Billingsauthor=B.+Salhiaauthor=A.+W.+Tolcherauthor=J.+M.+Trentauthor=S.+Moussesauthor=D.+Von+Hoffauthor=J.+D.+Carpten&title=Genome+and+transcriptome+sequencing+in+prospective+metastatic+triple-negative+breast+cancer+uncovers+therapeutic+vulnerabilities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities</span></div><div class="casAuthors">Craig, David W.; O'Shaughnessy, Joyce A.; Kiefer, Jeffrey A.; Aldrich, Jessica; Sinari, Shripad; Moses, Tracy M.; Wong, Shukmei; Dinh, Jennifer; Christoforides, Alexis; Blum, Joanne L.; Aitelli, Cristi L.; Osborne, Cynthia R.; Izatt, Tyler; Kurdoglu, Ahmet; Baker, Angela; Koeman, Julie; Barbacioru, Catalin; Sakarya, Onur; De La Vega, Francisco M.; Siddiqui, Asim; Hoang, Linh; Billings, Paul R.; Salhia, Bodour; Tolcher, Anthony W.; Trent, Jeffrey M.; Mousses, Spyro; Von Hoff, Daniel; Carpten, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-116</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2.  Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor prognosis with median survival of one year.  Here, we present initial analyses of whole genome and transcriptome sequencing data from 14 prospective mTNBC.  We have cataloged the collection of somatic genomic alterations in these advanced tumors, particularly those that may inform targeted therapies.  Genes mutated in multiple tumors included TP53, LRP1B, HERC1, CDH5, RB1, and NF1.  Notable genes involved in focal structural events were CTNNA1, PTEN, FBXW7, BRCA2, WT1, FGFR1, KRAS, HRAS, ARAF, BRAF, and PGCP.  Homozygous deletion of CTNNA1 was detected in 2 of 6 African Americans.  RNA sequencing revealed consistent overexpression of the FOXM1 gene when tumor gene expression was compared with nonmalignant breast samples.  Using an outlier anal. of gene expression comparing one cancer with all the others, we detected expression patterns unique to each patient's tumor.  Integrative DNA/RNA anal. provided evidence for deregulation of mutated genes, including the monoallelic expression of TP53 mutations.  Finally, mol. alterations in several cancers supported targeted therapeutic intervention on clin. trials with known inhibitors, particularly for alterations in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways.  In conclusion, whole genome and transcriptome profiling of mTNBC have provided insights into somatic events occurring in this difficult to treat cancer.  These genomic data have guided patients to investigational treatment trials and provide hypotheses for future trials in this irremediable cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-JLQZ9xmALVg90H21EOLACvtfcHk0lgIayI9iSXk9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVamug%253D%253D&md5=0cc86f6a13750602c4663ad034e9ff71</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0781%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DD.%2BW.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%2BA.%26aulast%3DKiefer%26aufirst%3DJ.%2BA.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DSinari%26aufirst%3DS.%26aulast%3DMoses%26aufirst%3DT.%2BM.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DDinh%26aufirst%3DJ.%26aulast%3DChristoforides%26aufirst%3DA.%26aulast%3DBlum%26aufirst%3DJ.%2BL.%26aulast%3DAitelli%26aufirst%3DC.%2BL.%26aulast%3DOsborne%26aufirst%3DC.%2BR.%26aulast%3DIzatt%26aufirst%3DT.%26aulast%3DKurdoglu%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DA.%26aulast%3DKoeman%26aufirst%3DJ.%26aulast%3DBarbacioru%26aufirst%3DC.%26aulast%3DSakarya%26aufirst%3DO.%26aulast%3DDe%2BLa%2BVega%26aufirst%3DF.%2BM.%26aulast%3DSiddiqui%26aufirst%3DA.%26aulast%3DHoang%26aufirst%3DL.%26aulast%3DBillings%26aufirst%3DP.%2BR.%26aulast%3DSalhia%26aufirst%3DB.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DTrent%26aufirst%3DJ.%2BM.%26aulast%3DMousses%26aufirst%3DS.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26atitle%3DGenome%2520and%2520transcriptome%2520sequencing%2520in%2520prospective%2520metastatic%2520triple-negative%2520breast%2520cancer%2520uncovers%2520therapeutic%2520vulnerabilities%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26issue%3D1%26spage%3D104%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Shah, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oloumi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turashvili, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bashashati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prentice, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khattra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burleigh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shumansky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crisan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliany, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heravi-Moussavi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birol, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varhol, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhalla, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moradian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelmon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueda, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pharoah, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damaraju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harkins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadigotla, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigaroudinia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tlsty, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaves, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserman, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntsman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, S.</span><span> </span><span class="NLM_article-title">The clonal and mutational evolution spectrum of primary triple-negative breast cancers</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x"> (</span><span class="NLM_issue">7403</span><span class="NLM_x">) </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=395-399&issue=7403&author=S.+P.+Shahauthor=A.+Rothauthor=R.+Goyaauthor=A.+Oloumiauthor=G.+Haauthor=Y.+Zhaoauthor=G.+Turashviliauthor=J.+Dingauthor=K.+Tseauthor=G.+Haffariauthor=A.+Bashashatiauthor=L.+M.+Prenticeauthor=J.+Khattraauthor=A.+Burleighauthor=D.+Yapauthor=V.+Bernardauthor=A.+McPhersonauthor=K.+Shumanskyauthor=A.+Crisanauthor=R.+Giulianyauthor=A.+Heravi-Moussaviauthor=J.+Rosnerauthor=D.+Laiauthor=I.+Birolauthor=R.+Varholauthor=A.+Tamauthor=N.+Dhallaauthor=T.+Zengauthor=K.+Maauthor=S.+K.+Chanauthor=M.+Griffithauthor=A.+Moradianauthor=S.+W.+Chengauthor=G.+B.+Morinauthor=P.+Watsonauthor=K.+Gelmonauthor=S.+Chiaauthor=S.+F.+Chinauthor=C.+Curtisauthor=O.+M.+Ruedaauthor=P.+D.+Pharoahauthor=S.+Damarajuauthor=J.+Mackeyauthor=K.+Hoonauthor=T.+Harkinsauthor=V.+Tadigotlaauthor=M.+Sigaroudiniaauthor=P.+Gascardauthor=T.+Tlstyauthor=J.+F.+Costelloauthor=I.+M.+Meyerauthor=C.+J.+Eavesauthor=W.+W.+Wassermanauthor=S.+Jonesauthor=D.+Huntsmanauthor=M.+Hirstauthor=C.+Caldasauthor=M.+A.+Marraauthor=S.+Aparicio&title=The+clonal+and+mutational+evolution+spectrum+of+primary+triple-negative+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DS.%2BP.%26aulast%3DRoth%26aufirst%3DA.%26aulast%3DGoya%26aufirst%3DR.%26aulast%3DOloumi%26aufirst%3DA.%26aulast%3DHa%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DTurashvili%26aufirst%3DG.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DTse%26aufirst%3DK.%26aulast%3DHaffari%26aufirst%3DG.%26aulast%3DBashashati%26aufirst%3DA.%26aulast%3DPrentice%26aufirst%3DL.%2BM.%26aulast%3DKhattra%26aufirst%3DJ.%26aulast%3DBurleigh%26aufirst%3DA.%26aulast%3DYap%26aufirst%3DD.%26aulast%3DBernard%26aufirst%3DV.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DShumansky%26aufirst%3DK.%26aulast%3DCrisan%26aufirst%3DA.%26aulast%3DGiuliany%26aufirst%3DR.%26aulast%3DHeravi-Moussavi%26aufirst%3DA.%26aulast%3DRosner%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DD.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DVarhol%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DDhalla%26aufirst%3DN.%26aulast%3DZeng%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGriffith%26aufirst%3DM.%26aulast%3DMoradian%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DS.%2BW.%26aulast%3DMorin%26aufirst%3DG.%2BB.%26aulast%3DWatson%26aufirst%3DP.%26aulast%3DGelmon%26aufirst%3DK.%26aulast%3DChia%26aufirst%3DS.%26aulast%3DChin%26aufirst%3DS.%2BF.%26aulast%3DCurtis%26aufirst%3DC.%26aulast%3DRueda%26aufirst%3DO.%2BM.%26aulast%3DPharoah%26aufirst%3DP.%2BD.%26aulast%3DDamaraju%26aufirst%3DS.%26aulast%3DMackey%26aufirst%3DJ.%26aulast%3DHoon%26aufirst%3DK.%26aulast%3DHarkins%26aufirst%3DT.%26aulast%3DTadigotla%26aufirst%3DV.%26aulast%3DSigaroudinia%26aufirst%3DM.%26aulast%3DGascard%26aufirst%3DP.%26aulast%3DTlsty%26aufirst%3DT.%26aulast%3DCostello%26aufirst%3DJ.%2BF.%26aulast%3DMeyer%26aufirst%3DI.%2BM.%26aulast%3DEaves%26aufirst%3DC.%2BJ.%26aulast%3DWasserman%26aufirst%3DW.%2BW.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DHuntsman%26aufirst%3DD.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26aulast%3DAparicio%26aufirst%3DS.%26atitle%3DThe%2520clonal%2520and%2520mutational%2520evolution%2520spectrum%2520of%2520primary%2520triple-negative%2520breast%2520cancers%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7403%26spage%3D395%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span> </span><span class="NLM_article-title">Tackling the diversity of triple-negative breast cancer</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">6380</span><span class="NLM_x">–</span> <span class="NLM_lpage">6388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1078-0432.CCR-13-0915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=24298068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOitb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6380-6388&issue=23&author=N.+C.+Turnerauthor=J.+S.+Reis-Filho&title=Tackling+the+diversity+of+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tackling the Diversity of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Turner, Nicholas C.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6380-6388</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) comprises a highly diverse collection of cancers.  Here, we review this diversity both in terms of gene expression subtypes and the repertoire of genetic events.  Transcriptomic analyses of TNBC have revealed at least six subtypes, with the luminal androgen receptor (luminal AR) or mol. apocrine cancers forming a distinct group within triple-neg. disease.  Distinct from the gene expression subtypes, a diverse set of genetic events have been described in TNBC, with a no. of potentially targetable genetic events found although all at relatively low frequency.  Clin. trials to define the clin. utility of therapies targeting these low-frequency events will require substantial screening efforts to identify sufficient patients.  Set against the diversity of TNBC, clin. studies of patients with triple-neg. disease will need to be either focused on molecularly defined subsets with upfront mol. stratification, or powered for a secondary endpoint anal. of a molecularly defined subset.  Such approaches will be crucial to realize the potential of precision medicine for patients with TNBCs.  Clin Cancer Res; 19(23); 6380-8. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBocxyXfUNR7Vg90H21EOLACvtfcHk0liFJRXC9OOscQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOitb7K&md5=c04fa1217cdcbef4d75f6ec845cbe401</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0915%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTackling%2520the%2520diversity%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2013%26volume%3D19%26issue%3D23%26spage%3D6380%26epage%3D6388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Tryfonopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corkery, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, M. J.</span><span> </span><span class="NLM_article-title">Src: a potential target for the treatment of triple-negative breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2234</span><span class="NLM_x">–</span> <span class="NLM_lpage">2240</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1093%2Fannonc%2Fmdq757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21357651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A280%3ADC%252BC3MflvFCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2234-2240&issue=10&author=D.+Tryfonopoulosauthor=S.+Walshauthor=D.+M.+Collinsauthor=L.+Flanaganauthor=C.+Quinnauthor=B.+Corkeryauthor=E.+W.+McDermottauthor=D.+Evoyauthor=A.+Pierceauthor=N.+O%E2%80%99Donovanauthor=J.+Crownauthor=M.+J.+Duffy&title=Src%3A+a+potential+target+for+the+treatment+of+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Src: a potential target for the treatment of triple-negative breast cancer</span></div><div class="casAuthors">Tryfonopoulos D; Walsh S; Collins D M; Flanagan L; Quinn C; Corkery B; McDermott E W; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy M J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2234-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancers lack expression of estrogen and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2).  Unlike other subgroups of patients with breast cancer, targeted therapy is currently unavailable for these patients.  The aim of this study was to investigate v-src sarcoma viral oncogene homolog (Src) as a potential target for the treatment of triple-negative breast cancer.  METHODS:  Expression of Src was measured in 87 triple-negative and 93 non-triple-negative breast cancers.  Dasatinib (an inhibitor of Src) was tested in a panel of breast cancer cell lines.  RESULTS:  Cytoplasmic expression of Src was detected in 83 (95%) triple-negative samples versus 78 (84%) non-triple-negative samples (P = 0.012), while membrane Src was detected in 78% triple-negative compared with 38% of non-triple-negative specimens (P < 0.0001).  Dasatinib inhibited growth in three of five triple-negative cell lines (IC(50) < 1 μM).  Dasatinib combined with cisplatin was synergistic in the three dasatinib-sensitive cell lines (combination index < 0.9).  Dasatinib, in combination with 5'-deoxy-5'-fluoruridine, displayed synergy or additivity.  Moderate synergy was observed with docetaxel (Taxotere) in two cell lines but the combination was antagonistic in HCC-1143 cells.  CONCLUSIONS:  We conclude that dasatinib with cisplatin is a rational drug combination for testing in triple-negative breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRLX-5M5TiggxyojvcjibhfW6udTcc2eYGf5popXWpbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MflvFCqsQ%253D%253D&md5=f91860cdb5da0f86ff6e0ef46eb3ff2f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq757%26sid%3Dliteratum%253Aachs%26aulast%3DTryfonopoulos%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DS.%26aulast%3DCollins%26aufirst%3DD.%2BM.%26aulast%3DFlanagan%26aufirst%3DL.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DCorkery%26aufirst%3DB.%26aulast%3DMcDermott%26aufirst%3DE.%2BW.%26aulast%3DEvoy%26aufirst%3DD.%26aulast%3DPierce%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26atitle%3DSrc%253A%2520a%2520potential%2520target%2520for%2520the%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26issue%3D10%26spage%3D2234%26epage%3D2240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span> </span><span class="NLM_article-title">Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnm.2309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21399647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVGntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=461-469&issue=4&author=S.+Zhangauthor=W.+C.+Huangauthor=P.+Liauthor=H.+Guoauthor=S.+B.+Pohauthor=S.+W.+Bradyauthor=Y.+Xiongauthor=L.+M.+Tsengauthor=S.+H.+Liauthor=Z.+Dingauthor=A.+A.+Sahinauthor=F.+J.+Estevaauthor=G.+N.+Hortobagyiauthor=D.+Yu&title=Combating+trastuzumab+resistance+by+targeting+SRC%2C+a+common+node+downstream+of+multiple+resistance+pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways</span></div><div class="casAuthors">Zhang, Siyuan; Huang, Wen-Chien; Li, Ping; Guo, Hua; Poh, Say-Bee; Brady, Samuel W.; Xiong, Yan; Tseng, Ling-Ming; Li, Shau-Hsuan; Ding, Zhaoxi; Sahin, Aysegul A.; Esteva, Francisco J.; Hortobagyi, Gabriel N.; Yu, Dihua</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">461-469</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Trastuzumab is a successful rationally designed ERBB2-targeted therapy.  However, about half of individuals with ERBB2-overexpressing breast cancer do not respond to trastuzumab-based therapies, owing to various resistance mechanisms.  Clin. applicable regimens for overcoming trastuzumab resistance of different mechanisms are not yet available.  We show that the nonreceptor tyrosine kinase c-SRC (SRC) is a key modulator of trastuzumab response and a common node downstream of multiple trastuzumab resistance pathways.  We find that SRC is activated in both acquired and de novo trastuzumab-resistant cells and uncover a novel mechanism of SRC regulation involving dephosphorylation by PTEN.  Increased SRC activation conferred considerable trastuzumab resistance in breast cancer cells and correlated with trastuzumab resistance in patients.  Targeting SRC in combination with trastuzumab sensitized multiple lines of trastuzumab-resistant cells to trastuzumab and eliminated trastuzumab-resistant tumors in vivo, suggesting the potential clin. application of this strategy to overcome trastuzumab resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAglfHbddvf7Vg90H21EOLACvtfcHk0liFJRXC9OOscQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVGntb8%253D&md5=e316dee0106724d2c593358dae9c7801</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnm.2309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2309%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DPoh%26aufirst%3DS.%2BB.%26aulast%3DBrady%26aufirst%3DS.%2BW.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DTseng%26aufirst%3DL.%2BM.%26aulast%3DLi%26aufirst%3DS.%2BH.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DCombating%2520trastuzumab%2520resistance%2520by%2520targeting%2520SRC%252C%2520a%2520common%2520node%2520downstream%2520of%2520multiple%2520resistance%2520pathways%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26issue%3D4%26spage%3D461%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kim, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haura, E. B.</span><span> </span><span class="NLM_article-title">Src kinases as therapeutic targets for cancer</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">595</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnrclinonc.2009.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=19787002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=587-595&issue=10&author=L.+C.+Kimauthor=L.+Songauthor=E.+B.+Haura&title=Src+kinases+as+therapeutic+targets+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Src kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Kim, Lori C.; Song, Lanxi; Haura, Eric B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">587-595</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Src family kinases have been extensively studied and found to be central mediators in multiple signaling pathways that are important in oncogenesis.  Preclin. studies have shown that SFK inhibitors can suppress tumor growth and metastases.  The authors of this Review discuss the potential use of these agents to target cancer in humans.  Src family kinases (SFKs) have a crit. role in cell adhesion, invasion, proliferation, survival, and angiogenesis during tumor development.  SFKs comprise nine family members that share similar structure and function.  Overexpression or high activation of SFKs occurs frequently in tumor tissues and they are central mediators in multiple signaling pathways that are important in oncogenesis.  SFKs can interact with tyrosine kinase receptors, such as EGFR and the VEGF receptor.  SFKs can affect cell proliferation via the Ras/ERK/MAPK pathway and can regulate gene expression via transcription factors such as STAT mols.  SFKs can also affect cell adhesion and migration via interaction with integrins, actins, GTPase-activating proteins, scaffold proteins, such as p130CAS and paxillin, and kinases such as focal adhesion kinases.  Furthermore, SFKs can regulate angiogenesis via gene expression of angiogenic growth factors, such as fibroblast growth factor, VEGF, and interleukin 8.  On the basis of these important findings, small-mol. SFK inhibitors have been developed and are undergoing early phase clin. testing.  In preclin. studies these agents can suppress tumor growth and metastases.  The agents seem to be safe in humans and could add to the therapeutic arsenal against subsets of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mbcbDFh577Vg90H21EOLACvtfcHk0lj3sQp8En9U5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbP&md5=5e9e587e835265d1c83857be11411dba</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2009.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2009.129%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DL.%2BC.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26atitle%3DSrc%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D6%26issue%3D10%26spage%3D587%26epage%3D595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Wheeler, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, E. F.</span><span> </span><span class="NLM_article-title">The role of Src in solid tumors</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">678</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=667-678&issue=7&author=D.+L.+Wheelerauthor=M.+Iidaauthor=E.+F.+Dunn&title=The+role+of+Src+in+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DDunn%26aufirst%3DE.%2BF.%26atitle%3DThe%2520role%2520of%2520Src%2520in%2520solid%2520tumors%26jtitle%3DOncologist%26date%3D2009%26volume%3D14%26issue%3D7%26spage%3D667%26epage%3D678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Targeting Src in breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1379</span><span class="NLM_x">–</span> <span class="NLM_lpage">1386</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1093%2Fannonc%2Fmdn291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=18487549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A280%3ADC%252BD1cvotV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1379-1386&issue=8&author=R.+S.+Finn&title=Targeting+Src+in+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src in breast cancer</span></div><div class="casAuthors">Finn R S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1379-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The clinical benefit of blocking oncogenic pathways in breast cancer and other malignancies has validated this approach and ushered in the era of molecularly targeted therapeutics.  Src and its family members make up the largest group of nonreceptor tyrosine kinases.  In laboratory models, these proteins have been shown to play a critical role in cellular growth and proliferation, angiogenesis, and invasion and metastasis.  In addition, Src plays an important role in osteoclast activation and bone resorption, which are often aberrantly activated in the setting of bone metastases.  Given its role in these functions, blocking Src kinase would be predicted to have a broad therapeutic benefit in patients with Src-dependent cancers.  In this review, we highlight the rationale for targeting Src in breast cancer, including laboratory and clinical data implicating it in these signaling pathways, and review small-molecule tyrosine kinase inhibitors currently in clinical development.  Identifying which patients should be selected for Src-directed therapies will be important to the clinical success of these agents.  Importantly, recent preclinical data support a role for this class of inhibitors in basal-type/triple-negative breast cancer, which represents a group of patients with limited effective treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSq3-Zi9cm6LUNHe_gFldTbfW6udTcc2eZtoZJtciuJR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvotV2rsw%253D%253D&md5=b4f29b2ada4dcb6c89c0301a8440c617</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdn291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdn291%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DTargeting%2520Src%2520in%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2008%26volume%3D19%26issue%3D8%26spage%3D1379%26epage%3D1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Shields, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiede, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurzov, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiganis, T.</span><span> </span><span class="NLM_article-title">TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1128%2FMCB.01016-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=23166300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=557-570&issue=3&author=B.+J.+Shieldsauthor=F.+Wiedeauthor=E.+N.+Gurzovauthor=K.+Weeauthor=C.+Hauserauthor=H.+J.+Zhuauthor=T.+J.+Molloyauthor=S.+A.+O%E2%80%99Tooleauthor=R.+J.+Dalyauthor=R.+L.+Sutherlandauthor=C.+A.+Mitchellauthor=C.+A.+McLeanauthor=T.+Tiganis&title=TCPTP+regulates+SFK+and+STAT3+signaling+and+is+lost+in+triple-negative+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers</span></div><div class="casAuthors">Shields, Benjamin J.; Wiede, Florian; Gurzov, Esteban N.; Wee, Kenneth; Hauser, Christine; Zhu, Hong-Jian; Molloy, Timothy J.; O'Toole, Sandra A.; Daly, Roger J.; Sutherland, Robert L.; Mitchell, Christina A.; McLean, Catriona A.; Tiganis, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">557-570</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tyrosine phosphorylation-dependent signaling, as mediated by members of the epidermal growth factor receptor (EGFR) family (ErbB1 to -4) of protein tyrosine kinases (PTKs), Src family PTKs (SFKs), and cytokines such as interleukin-6 (IL-6) that signal via signal transducer and activator of transcription 3 (STAT3), is crit. to the development and progression of many human breast cancers.  EGFR, SFKs, and STAT3 can serve as substrates for the protein tyrosine phosphatase TCPTP (PTPN2).  Here we report that TCPTP protein levels are decreased in a subset of breast cancer cell lines in vitro and that TCPTP protein is absent in a large proportion of "triple-neg." primary human breast cancers.  Homozygous TCPTP deficiency in murine mammary fat pads in vivo is assocd. with elevated SFK and STAT3 signaling, whereas TCPTP deficiency in human breast cancer cell lines enhances SFK and STAT3 signaling.  On the other hand, TCPTP reconstitution in human breast cancer cell lines severely impaired cell proliferation and suppressed anchorage-independent growth in vitro and xenograft growth in vivo.  These studies establish TCPTP's potential to serve as a tumor suppressor in human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKrzpgI9BYrVg90H21EOLACvtfcHk0lj3sQp8En9U5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOitL0%253D&md5=82593972a2f8ee8979199c2d10903114</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FMCB.01016-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01016-12%26sid%3Dliteratum%253Aachs%26aulast%3DShields%26aufirst%3DB.%2BJ.%26aulast%3DWiede%26aufirst%3DF.%26aulast%3DGurzov%26aufirst%3DE.%2BN.%26aulast%3DWee%26aufirst%3DK.%26aulast%3DHauser%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DH.%2BJ.%26aulast%3DMolloy%26aufirst%3DT.%2BJ.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DS.%2BA.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DMitchell%26aufirst%3DC.%2BA.%26aulast%3DMcLean%26aufirst%3DC.%2BA.%26aulast%3DTiganis%26aufirst%3DT.%26atitle%3DTCPTP%2520regulates%2520SFK%2520and%2520STAT3%2520signaling%2520and%2520is%2520lost%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2013%26volume%3D33%26issue%3D3%26spage%3D557%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hochgrafe, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browne, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta Cubas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehrbach, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croucher, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickwood, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulghourjian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shearer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swarbrick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faratian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biankin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raftery, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span> </span><span class="NLM_article-title">Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">9391</span><span class="NLM_x">–</span> <span class="NLM_lpage">9401</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=9391-9401&issue=22&author=F.+Hochgrafeauthor=L.+Zhangauthor=S.+A.+O%E2%80%99Tooleauthor=B.+C.+Browneauthor=M.+Pineseauthor=A.+Porta+Cubasauthor=G.+M.+Lehrbachauthor=D.+R.+Croucherauthor=D.+Rickwoodauthor=A.+Boulghourjianauthor=R.+Shearerauthor=R.+Nairauthor=A.+Swarbrickauthor=D.+Faratianauthor=P.+Mullenauthor=D.+J.+Harrisonauthor=A.+V.+Biankinauthor=R.+L.+Sutherlandauthor=M.+J.+Rafteryauthor=R.+J.+Daly&title=Tyrosine+phosphorylation+profiling+reveals+the+signaling+network+characteristics+of+Basal+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHochgrafe%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DS.%2BA.%26aulast%3DBrowne%26aufirst%3DB.%2BC.%26aulast%3DPinese%26aufirst%3DM.%26aulast%3DPorta%2BCubas%26aufirst%3DA.%26aulast%3DLehrbach%26aufirst%3DG.%2BM.%26aulast%3DCroucher%26aufirst%3DD.%2BR.%26aulast%3DRickwood%26aufirst%3DD.%26aulast%3DBoulghourjian%26aufirst%3DA.%26aulast%3DShearer%26aufirst%3DR.%26aulast%3DNair%26aufirst%3DR.%26aulast%3DSwarbrick%26aufirst%3DA.%26aulast%3DFaratian%26aufirst%3DD.%26aulast%3DMullen%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DD.%2BJ.%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DRaftery%26aufirst%3DM.%2BJ.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DTyrosine%2520phosphorylation%2520profiling%2520reveals%2520the%2520signaling%2520network%2520characteristics%2520of%2520Basal%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26issue%3D22%26spage%3D9391%26epage%3D9401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowery, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span> </span><span class="NLM_article-title">SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">5764</span><span class="NLM_x">–</span> <span class="NLM_lpage">5774</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=5764-5774&issue=18&author=S.+Zhangauthor=W.+C.+Huangauthor=L.+Zhangauthor=C.+Zhangauthor=F.+J.+Loweryauthor=Z.+Dingauthor=H.+Guoauthor=H.+Wangauthor=S.+Huangauthor=A.+A.+Sahinauthor=K.+D.+Aldapeauthor=P.+S.+Steegauthor=D.+Yu&title=SRC+family+kinases+as+novel+therapeutic+targets+to+treat+breast+cancer+brain+metastases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLowery%26aufirst%3DF.%2BJ.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DSRC%2520family%2520kinases%2520as%2520novel%2520therapeutic%2520targets%2520to%2520treat%2520breast%2520cancer%2520brain%2520metastases%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D18%26spage%3D5764%26epage%3D5774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Park, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whichard, Z. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, S. J.</span><span> </span><span class="NLM_article-title">Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines—Lessons for design of combination targeted therapy</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1016%2Fj.canlet.2012.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22306341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFKntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2012&pages=104-110&issue=1&author=B.+J.+Parkauthor=Z.+L.+Whichardauthor=S.+J.+Corey&title=Dasatinib+synergizes+with+both+cytotoxic+and+signal+transduction+inhibitors+in+heterogeneous+breast+cancer+cell+lines%E2%80%94Lessons+for+design+of+combination+targeted+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines - Lessons for design of combination targeted therapy</span></div><div class="casAuthors">Park, Brian J.; Whichard, Zakary L.; Corey, Seth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-110</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics.  Multi-cytotoxic drug regimens have been highly successful, yet many studies in targeted therapeutics have centered on a single agent.  We investigated whether the Src/Abl kinase inhibitor dasatinib displays synergy with other agents in molecularly heterogeneous breast cancer cell lines.  MCF-7, SKBR-3, and MDA-MB-231 display different signaling and gene signatures profiles due to expression of the estrogen receptor, ErbB2, or neither.  Cell proliferation was measured following treatment with dasatinib ± cytotoxic (paclitaxel, ixabepilone) or molecularly targeted agents (tamoxifen, rapamycin, sorafenib, pan PI3K inhibitor LY294002, and MEK/ERK inhibitor U0126).  Dose-responses for single or combination drugs were calcd. and analyzed by the Chou-Talalay method.  The drugs with the greatest level of synergy with dasatinib were rapamycin, ixabepilone, and sorafenib, for the MDA-MB-231, MCF-7, and SK-BR-3 cell lines resp.  However, dasatinib synergized with both cytotoxic and molecularly targeted agents in all three molecularly heterogeneous breast cancer cell lines.  These results suggest that effectiveness of rationally designed therapies may not entirely rest on precise identification of gene signatures or mol. profiling.  Since a systems anal. that reveals emergent properties cannot be easily performed for each cancer case, multi-drug regimens in the near future will still involve empirical design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzrsz8f_BOQrVg90H21EOLACvtfcHk0liChM8-y8Y86Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFKntLw%253D&md5=6c054ce2f8e86d62408010357619be71</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BJ.%26aulast%3DWhichard%26aufirst%3DZ.%2BL.%26aulast%3DCorey%26aufirst%3DS.%2BJ.%26atitle%3DDasatinib%2520synergizes%2520with%2520both%2520cytotoxic%2520and%2520signal%2520transduction%2520inhibitors%2520in%2520heterogeneous%2520breast%2520cancer%2520cell%2520lines%25E2%2580%2594Lessons%2520for%2520design%2520of%2520combination%2520targeted%2520therapy%26jtitle%3DCancer%2520Lett.%26date%3D2012%26volume%3D320%26issue%3D1%26spage%3D104%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Duffy, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span> </span><span class="NLM_article-title">Targeted therapy for triple-negative breast cancer: Where are we?</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2471</span><span class="NLM_x">–</span> <span class="NLM_lpage">2477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1002%2Fijc.27632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22581656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFKmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2012&pages=2471-2477&issue=11&author=M.+J.+Duffyauthor=P.+M.+McGowanauthor=J.+Crown&title=Targeted+therapy+for+triple-negative+breast+cancer%3A+Where+are+we%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for triple-negative breast cancer: Where are we?</span></div><div class="casAuthors">Duffy, Michael J.; McGowan, Patricia M.; Crown, John</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2471-2477</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Breast cancers that are neg. for estrogen receptor (ER), progesterone receptors (PR) and HER2, using std. clin. assays, have been dubbed triple-neg. (TN).  Unlike other mol. subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer.  Preclin. studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2).  Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer.  The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnmJkW7zwQsbVg90H21EOLACvtfcHk0liChM8-y8Y86Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFKmurg%253D&md5=3e09cb2672f68bc17b80bbc17253f039</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fijc.27632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27632%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DMcGowan%26aufirst%3DP.%2BM.%26aulast%3DCrown%26aufirst%3DJ.%26atitle%3DTargeted%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%253A%2520Where%2520are%2520we%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D131%26issue%3D11%26spage%3D2471%26epage%3D2477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaspy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchekmedyian, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1007%2Fs10549-006-9463-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=17268817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSlsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2007&pages=319-326&issue=3&author=R.+S.+Finnauthor=J.+Deringauthor=C.+Gintherauthor=C.+A.+Wilsonauthor=P.+Glaspyauthor=N.+Tchekmedyianauthor=D.+J.+Slamon&title=Dasatinib%2C+an+orally+active+small+molecule+inhibitor+of+both+the+src+and+abl+kinases%2C+selectively+inhibits+growth+of+basal-type%2F%E2%80%9Ctriple-negative%E2%80%9D+breast+cancer+cell+lines+growing+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro</span></div><div class="casAuthors">Finn, Richard S.; Dering, Judy; Ginther, Charles; Wilson, Cindy A.; Glaspy, Padraic; Tchekmedyian, Nishan; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Dasatinib is an orally active small mol. kinase inhibitor of both the src and abl proteins.  To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer cell lines that have been mol. profiled using Agilent Microarrays.  They represent both luminal and basal breast cancer subtypes based on the relative gene expression of cytokeratin (CK) 8/CK18 and CK5/CK17, resp., and those that have undergone an epithelial-to-mesenchymal transition (post-EMT) based on their expression of vimentin and the loss of CKs.  When treated with 1 μM dasatinib in vitro 8 of them were highly sensitive (>60% growth inhibition), 10 of them were moderately sensitive (40-59% growth inhibition), and 21 were resistant to dasatinib.  A highly significant relationship between breast cancer subtype and sensitivity to dasatinib was obsd. (χ2 = 9.66 and P = 0.008).  Specifically, basal-type and post-EMT breast cancer cell lines were most sensitive to growth inhibition by dasatinib.  In an attempt to identify potential predictive markers of dasatinib response other than breast cancer subtype we analyzed the baseline gene expression profiles for differentially expressed genes.  We identified a set of three biol. relevant genes whose elevated expression is assocd. with dasatinib inhibition including moesin, caveolin-1, and yes-assocd. protein-1 with a sensitivity and specificity of 88 and 86%, resp.  Importantly, these data provide scientific rationale for the clin. development of dasatinib in the treatment of women with "triple-neg." breast cancer, a subtype that is categorized as being aggressive and lacking effective treatments (i.e. hormonal manipulation or trastuzumab).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuiY_J2m5UELVg90H21EOLACvtfcHk0ljWPLgmRsWC-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSlsr3N&md5=82beaf55532a0440f64e215ec57df02e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs10549-006-9463-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-006-9463-x%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DC.%2BA.%26aulast%3DGlaspy%26aufirst%3DP.%26aulast%3DTchekmedyian%26aufirst%3DN.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DDasatinib%252C%2520an%2520orally%2520active%2520small%2520molecule%2520inhibitor%2520of%2520both%2520the%2520src%2520and%2520abl%2520kinases%252C%2520selectively%2520inhibits%2520growth%2520of%2520basal-type%252F%25E2%2580%259Ctriple-negative%25E2%2580%259D%2520breast%2520cancer%2520cell%2520lines%2520growing%2520in%2520vitro%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2007%26volume%3D105%26issue%3D3%26spage%3D319%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">El Touny, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenerhoff, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J. E.</span><span> </span><span class="NLM_article-title">Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=156-168&issue=1&author=L.+H.+El+Tounyauthor=A.+Vieiraauthor=A.+Mendozaauthor=C.+Khannaauthor=M.+J.+Hoenerhoffauthor=J.+E.+Green&title=Combined+SFK%2FMEK+inhibition+prevents+metastatic+outgrowth+of+dormant+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BTouny%26aufirst%3DL.%2BH.%26aulast%3DVieira%26aufirst%3DA.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DKhanna%26aufirst%3DC.%26aulast%3DHoenerhoff%26aufirst%3DM.%2BJ.%26aulast%3DGreen%26aufirst%3DJ.%2BE.%26atitle%3DCombined%2520SFK%252FMEK%2520inhibition%2520prevents%2520metastatic%2520outgrowth%2520of%2520dormant%2520tumor%2520cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26issue%3D1%26spage%3D156%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Bianchi-Smiraglia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paesante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakin, A. V.</span><span> </span><span class="NLM_article-title">Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">25</span><span class="NLM_x">) </span> <span class="NLM_fpage">3049</span><span class="NLM_x">–</span> <span class="NLM_lpage">3058</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=3049-3058&issue=25&author=A.+Bianchi-Smiragliaauthor=S.+Paesanteauthor=A.+V.+Bakin&title=Integrin+beta5+contributes+to+the+tumorigenic+potential+of+breast+cancer+cells+through+the+Src-FAK+and+MEK-ERK+signaling+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi-Smiraglia%26aufirst%3DA.%26aulast%3DPaesante%26aufirst%3DS.%26aulast%3DBakin%26aufirst%3DA.%2BV.%26atitle%3DIntegrin%2520beta5%2520contributes%2520to%2520the%2520tumorigenic%2520potential%2520of%2520breast%2520cancer%2520cells%2520through%2520the%2520Src-FAK%2520and%2520MEK-ERK%2520signaling%2520pathways%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26issue%3D25%26spage%3D3049%26epage%3D3058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&issue=23&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26issue%3D23%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterbein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plé, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, G.</span><span> </span><span class="NLM_article-title"><i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">6465</span><span class="NLM_x">–</span> <span class="NLM_lpage">6488</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060434q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6465-6488&issue=22&author=L.+F.+Hennequinauthor=J.+Allenauthor=J.+Breedauthor=J.+Curwenauthor=M.+Fennellauthor=T.+P.+Greenauthor=C.+Lambert-van+der+Bremptauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Olivierauthor=L.+Otterbeinauthor=P.+A.+Pl%C3%A9author=N.+Warinauthor=G.+Costello&title=N-%285-Chloro-1%2C3-benzodioxol-4-yl%29-7-%5B2-%284-methylpiperazin-1-yl%29ethoxy%5D-5-%28tetrahydro-2H-pyran-4-yloxy%29quinazolin-4-amine%2C+a+novel%2C+highly+selective%2C+orally+available%2C+dual-specific+c-Src%2FAbl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm060434q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060434q%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DOtterbein%26aufirst%3DL.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%2BA.%26aulast%3DWarin%26aufirst%3DN.%26aulast%3DCostello%26aufirst%3DG.%26atitle%3DN-%25285-Chloro-1%252C3-benzodioxol-4-yl%2529-7-%255B2-%25284-methylpiperazin-1-yl%2529ethoxy%255D-5-%2528tetrahydro-2H-pyran-4-yloxy%2529quinazolin-4-amine%252C%2520a%2520novel%252C%2520highly%2520selective%252C%2520orally%2520available%252C%2520dual-specific%2520c-Src%252FAbl%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D22%26spage%3D6465%26epage%3D6488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Ma, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L. H.</span><span> </span><span class="NLM_article-title">PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1007%2Fs10549-010-1302-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21181437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Giu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=85-96&issue=1&author=J.+G.+Maauthor=H.+Huangauthor=S.+M.+Chenauthor=Y.+Chenauthor=X.+L.+Xinauthor=L.+P.+Linauthor=J.+Dingauthor=H.+Liuauthor=L.+H.+Meng&title=PH006%2C+a+novel+and+selective+Src+kinase+inhibitor%2C+suppresses+human+breast+cancer+growth+and+metastasis+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo</span></div><div class="casAuthors">Ma, Jin-gui; Huang, He; Chen, Si-meng; Chen, Yi; Xin, Xian-liang; Lin, Li-ping; Ding, Jian; Liu, Hong; Meng, Ling-hua</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-96</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The central role of Src in tumor progression and metastasis has validated it as an attractive therapeutic target for the treatment of human breast cancer.  The aim of this study was to identify potential Src kinase inhibitor, explore its activity, and mechanism of action in human breast cancer.  A strategy integrating focused combinatorial library design, virtual screening, chem. synthesis, and high-throughput screening was adopted and a novel 6-hydrazinopurine-based inhibitor of c-Src kinase PH006 was obtained.  The kinase enzymic activities were measured by ELISA.  The binding mode between PH006 and Src was profiled by surface plasmon resonance approach and mol. simulation.  The anti-proliferative activity was evaluated by Sulforhodamin B (SRB) and Colony formation.  The anti-invasion and anti-migration activities were assessed by trans-well and wound healing assay.  Results indicated that PH006 was an ATP-competitive Src inhibitor, which selectively inhibited c-Src with an IC50 of 0.38 μM among a panel of 14 diverse tyrosine kinases.  PH006 potently inhibited c-Src phosphorylation and c-Src-dependent signal transduction, resulting in inhibition of cell proliferation, migration, and invasion in human breast cancer MDA-MB-231 cells.  Further study demonstrated that the anti-proliferative activity of PH006 was ascribed to its capability to arrest cells in G1 phase, while its anti-motility activity was related to suppression of MMP2/9 and HGF secretion.  Moreover, PH006 exhibited potent activity against tumor growth as well as metastasis of human breast cancer MDA-MB-435 xenograft beard in nude mice, which was accompanied with reduced Src/FAK signaling in tumor tissue.  Taken together, PH006 is a novel selective inhibitor of c-Src and possesses potent activity against breast cancer growth and metastasis, which could be potentially developed as a lead candidate against breast cancers with elevated Src tyrosine kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM46C77SEoerVg90H21EOLACvtfcHk0lghHyGBdrLB6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Giu7zF&md5=a63e1fa2dea525912df79df32fd93243</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs10549-010-1302-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-010-1302-4%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%2BG.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXin%26aufirst%3DX.%2BL.%26aulast%3DLin%26aufirst%3DL.%2BP.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMeng%26aufirst%3DL.%2BH.%26atitle%3DPH006%252C%2520a%2520novel%2520and%2520selective%2520Src%2520kinase%2520inhibitor%252C%2520suppresses%2520human%2520breast%2520cancer%2520growth%2520and%2520metastasis%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D130%26issue%3D1%26spage%3D85%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kwarcinski, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffey, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soellner, M. B.</span><span> </span><span class="NLM_article-title">Irreversible Inhibitors of c-Src kinase that target a nonconserved cysteine</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1910</span><span class="NLM_x">–</span> <span class="NLM_lpage">1917</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb300337u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1910-1917&issue=11&author=F.+E.+Kwarcinskiauthor=C.+C.+Foxauthor=M.+E.+Steffeyauthor=M.+B.+Soellner&title=Irreversible+Inhibitors+of+c-Src+kinase+that+target+a+nonconserved+cysteine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb300337u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300337u%26sid%3Dliteratum%253Aachs%26aulast%3DKwarcinski%26aufirst%3DF.%2BE.%26aulast%3DFox%26aufirst%3DC.%2BC.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DIrreversible%2520Inhibitors%2520of%2520c-Src%2520kinase%2520that%2520target%2520a%2520nonconserved%2520cysteine%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26issue%3D11%26spage%3D1910%26epage%3D1917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Gushwa, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Selective targeting of distinct active site nucleophiles by irreversible Src-family kinase inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x"> (</span><span class="NLM_issue">50</span><span class="NLM_x">) </span> <span class="NLM_fpage">20214</span><span class="NLM_x">–</span> <span class="NLM_lpage">20217</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja310659j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=20214-20217&issue=50&author=N.+N.+Gushwaauthor=S.+Kangauthor=J.+Chenauthor=J.+Taunton&title=Selective+targeting+of+distinct+active+site+nucleophiles+by+irreversible+Src-family+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja310659j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja310659j%26sid%3Dliteratum%253Aachs%26aulast%3DGushwa%26aufirst%3DN.%2BN.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DSelective%2520targeting%2520of%2520distinct%2520active%2520site%2520nucleophiles%2520by%2520irreversible%2520Src-family%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26issue%3D50%26spage%3D20214%26epage%3D20217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Anbalagan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glodowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hangauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, B.</span><span> </span><span class="NLM_article-title">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1007%2Fs10549-011-1513-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21509526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=391-409&issue=2&author=M.+Anbalaganauthor=L.+Carrierauthor=S.+Glodowskiauthor=D.+Hangauerauthor=B.+Shanauthor=B.+Rowan&title=KX-01%2C+a+novel+Src+kinase+inhibitor+directed+toward+the+peptide+substrate+site%2C+synergizes+with+tamoxifen+in+estrogen+receptor+%CE%B1+positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span></div><div class="casAuthors">Anbalagan, Muralidharan; Carrier, Latonya; Glodowski, Seth; Hangauer, David; Shan, Bin; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-409</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX-01 is the first clin. Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward Src kinase.  The present study was designed to evaluate the effects of KX-01 as a single agent and in combination with tamoxifen (TAM) on cell growth and apoptosis of ERα pos. breast cancer in vitro and in vivo.  Flow cytometry demonstrated that KX-01 induced cell cycle arrest in G2/M phase.  Immunofluorescent staining for mitotic phase markers and TUNEL staining indicated that cells had arrested in the mitotic phase and mitotic arrested cells were undergoing apoptosis.  KX-01 induced nuclear accumulation of cyclin B1, and activation of CDK1, MPM2, and Cdc25C that is required for progression past the G2/M checkpoint.  Apoptosis resulted from activation of caspases 6, 7, 8, and 9.  Combinational index anal. revealed that combinations of KX-01 with TAM resulted in synergistic growth inhibition of breast cancer cell lines.  KX-01 combined with TAM resulted in decreased ERα phosphorylation at Src-regulated phosphorylation sites serines 118 and 167 that were assocd. with reduced ERα transcriptional activity.  Orally administered KX-01 resulted in a dose dependent growth inhibition of MCF-7 tumor xenografts, and in combination with TAM exhibited synergistic growth inhibition.  Immunohistochem. anal. revealed that combinational treatment reduced angiogenesis, and ERα signaling in tumors compared to either drug alone that may underlie the synergistic tumor growth inhibition.  Combinations of KX-01 with endocrine therapy present a promising new strategy for clin. management of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDjBSgfh5qJbVg90H21EOLACvtfcHk0lh9GLYAROTeyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D&md5=e55cc94c076cfd5f38a715c4b55b15dd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1513-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1513-3%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DGlodowski%26aufirst%3DS.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DRowan%26aufirst%3DB.%26atitle%3DKX-01%252C%2520a%2520novel%2520Src%2520kinase%2520inhibitor%2520directed%2520toward%2520the%2520peptide%2520substrate%2520site%252C%2520synergizes%2520with%2520tamoxifen%2520in%2520estrogen%2520receptor%2520%25CE%25B1%2520positive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D132%26issue%3D2%26spage%3D391%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fex, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">2-Aminothiazole as a novel kinase inhibitor template. Structure–activity relationship studies toward the discovery of <i>N</i>-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">6819</span><span class="NLM_x">–</span> <span class="NLM_lpage">6832</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&issue=23&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-Aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure%E2%80%93activity+relationship+studies+toward+the+discovery+of+N-%282-chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-Aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure%25E2%2580%2593activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D23%26spage%3D6819%26epage%3D6832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengala, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sy, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, L. J.</span><span> </span><span class="NLM_article-title">Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">6905</span><span class="NLM_x">–</span> <span class="NLM_lpage">6913</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1078-0432.CCR-11-0288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22028489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6905-6913&issue=21&author=R.+S.+Finnauthor=C.+Bengalaauthor=N.+Ibrahimauthor=H.+Rocheauthor=J.+Sparanoauthor=L.+C.+Straussauthor=J.+Fairchildauthor=O.+Syauthor=L.+J.+Goldstein&title=Dasatinib+as+a+single+agent+in+triple-negative+breast+cancer%3A+results+of+an+open-label+phase+2+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study</span></div><div class="casAuthors">Finn, Richard S.; Bengala, Carmelo; Ibrahim, Nuhad; Roche, Henri; Sparano, Joseph; Strauss, Lewis C.; Fairchild, Justin; Sy, Oumar; Goldstein, Lori J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6905-6913</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclin. antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-neg., or basal-like, breast cancer cell lines.  This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-neg. breast cancer (TNBC).  Exptl. Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID.  Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics.  RESULTS: Of the 44 treated patients, 43 were response evaluable.  ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 wk, resp.  Of 11 patients with stable disease, two continued for more than 16 wk, thus protocol-defined DCR was 9.3%.  Median PFS was 8.3 wk (95% CI: 7.3-15.3).  Five patients discontinued before first tumor assessment.  No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5% of patients were fatigue (9.1%), diarrhea, pleural effusion, and dyspnea (all 6.8%).  Lab. abnormalities were uncommon.  Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose redn., and serious AEs were lower with dasatinib 70 mg BID.  CONCLUSIONS: Single-agent dasatinib has limited activity in unselected patients with TNBC.  Dasatinib 70 mg BID was better tolerated than 100 mg BID.  Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.  Clin Cancer Res; 17(21); 6905-13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1kTbssh-wALVg90H21EOLACvtfcHk0lh9GLYAROTeyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzE&md5=a9133015486c0f5d61a2b6cc33ab7e53</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0288%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DBengala%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DRoche%26aufirst%3DH.%26aulast%3DSparano%26aufirst%3DJ.%26aulast%3DStrauss%26aufirst%3DL.%2BC.%26aulast%3DFairchild%26aufirst%3DJ.%26aulast%3DSy%26aufirst%3DO.%26aulast%3DGoldstein%26aufirst%3DL.%2BJ.%26atitle%3DDasatinib%2520as%2520a%2520single%2520agent%2520in%2520triple-negative%2520breast%2520cancer%253A%2520results%2520of%2520an%2520open-label%2520phase%25202%2520study%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2011%26volume%3D17%26issue%3D21%26spage%3D6905%26epage%3D6913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">4701</span><span class="NLM_x">–</span> <span class="NLM_lpage">4719</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&issue=12&author=W.+S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-yl%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-Abelson+%28BCR-ABL%29+kinase+including+the+T315I+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-Abelson%2520%2528BCR-ABL%2529%2520kinase%2520including%2520the%2520T315I%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D12%26spage%3D4701%26epage%3D4719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&issue=7&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0li57JnKn3isQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D7%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span>GOLD, version <span class="NLM_edition">5.0</span>; <span class="NLM_publisher-name">Cambridge Crystallographic Data Centre</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=GOLD%2C+version+5.0%3B+Cambridge+Crystallographic+Data+Centre%3A+Cambridge%2C+U.K."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGOLD%26pub%3DCambridge%2520Crystallographic%2520Data%2520Centre" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301581y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=879-894&issue=3&author=X.+Renauthor=X.+Panauthor=Z.+Zhangauthor=D.+Wangauthor=X.+Luauthor=Y.+Liauthor=D.+Wenauthor=H.+Longauthor=J.+Luoauthor=Y.+Fengauthor=X.+Zhuangauthor=F.+Zhangauthor=J.+Liuauthor=F.+Lengauthor=X.+Langauthor=Y.+Baiauthor=M.+Sheauthor=Z.+Tuauthor=J.+Panauthor=K.+Ding&title=Identification+of+GZD824+as+an+orally+bioavailable+inhibitor+that+targets+phosphorylated+and+nonphosphorylated+breakpoint+cluster+region-Abelson+%28Bcr-Abl%29+kinase+and+overcomes+clinically+acquired+mutation-induced+resistance+against+imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm301581y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301581y%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLeng%26aufirst%3DF.%26aulast%3DLang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DShe%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520GZD824%2520as%2520an%2520orally%2520bioavailable%2520inhibitor%2520that%2520targets%2520phosphorylated%2520and%2520nonphosphorylated%2520breakpoint%2520cluster%2520region-Abelson%2520%2528Bcr-Abl%2529%2520kinase%2520and%2520overcomes%2520clinically%2520acquired%2520mutation-induced%2520resistance%2520against%2520imatinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D3%26spage%3D879%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Balko, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuba, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhola, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granja-Ingram, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meszoely, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowsett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemke-Hale, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Angulo, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span> </span><span class="NLM_article-title">Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1052</span><span class="NLM_x">–</span> <span class="NLM_lpage">1059</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnm.2795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22683778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Chu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1052-1059&issue=7&author=J.+M.+Balkoauthor=R.+S.+Cookauthor=D.+B.+Vaughtauthor=M.+G.+Kubaauthor=T.+W.+Millerauthor=N.+E.+Bholaauthor=M.+E.+Sandersauthor=N.+M.+Granja-Ingramauthor=J.+J.+Smithauthor=I.+M.+Meszoelyauthor=J.+Salterauthor=M.+Dowsettauthor=K.+Stemke-Haleauthor=A.+M.+Gonzalez-Anguloauthor=G.+B.+Millsauthor=J.+A.+Pintoauthor=H.+L.+Gomezauthor=C.+L.+Arteaga&title=Profiling+of+residual+breast+cancers+after+neoadjuvant+chemotherapy+identifies+DUSP4+deficiency+as+a+mechanism+of+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance</span></div><div class="casAuthors">Balko, Justin M.; Cook, Rebecca S.; Vaught, David B.; Kuba, Maria G.; Miller, Todd W.; Bhola, Neil E.; Sanders, Melinda E.; Granja-Ingram, Nara M.; Smith, J. Joshua; Meszoely, Ingrid M.; Salter, Janine; Dowsett, Mitch; Stemke-Hale, Katherine; Gonzalez-Angulo, Ana M.; Mills, Gordon B.; Pinto, Joseph A.; Gomez, Henry L.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1052-1059</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neoadjuvant chemotherapy (NAC) induces a pathol. complete response (pCR) in ∼30% of patients with breast cancer.  However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR.  We hypothesized that mol. profiling of tumors after NAC would identify genes assocd. with drug resistance.  Digital transcript counting was used to profile surgically resected breast cancers after NAC.  Low concns. of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status.  BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes.  DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.  Reduced DUSP4 expression in primary tumors after NAC was assocd. with treatment-refractory high Ki-67 scores and shorter recurrence-free survival.  Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts.  Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6dt_kLh8G67Vg90H21EOLACvtfcHk0lgHLJExS-6z0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Chu70%253D&md5=8e547efaba292ce2cddafd8345038374</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnm.2795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2795%26sid%3Dliteratum%253Aachs%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DCook%26aufirst%3DR.%2BS.%26aulast%3DVaught%26aufirst%3DD.%2BB.%26aulast%3DKuba%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DT.%2BW.%26aulast%3DBhola%26aufirst%3DN.%2BE.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DGranja-Ingram%26aufirst%3DN.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DMeszoely%26aufirst%3DI.%2BM.%26aulast%3DSalter%26aufirst%3DJ.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DStemke-Hale%26aufirst%3DK.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DPinto%26aufirst%3DJ.%2BA.%26aulast%3DGomez%26aufirst%3DH.%2BL.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DProfiling%2520of%2520residual%2520breast%2520cancers%2520after%2520neoadjuvant%2520chemotherapy%2520identifies%2520DUSP4%2520deficiency%2520as%2520a%2520mechanism%2520of%2520drug%2520resistance%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26issue%3D7%26spage%3D1052%26epage%3D1059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Giltnane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balko, J. M.</span><span> </span><span class="NLM_article-title">Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer</span> <span class="citation_source-journal">Discovery Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">95</span><span class="NLM_x">) </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=275-283&issue=95&author=J.+M.+Giltnaneauthor=J.+M.+Balko&title=Rationale+for+targeting+the+Ras%2FMAPK+pathway+in+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26atitle%3DRationale%2520for%2520targeting%2520the%2520Ras%252FMAPK%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DDiscovery%2520Med.%26date%3D2014%26volume%3D17%26issue%3D95%26spage%3D275%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">952</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1535-7163.MCT-11-0679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22319204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=952-962&issue=4&author=Y.+Panauthor=Y.+Xuauthor=S.+Fengauthor=S.+Luoauthor=R.+Zhengauthor=J.+Yangauthor=L.+Wangauthor=L.+Zhongauthor=H.+Y.+Yangauthor=B.+L.+Wangauthor=Y.+Yuauthor=J.+Liuauthor=Z.+Caoauthor=X.+Wangauthor=P.+Jiauthor=Z.+Wangauthor=X.+Chenauthor=S.+Zhangauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=SKLB1206%2C+a+novel+orally+available+multikinase+inhibitor+targeting+EGFR+activating+and+T790M+mutants%2C+ErbB2%2C+ErbB4%2C+and+VEGFR2%2C+displays+potent+antitumor+activity+both+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo</span></div><div class="casAuthors">Pan, Youli; Xu, Yong; Feng, Shan; Luo, Shidong; Zheng, Renlin; Yang, Jiao; Wang, Lijiao; Zhong, Lei; Yang, Han-Yu; Wang, Bing-Lin; Yu, Yang; Liu, Jingjing; Cao, Zhixing; Wang, Xiaoyan; Ji, Pan; Wang, Zerong; Chen, Xin; Zhang, Shuang; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">952-962</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-epidermal growth factor receptor (EGFR) treatment has been successfully applied in clin. cancer therapy.  However, the clin. efficacy of first-generation reversible EGFR inhibitors, such as gefitinib and erlotinib, is limited by the development of drug-resistant mutations, including the gatekeeper T790M mutation and upregulation of alternative signaling pathways.  Second-generation irreversible EGFR inhibitors that were designed to overcome the drug resistance due to the T790M mutation have thus far had limited success.  Here, we report a novel reversible EGFR inhibitor, SKLB1206, which has potent activity against EGFR with gefitinib-sensitive and -resistant (T790M) mutations.  In addn., SKLB1206 has also considerable inhibition potency against some other related oncokinases, including ErbB2, ErbB4, and VEGF receptor 2 (VEGFR2).  SKLB1206 exhibited highly antiproliferative activity against a range of EGFR-mutant cell lines, including gefitinib-sensitive and -resistant cell lines, and EGFR or ErbB2-overexpressing cell lines.  SKLB1206 also showed a potent antiangiogenesis effect in vitro, in a zebrafish embryonic angiogenesis assay, and in an alginate-encapsulate tumor cell assay.  In vivo, oral administration of SKLB1206 showed complete tumor regression in gefitinib-sensitive HCC827 and PC-9 xenograft models and showed a considerable antitumor effect on the gefitinib-resistant H1975 model as well as other EGFR/ErbB2-overexpressing or -dependent tumor models including A431, LoVo, and N87 established in athymic mice.  SKLB1206 also showed a very good oral bioavailability (50.1%).  Collectively, these preclin. evaluations may support clin. development of SKLB1206 for cancers with EGFR-activating/resistance mutations or EGFR/ErbB2 overexpressed.  Mol Cancer Ther; 11(4); 952-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohH2DvdBSqXrVg90H21EOLACvtfcHk0lj5EEOb7Je9Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2nurw%253D&md5=a920e9291f2fd615abb65de95f9a192a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0679%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DSKLB1206%252C%2520a%2520novel%2520orally%2520available%2520multikinase%2520inhibitor%2520targeting%2520EGFR%2520activating%2520and%2520T790M%2520mutants%252C%2520ErbB2%252C%2520ErbB4%252C%2520and%2520VEGFR2%252C%2520displays%2520potent%2520antitumor%2520activity%2520both%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D952%26epage%3D962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 29 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Takenori Furukawa, Hiroyuki Kimura, Hanae Torimoto, Yusuke Yagi, Hidekazu Kawashima, Kenji Arimitsu, <span class="NLM_string-name hlFld-ContribAuthor">Hiroyuki Yasui</span>. </span><span class="cited-content_cbyCitation_article-title">A Putative Single-Photon Emission CT Imaging Tracer for Erythropoietin-Producing Hepatocellular A2 Receptor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00030%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DA%252BPutative%252BSingle-Photon%252BEmission%252BCT%252BImaging%252BTracer%252Bfor%252BErythropoietin-Producing%252BHepatocellular%252BA2%252BReceptor%26aulast%3DFurukawa%26aufirst%3DTakenori%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D17012021%26date%3D09072021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Minru Liao, Jin Zhang, Guan Wang, Leiming Wang, Jie Liu, Liang Ouyang, <span class="NLM_string-name hlFld-ContribAuthor">Bo Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2382-2418. <a href="https://doi.org/10.1021/acs.jmedchem.0c01180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BDrug%252BDiscovery%252Bin%252BTriple%252BNegative%252BBreast%252BCancer%25253A%252BCurrent%252BSituation%252Band%252BFuture%252BDirections%26aulast%3DLiao%26aufirst%3DMinru%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D07072020%26date%3D02032021%26volume%3D64%26issue%3D5%26spage%3D2382%26epage%3D2418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guangyan Du, Suman Rao, Deepak Gurbani, Nathaniel J. Henning, Jie Jiang, Jianwei Che, Annan Yang, Scott B. Ficarro, Jarrod A. Marto, Andrew J. Aguirre, Peter K. Sorger, Kenneth D. Westover, Tinghu Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Nathanael S. Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (4)
                                     , 1624-1641. <a href="https://doi.org/10.1021/acs.jmedchem.9b01502" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01502%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252Ba%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252Bfor%252BSRC%252BKinase%252BThat%252BTargets%252Ba%252BP-Loop%252BCysteine%26aulast%3DDu%26aufirst%3DGuangyan%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D09092019%26date%3D30012020%26date%3D14012020%26volume%3D63%26issue%3D4%26spage%3D1624%26epage%3D1641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amir Assadieskandar, Caiqun Yu, Pierre Maisonneuve, Igor Kurinov, Frank Sicheri, <span class="NLM_string-name hlFld-ContribAuthor">Chao Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (7)
                                     , 1074-1080. <a href="https://doi.org/10.1021/acsmedchemlett.9b00194" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00194%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRigidification%252BDramatically%252BImproves%252BInhibitor%252BSelectivity%252Bfor%252BRAF%252BKinases%26aulast%3DAssadieskandar%26aufirst%3DAmir%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D29042019%26date%3D04062019%26date%3D07062019%26date%3D04062019%26volume%3D10%26issue%3D7%26spage%3D1074%26epage%3D1080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Jiao</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Ya-Ping  Li</span>, <span class="hlFld-ContribAuthor ">Rong-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming-Wu  Zheng</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Shen-Zhen  Huang</span>, <span class="hlFld-ContribAuthor ">Chun-Li  Song</span>, <span class="hlFld-ContribAuthor ">Wan-Ting  Lin</span>, <span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Bing  Peng</span>, <span class="hlFld-ContribAuthor ">Jun-Hong  Han</span>, <span class="hlFld-ContribAuthor ">Guang-Wen  Lu</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (21)
                                     , 9788-9805. <a href="https://doi.org/10.1021/acs.jmedchem.6b00943" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00943</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00943%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFrom%252BLead%252Bto%252BDrug%252BCandidate%25253A%252BOptimization%252Bof%252B3-%252528Phenylethynyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-amine%252BDerivatives%252Bas%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BTriple%252BNegative%252BBreast%252BCancer%26aulast%3DZhang%26aufirst%3DChun-Hui%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26062016%26date%3D26102016%26date%3D10112016%26date%3D14102016%26volume%3D59%26issue%3D21%26spage%3D9788%26epage%3D9805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Craig  Fraser</span>, <span class="hlFld-ContribAuthor ">John C.  Dawson</span>, <span class="hlFld-ContribAuthor ">Reece  Dowling</span>, <span class="hlFld-ContribAuthor ">Douglas R.  Houston</span>, <span class="hlFld-ContribAuthor ">Jason T.  Weiss</span>, <span class="hlFld-ContribAuthor ">Alison F.  Munro</span>, <span class="hlFld-ContribAuthor ">Morwenna  Muir</span>, <span class="hlFld-ContribAuthor ">Lea  Harrington</span>, <span class="hlFld-ContribAuthor ">Scott P.  Webster</span>, <span class="hlFld-ContribAuthor ">Margaret C.  Frame</span>, <span class="hlFld-ContribAuthor ">Valerie G.  Brunton</span>, <span class="hlFld-ContribAuthor ">E. Elizabeth  Patton</span>, <span class="hlFld-ContribAuthor ">Neil O.  Carragher</span>, and <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>  . </span><span class="cited-content_cbyCitation_article-title">Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (10)
                                     , 4697-4710. <a href="https://doi.org/10.1021/acs.jmedchem.6b00065" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00065%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRapid%252BDiscovery%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BPyrazolopyrimidines%252BThat%252BPotently%252BSuppress%252BBreast%252BCancer%252BCell%252BGrowth%252Bvia%252BSRC%252BKinase%252BInhibition%252Bwith%252BExceptional%252BSelectivity%252Bover%252BABL%252BKinase%26aulast%3DFraser%26aufirst%3DCraig%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D14012016%26date%3D04052016%26date%3D26052016%26date%3D26042016%26volume%3D59%26issue%3D10%26spage%3D4697%26epage%3D4710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Liu</span>, <span class="hlFld-ContribAuthor ">Alvin  Kung</span>, <span class="hlFld-ContribAuthor ">Brock  Malinoski</span>, <span class="hlFld-ContribAuthor ">G. K. Surya  Prakash</span>, and <span class="hlFld-ContribAuthor ">Chao  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (23)
                                     , 9228-9237. <a href="https://doi.org/10.1021/acs.jmedchem.5b01125" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01125%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BAlkyne-Containing%252BPyrazolopyrimidines%252BTo%252BOvercome%252BDrug%252BResistance%252Bof%252BBcr-Abl%252BKinase%26aulast%3DLiu%26aufirst%3DXu%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D17072015%26date%3D20112015%26date%3D10122015%26date%3D12112015%26volume%3D58%26issue%3D23%26spage%3D9228%26epage%3D9237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eddie L  Myers</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5–6 Systems: Other Four Heteroatoms 2:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00056-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00056-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00056-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00056-1%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5%2525E2%252580%2525936%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25253A2%26aulast%3DMyers%26aufirst%3DEddie%2BL%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Lasagna</span>, <span class="hlFld-ContribAuthor ">M.S.  Hielpos</span>, <span class="hlFld-ContribAuthor ">C.  Ventura</span>, <span class="hlFld-ContribAuthor ">M.N.  Mardirosian</span>, <span class="hlFld-ContribAuthor ">G.  Martín</span>, <span class="hlFld-ContribAuthor ">N.  Miret</span>, <span class="hlFld-ContribAuthor ">A.  Randi</span>, <span class="hlFld-ContribAuthor ">M.  Núñez</span>, <span class="hlFld-ContribAuthor ">C.  Cocca</span>. </span><span class="cited-content_cbyCitation_article-title">Chlorpyrifos subthreshold exposure induces epithelial-mesenchymal transition in breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Ecotoxicology and Environmental Safety</span><span> <strong>2020,</strong> <em>205 </em>, 111312. <a href="https://doi.org/10.1016/j.ecoenv.2020.111312" title="DOI URL">https://doi.org/10.1016/j.ecoenv.2020.111312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ecoenv.2020.111312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ecoenv.2020.111312%26sid%3Dliteratum%253Aachs%26jtitle%3DEcotoxicology%2520and%2520Environmental%2520Safety%26atitle%3DChlorpyrifos%252Bsubthreshold%252Bexposure%252Binduces%252Bepithelial-mesenchymal%252Btransition%252Bin%252Bbreast%252Bcancer%252Bcells%26aulast%3DLasagna%26aufirst%3DM.%26date%3D2020%26volume%3D205%26spage%3D111312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeepsinh  Chavda</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112675. <a href="https://doi.org/10.1016/j.ejmech.2020.112675" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112675%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystemic%252Breview%252Bon%252BB-RafV600E%252Bmutation%252Bas%252Bpotential%252Btherapeutic%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChavda%26aufirst%3DJaydeepsinh%26date%3D2020%26volume%3D206%26spage%3D112675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chuan-ce  Sun</span>, <span class="hlFld-ContribAuthor ">Li-chuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Cheng-long  Gao</span>, <span class="hlFld-ContribAuthor ">Hao-ran  Zhang</span>, <span class="hlFld-ContribAuthor ">Ri-lei  Yu</span>, <span class="hlFld-ContribAuthor ">Cong-min  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and screening of SGK1, Src dual inhibitors using pharmacophore models, molecular docking, and molecular dynamics simulation. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (41)
                                     , 17815-17820. <a href="https://doi.org/10.1039/D0NJ02249G" title="DOI URL">https://doi.org/10.1039/D0NJ02249G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ02249G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ02249G%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DDesign%252Band%252Bscreening%252Bof%252BSGK1%25252C%252BSrc%252Bdual%252Binhibitors%252Busing%252Bpharmacophore%252Bmodels%25252C%252Bmolecular%252Bdocking%25252C%252Band%252Bmolecular%252Bdynamics%252Bsimulation%26aulast%3DSun%26aufirst%3DChuan-ce%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D41%26spage%3D17815%26epage%3D17820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Luo</span>, <span class="hlFld-ContribAuthor ">Cherukupalli  Srinivasulu</span>, <span class="hlFld-ContribAuthor ">Xia  Hao</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">The increasing impact of Chinese innovative drug research on the global stage with a focus on drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (10)
                                     , 1115-1120. <a href="https://doi.org/10.1080/17460441.2020.1775577" title="DOI URL">https://doi.org/10.1080/17460441.2020.1775577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1775577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1775577%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DThe%252Bincreasing%252Bimpact%252Bof%252BChinese%252Binnovative%252Bdrug%252Bresearch%252Bon%252Bthe%252Bglobal%252Bstage%252Bwith%252Ba%252Bfocus%252Bon%252Bdrug%252Bdiscovery%26aulast%3DLuo%26aufirst%3DWei%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D10%26spage%3D1115%26epage%3D1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelly  Pathania</span>, <span class="hlFld-ContribAuthor ">Ravindra K  Rawal</span>. </span><span class="cited-content_cbyCitation_article-title">An update on chemical classes targeting ERK1/2 for the management of cancer. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em><a href="https://doi.org/10.4155/fmc-2019-0339" title="DOI URL">https://doi.org/10.4155/fmc-2019-0339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0339%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bon%252Bchemical%252Bclasses%252Btargeting%252BERK1%25252F2%252Bfor%252Bthe%252Bmanagement%252Bof%252Bcancer%26aulast%3DPathania%26aufirst%3DShelly%26date%3D2020%26date%3D2020%26volume%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P.  Muthuraja</span>, <span class="hlFld-ContribAuthor ">V.  Veeramani</span>, <span class="hlFld-ContribAuthor ">S.  Prakash</span>, <span class="hlFld-ContribAuthor ">M.  Himesh</span>, <span class="hlFld-ContribAuthor ">U.  Venkatasubramanian</span>, <span class="hlFld-ContribAuthor ">P.  Manisankar</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>, 493-504. <a href="https://doi.org/10.1016/j.bioorg.2018.12.014" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.12.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.12.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DStructure-activity%252Brelationship%252Bof%252Bpyrazolo%252Bpyrimidine%252Bderivatives%252Bas%252Binhibitors%252Bof%252Bmitotic%252Bkinesin%252BEg5%252Band%252Banticancer%252Bagents%26aulast%3DMuthuraja%26aufirst%3DP.%26date%3D2019%26volume%3D84%26spage%3D493%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ho Jin  Lee</span>, <span class="hlFld-ContribAuthor ">Phuong Chi  Pham</span>, <span class="hlFld-ContribAuthor ">Seung Yeob  Hyun</span>, <span class="hlFld-ContribAuthor ">Byungyeob  Baek</span>, <span class="hlFld-ContribAuthor ">Byungjin  Kim</span>, <span class="hlFld-ContribAuthor ">Yunha  Kim</span>, <span class="hlFld-ContribAuthor ">Hye-Young  Min</span>, <span class="hlFld-ContribAuthor ">Jeeyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Ho-Young  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0802-4" title="DOI URL">https://doi.org/10.1186/s12943-018-0802-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0802-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0802-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DDevelopment%252Bof%252Ba%252B4-aminopyrazolo%25255B3%25252C4-d%25255Dpyrimidine-based%252Bdual%252BIGF1R%25252FSrc%252Binhibitor%252Bas%252Ba%252Bnovel%252Banticancer%252Bagent%252Bwith%252Bminimal%252Btoxicity%26aulast%3DLee%26aufirst%3DHo%2BJin%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Usama M.  Ammar</span>, <span class="hlFld-ContribAuthor ">Mohammed S.  Abdel-Maksoud</span>, <span class="hlFld-ContribAuthor ">Chang-Hyun  Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 144-166. <a href="https://doi.org/10.1016/j.ejmech.2018.09.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bof%252BRAF%252B%252528rapidly%252Baccelerated%252Bfibrosarcoma%252529%252Binhibitors%252Bas%252Banti-cancer%252Bagents%26aulast%3DAmmar%26aufirst%3DUsama%2BM.%26date%3D2018%26volume%3D158%26spage%3D144%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longquan  Lou</span>, <span class="hlFld-ContribAuthor ">Ziyi  Yu</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Shui  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">c‐Src inhibitor selectively inhibits triple‐negative breast cancer overexpressed Vimentin in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2018,</strong> <em>109 </em>
                                    (5)
                                     , 1648-1659. <a href="https://doi.org/10.1111/cas.13572" title="DOI URL">https://doi.org/10.1111/cas.13572</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.13572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.13572%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3Dc%2525E2%252580%252590Src%252Binhibitor%252Bselectively%252Binhibits%252Btriple%2525E2%252580%252590negative%252Bbreast%252Bcancer%252Boverexpressed%252BVimentin%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%26aulast%3DLou%26aufirst%3DLongquan%26date%3D2018%26date%3D2018%26volume%3D109%26issue%3D5%26spage%3D1648%26epage%3D1659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhongzhen  Yang</span>, <span class="hlFld-ContribAuthor ">Yong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Weijian  Li</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Yong  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis and Evaluation of B-Homo Palmatine and Berberine Derivatives as p300 Histone Acetyltransferase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (8)
                                     , 1041-1052. <a href="https://doi.org/10.1002/ejoc.201701693" title="DOI URL">https://doi.org/10.1002/ejoc.201701693</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201701693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201701693%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTotal%252BSynthesis%252Band%252BEvaluation%252Bof%252BB-Homo%252BPalmatine%252Band%252BBerberine%252BDerivatives%252Bas%252Bp300%252BHistone%252BAcetyltransferase%252BInhibitors%26aulast%3DYang%26aufirst%3DZhongzhen%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D8%26spage%3D1041%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Saueressig</span>, <span class="hlFld-ContribAuthor ">Josiane  Tessmann</span>, <span class="hlFld-ContribAuthor ">Rosiane  Mastelari</span>, <span class="hlFld-ContribAuthor ">Liziane Pereira  da Silva</span>, <span class="hlFld-ContribAuthor ">Julieti  Buss</span>, <span class="hlFld-ContribAuthor ">Natalia Vieira  Segatto</span>, <span class="hlFld-ContribAuthor ">Karine Rech  Begnini</span>, <span class="hlFld-ContribAuthor ">Bruna  Pacheco</span>, <span class="hlFld-ContribAuthor ">Cláudio Martin Pereira  de Pereira</span>, <span class="hlFld-ContribAuthor ">Tiago  Collares</span>, <span class="hlFld-ContribAuthor ">Fabiana Kömmling  Seixas</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistic effect of pyrazoles derivatives and doxorubicin in claudin-low breast cancer subtype. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2018,</strong> <em>98 </em>, 390-398. <a href="https://doi.org/10.1016/j.biopha.2017.12.062" title="DOI URL">https://doi.org/10.1016/j.biopha.2017.12.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2017.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2017.12.062%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DSynergistic%252Beffect%252Bof%252Bpyrazoles%252Bderivatives%252Band%252Bdoxorubicin%252Bin%252Bclaudin-low%252Bbreast%252Bcancer%252Bsubtype%26aulast%3DSaueressig%26aufirst%3DSilvia%26date%3D2018%26volume%3D98%26spage%3D390%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amir  Assadieskandar</span>, <span class="hlFld-ContribAuthor ">Caiqun  Yu</span>, <span class="hlFld-ContribAuthor ">Pierre  Maisonneuve</span>, <span class="hlFld-ContribAuthor ">Xu  Liu</span>, <span class="hlFld-ContribAuthor ">Ying-Chu  Chen</span>, <span class="hlFld-ContribAuthor ">G.K. Surya  Prakash</span>, <span class="hlFld-ContribAuthor ">Igor  Kurinov</span>, <span class="hlFld-ContribAuthor ">Frank  Sicheri</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of rigidity on the selectivity of protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>146 </em>, 519-528. <a href="https://doi.org/10.1016/j.ejmech.2018.01.053" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.053%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEffects%252Bof%252Brigidity%252Bon%252Bthe%252Bselectivity%252Bof%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DAssadieskandar%26aufirst%3DAmir%26date%3D2018%26volume%3D146%26spage%3D519%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhaoping  Pan</span>, <span class="hlFld-ContribAuthor ">Yujuan  Chen</span>, <span class="hlFld-ContribAuthor ">Jingyan  Liu</span>, <span class="hlFld-ContribAuthor ">Qinglin  Jiang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Li  Guo</span>, <span class="hlFld-ContribAuthor ">Gu  He</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 517-528. <a href="https://doi.org/10.1016/j.ejmech.2017.12.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bpolo-like%252Bkinase%252B1%25252Feukaryotic%252Belongation%252Bfactor%252B2%252Bkinase%252B%252528PLK1%25252FEEF2K%252529%252Bdual%252Binhibitors%252Bfor%252Bregulating%252Bbreast%252Bcancer%252Bcells%252Bapoptosis%252Band%252Bautophagy%26aulast%3DPan%26aufirst%3DZhaoping%26date%3D2018%26volume%3D144%26spage%3D517%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shu  Zhou</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Luo</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Xiao-Juan  Jiang</span>, <span class="hlFld-ContribAuthor ">Qi  Fu</span>, <span class="hlFld-ContribAuthor ">Xin  Long</span>, <span class="hlFld-ContribAuthor ">Jin-ku  Bao</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (9)
                                     , 1489-1495. <a href="https://doi.org/10.1039/C7OB02344H" title="DOI URL">https://doi.org/10.1039/C7OB02344H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB02344H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB02344H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DStructure-based%252Bdiscovery%252Bof%252Bnew%252Bmaternal%252Bembryonic%252Bleucine%252Bzipper%252Bkinase%252Binhibitors%26aulast%3DZhou%26aufirst%3DShu%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D9%26spage%3D1489%26epage%3D1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Bian  Ming</span>, <span class="hlFld-ContribAuthor ">Guo-Hua  Gong</span>, <span class="hlFld-ContribAuthor ">Di  Wang</span>, <span class="hlFld-ContribAuthor ">Gui-Lan  Bao</span>, <span class="hlFld-ContribAuthor ">Li-Jun  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Current research on anti-breast cancer synthetic compounds. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (8)
                                     , 4386-4416. <a href="https://doi.org/10.1039/C7RA12912B" title="DOI URL">https://doi.org/10.1039/C7RA12912B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA12912B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA12912B%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DCurrent%252Bresearch%252Bon%252Banti-breast%252Bcancer%252Bsynthetic%252Bcompounds%26aulast%3DLiu%26aufirst%3DJia%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D8%26spage%3D4386%26epage%3D4416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhishan  Cui</span>, <span class="hlFld-ContribAuthor ">Shaopeng  Chen</span>, <span class="hlFld-ContribAuthor ">Yanwei  Wang</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Yuzong  Chen</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>136 </em>, 372-381. <a href="https://doi.org/10.1016/j.ejmech.2017.05.006" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.006%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bazaacridine%252Bderivatives%252Bas%252Bdual-target%252BEGFR%252Band%252BSrc%252Bkinase%252Binhibitors%252Bfor%252Bantitumor%252Btreatment%26aulast%3DCui%26aufirst%3DZhishan%26date%3D2017%26volume%3D136%26spage%3D372%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yin  Chen</span>, <span class="hlFld-ContribAuthor ">Yaxin  Zheng</span>, <span class="hlFld-ContribAuthor ">Qinglin  Jiang</span>, <span class="hlFld-ContribAuthor ">Feifei  Qin</span>, <span class="hlFld-ContribAuthor ">Yonghui  Zhang</span>, <span class="hlFld-ContribAuthor ">Leilei  Fu</span>, <span class="hlFld-ContribAuthor ">Gu  He</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>127 </em>, 997-1011. <a href="https://doi.org/10.1016/j.ejmech.2016.11.009" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.11.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.11.009%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIntegrated%252Bbioinformatics%25252C%252Bcomputational%252Band%252Bexperimental%252Bmethods%252Bto%252Bdiscover%252Bnovel%252BRaf%25252Fextracellular-signal%252Bregulated%252Bkinase%252B%252528ERK%252529%252Bdual%252Binhibitors%252Bagainst%252Bbreast%252Bcancer%252Bcells%26aulast%3DChen%26aufirst%3DYin%26date%3D2017%26volume%3D127%26spage%3D997%26epage%3D1011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaocong  Guan</span>, <span class="hlFld-ContribAuthor ">Dong  Lu</span>, <span class="hlFld-ContribAuthor ">Yong  Xi</span>, <span class="hlFld-ContribAuthor ">Shiyu  Jin</span>, <span class="hlFld-ContribAuthor ">Hui  Chen</span>, <span class="hlFld-ContribAuthor ">Limin  Zeng</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Youhong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 122-132. <a href="https://doi.org/10.1016/j.ejmech.2016.10.003" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BPonatinib%252Banalogues%252Bfor%252Breducing%252BKDR%252Bactivity%252Bas%252Bpotent%252BFGFRs%252Binhibitors%26aulast%3DLiu%26aufirst%3DYang%26date%3D2017%26volume%3D126%26spage%3D122%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rabia A.  Gilani</span>, <span class="hlFld-ContribAuthor ">Sameer  Phadke</span>, <span class="hlFld-ContribAuthor ">Li Wei  Bao</span>, <span class="hlFld-ContribAuthor ">Eric J.  Lachacz</span>, <span class="hlFld-ContribAuthor ">Michele L.  Dziubinski</span>, <span class="hlFld-ContribAuthor ">Kristoffer R.  Brandvold</span>, <span class="hlFld-ContribAuthor ">Michael E.  Steffey</span>, <span class="hlFld-ContribAuthor ">Frank E.  Kwarcinski</span>, <span class="hlFld-ContribAuthor ">Carrie R.  Graveel</span>, <span class="hlFld-ContribAuthor ">Kelley M.  Kidwell</span>, <span class="hlFld-ContribAuthor ">Sofia D.  Merajver</span>, <span class="hlFld-ContribAuthor ">Matthew B.  Soellner</span>. </span><span class="cited-content_cbyCitation_article-title">UM-164: A Potent c-Src/p38 Kinase Inhibitor with
              In Vivo
              Activity against Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2016,</strong> <em>22 </em>
                                    (20)
                                     , 5087-5096. <a href="https://doi.org/10.1158/1078-0432.CCR-15-2158" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-15-2158</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-15-2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-15-2158%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DUM-164%25253A%252BA%252BPotent%252Bc-Src%25252Fp38%252BKinase%252BInhibitor%252Bwith%252BIn%252BVivo%252BActivity%252Bagainst%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DGilani%26aufirst%3DRabia%2BA.%26date%3D2016%26date%3D2016%26volume%3D22%26issue%3D20%26spage%3D5087%26epage%3D5096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Wu  Zheng</span>, <span class="hlFld-ContribAuthor ">Chun-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Mei  Huang</span>, <span class="hlFld-ContribAuthor ">Ya-Ping  Li</span>, <span class="hlFld-ContribAuthor ">Wan-Ting  Lin</span>, <span class="hlFld-ContribAuthor ">Rong-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Xin-Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2016,</strong> <em>15 </em>
                                    (3)
                                     , 366-378. <a href="https://doi.org/10.1158/1535-7163.MCT-15-0501" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-15-0501</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-15-0501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-15-0501%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DPreclinical%252BEvaluation%252Bof%252Ba%252BNovel%252BOrally%252BAvailable%252BSRC%25252FRaf%25252FVEGFR2%252BInhibitor%25252C%252BSKLB646%25252C%252Bin%252Bthe%252BTreatment%252Bof%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DZheng%26aufirst%3DMing-Wu%26date%3D2016%26date%3D2015%26volume%3D15%26issue%3D3%26spage%3D366%26epage%3D378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhishan  Cui</span>, <span class="hlFld-ContribAuthor ">Xi  Li</span>, <span class="hlFld-ContribAuthor ">Lulu  Li</span>, <span class="hlFld-ContribAuthor ">Bin  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Yuzong  Chen</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Hongxia  Liu</span>, <span class="hlFld-ContribAuthor ">Weiyi  Xie</span>, <span class="hlFld-ContribAuthor ">Ti  Yang</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (2)
                                     , 261-269. <a href="https://doi.org/10.1016/j.bmc.2015.12.011" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.12.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.12.011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bacridine%252Bderivatives%252Bas%252Bmulti-target%252BSrc%252Band%252BMEK%252Bkinase%252Binhibitors%252Bfor%252Banti-tumor%252Btreatment%26aulast%3DCui%26aufirst%3DZhishan%26date%3D2016%26volume%3D24%26issue%3D2%26spage%3D261%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative Src inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Structures of ponatinib and compound <b>1a</b>. (B) Schematic showing regions that are the focus of structural modifications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes for Compounds <b>1a</b>–<b>h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NIS, DMF, 80 °C, N<sub>2</sub>; (b) R<sub>3</sub>-X(Br, I) or R<sub>3</sub>-OMs, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, N<sub>2</sub>; (c) MeOH, conc H<sub>2</sub>SO<sub>4 cat</sub>, reflux; (d) ethynyltrimethylsilane, CuI, Pd(PPh<sub>3</sub>)<sub>4</sub>, triethylamine, THF, rt, N<sub>2</sub>; (e) (i) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, (ii) NaOH, H<sub>2</sub>O, rt; (f) diisobutylaluminum hydride, anhydrous THF, N<sub>2</sub>, rt; (g) pyridinium <i>p</i>-toluenesulfonate, amine, sodium triacetoxyborohydride, EA, N<sub>2</sub>, 110–50 °C; (h) (i) SOCl<sub>2</sub>, 80 °C, (ii) DIPEA, EA, 0 °C to rt ((iii) this step only for <b>10h</b>, LiOH, THF/H<sub>2</sub>O, rt); (j) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes for Compounds <b>1i</b>–<b>r</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>; (b) TFA, DCM, 0 °C to rt; (c) acrylyl chloride, triethylamine, DCM, −10 °C to rt.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes for Compounds <b>14a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, ethynyltrimethylsilane, triethylamine, DMF, 80 °C, N<sub>2</sub>; (b) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (c) (i) SOCl<sub>2</sub>, 80 °C, (ii) 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (<b>7a</b>), DIPEA, EA, 0 °C to rt; (d) CuI, (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, DIPEA, DMF, 80 °C, N<sub>2</sub>; (e) BBr<sub>3</sub>, DCM, −78 °C to rt; (f) MeOH, conc H<sub>2</sub>SO<sub>4 cat</sub>, reflux; (g) NaIO<sub>4,</sub> I<sub>2</sub>, conc H<sub>2</sub>SO<sub>4</sub>, acetic anhydride, acetic acid, 5–40 °C; (h) EtOH/H<sub>2</sub>O, NaOH, rt.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Preliminary in vivo anti-TNBC assays of compounds <b>1n</b>, <b>1i</b>, and <b>1j</b>. Daily oral administration of compounds <b>1n</b>, <b>1i</b>, and <b>1j</b> at concentrations of 40 mg kg<sup>–1</sup> d<sup>–1</sup>, respectively, was initiated when the MDA-MB-231 tumors reached approximately 200 mm<sup>3</sup> in volume (three mice per group). Points indicate mean tumor volume (mm<sup>3</sup>); bars indicate SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) <b>1j</b> inhibited colony formation of MDA-MB-231 cells. MDA-MB-231 cells were seeded in six-well plates and treated with <b>1j</b> or dasatinib for 12 days. Colonies were stained with crystal violet and pictures taken. (B, C) <b>1j</b> induced apoptosis and G<sub>0</sub>/G<sub>1</sub> cell cycle arrest of MDA-MB-231 cells. MDA-MB-231 cells were harvested after treatment with various concentrations of <b>1j</b> and dasatinib for 24 and 48 h. Cells were stained with an annexin V-FITC apoptosis detection kit or cell cycle and apoptosis analysis kit, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) <b>1j</b> inhibited MDA-MB-231 cell migration in wound healing assay. Cells were wounded by the pipet and then treated with various concentrations of compounds for 20 h. Scale bar, 100 μm. (B) <b>1j</b> inhibited MDA-MB-231 cells invasion in transwell invasion assay. The bottom chambers of the transwells were filled with 600 μL of DMEM with 10% FBS, while the top chambers were seeded with 1 × 10<sup>5</sup> MDA-MB-231 cells in 200 μL of DMEM and treated with different concentrations of compounds for 24 h. Scale bar, 50 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>1j</b> inhibited the phosphorylation of Src and its downstream signaling proteins and the activation of MAPK signaling proteins in cell cultures. MDA-MB-231 cells were treated with <b>1j</b> or dasatinib for 20 h. Cells were lysed, and the proteins were analyzed by Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/medium/jm-2015-00270a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) In vivo antitumor efficacy of <b>1j</b> against MDA-MB-231 tumor xenograft models. Daily oral administration of <b>1j</b> at concentrations of 7.5, 15, 30 mg kg<sup>–1</sup> d<sup>–1</sup> and paclitaxel at a dose of 10 mg kg<sup>–1</sup> week<sup>–1</sup> though tail vein injection were initiated when the MDA-MB-231 tumors reached appoximately 200 mm<sup>3</sup> in volume (6 mice per group). Points indicate mean tumor volume (mm<sup>3</sup>); bars indicate SD; iv, intravenous. (B) Mechanism of action of <b>1j</b> in human tumor xenograft models. Mice bearing MDA-MB-231 tumor xenograft which was treated with <b>1j</b> at 30 mg/kg were humanly euthanized at the end of the experiment, and the tumor tissues were removed for further immunohistochemistry analysis and TUNEL detection. Scale bar, 50 μm. (C) Plasma concentration–time curve of <b>1j</b> in SD rats after a single oral dose of 10 mg/kg. Blood was collected at the indicated times, and the plasma concentrations were determined by LC/MS. Points, mean; bars, SD; <i>n</i> = 5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-9/acs.jmedchem.5b00270/20150508/images/large/jm-2015-00270a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00270&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Foulkes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1948</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&issue=20&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0lhz-0trpzzqUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D20%26spage%3D1938%26epage%3D1948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Carey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer: disease entity or title of convenience?</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">692</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnrclinonc.2010.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=20877296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252Fgt1Kjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=683-692&issue=12&author=L.+Careyauthor=E.+Winerauthor=G.+Vialeauthor=D.+Cameronauthor=L.+Gianni&title=Triple-negative+breast+cancer%3A+disease+entity+or+title+of+convenience%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer: disease entity or title of convenience?</span></div><div class="casAuthors">Carey Lisa; Winer Eric; Viale Giuseppe; Cameron David; Gianni Luca</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">683-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This Review outlines the understanding and management of triple-negative breast cancer (TNBC).  TNBC shares morphological and genetic abnormalities with basal-like breast cancer (BLBC), a subgroup of breast cancer defined by gene-expression profiling.  However, TNBC and BLBC tumors are heterogeneous and overlap is incomplete.  Breast cancers found in BRCA1 mutation carriers are also frequently triple negative and basal like.  TNBC and BLBC occur most frequently in young women, especially African Americans, and tend to exhibit aggressive, metastatic behavior.  These tumors respond to conventional chemotherapy but relapse more frequently than hormone receptor-positive, luminal subtypes and have a worse prognosis.  New systemic therapies are urgently needed as most patients with TNBC and/or BLBC relapse with distant metastases, and hormonal therapies and HER2-targeted agents are ineffective in this group of tumors.  Poly (ADP-ribose) polymerase inhibitors, angiogenesis inhibitors, EGFR-targeted agents, and src kinase and mTOR inhibitors are among the therapeutic agents being actively investigated in clinical trials in patients with TNBC and/or BRCA1-associated tumors.  Increased understanding of the genetic abnormalities involved in the pathogenesis of TNBC, BLBC and BRCA1-associated tumors is opening up new therapeutic possibilities for these hard-to-treat breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlqlWDxtx3xkewzGPswiWOfW6udTcc2eZQBKbcntEv47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252Fgt1Kjsg%253D%253D&md5=8136a61a205486e4613c63fd7ac9a39b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.154%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DL.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520disease%2520entity%2520or%2520title%2520of%2520convenience%253F%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D7%26issue%3D12%26spage%3D683%26epage%3D692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Cleator, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombes, R. C.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer: therapeutic options</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1016%2FS1470-2045%2807%2970074-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=17329194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A280%3ADC%252BD2s7ivFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=235-244&issue=3&author=S.+Cleatorauthor=W.+Hellerauthor=R.+C.+Coombes&title=Triple-negative+breast+cancer%3A+therapeutic+options"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer: therapeutic options</span></div><div class="casAuthors">Cleator Susan; Heller Wolfgang; Coombes R Charles</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-44</span>
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    </div><div class="casAbstract">Triple-negative breast cancers are defined by a lack of expression of oestrogen, progesterone, and ERBB2 receptors.  This subgroup accounts for 15% of all types of breast cancer and for a higher percentage of breast cancer arising in African and African-American women who are premenopausal.  Because of the absence of specific treatment guidelines for this subgroup, triple-negative breast cancers are managed with standard treatment; however, such treatment leaves them associated with a high rate of local and systemic relapse.  Histologically, such cancers are poorly differentiated, and most fall into the basal subgroup of breast cancers, characterised by staining for basal markers (ie, cytokeratin 5/6).  Analyses of microarray gene-expression profiling data show that they form a homogeneous group (or so-called cluster) in transcriptional terms and, increasingly, research studies are identifying basal cancers on the basis of exhibiting this distinctive transcriptional profile.  Histologically and transcriptionally, triple-negative breast cancers have many similarities to BRCA1-associated breast cancers, which suggests that dysfunction in BRCA1 or related pathways occurs in this subset of sporadic cancers.  In this review, we discuss the molecular features of triple-negative breast cancers and consider how the use of existing cytotoxic agents can be optimised for this patient group.  We discuss the implications of a possible underlying BRCA1-pathway dysfunction in this subgroup in terms of treatment and we also investigate the predominant proliferative signals and the on-going research addressing the suitability of these signals as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkJlxHGuTx0Xl8icjszYl0fW6udTcc2eYCrfeRWEAk97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7ivFKjsA%253D%253D&md5=d51518f923eb499081a8aca8f651357e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2807%2970074-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252807%252970074-8%26sid%3Dliteratum%253Aachs%26aulast%3DCleator%26aufirst%3DS.%26aulast%3DHeller%26aufirst%3DW.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520therapeutic%2520options%26jtitle%3DLancet%2520Oncol.%26date%3D2007%26volume%3D8%26issue%3D3%26spage%3D235%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Higgins, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Targeted therapies for breast cancer</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">3797</span><span class="NLM_x">–</span> <span class="NLM_lpage">3803</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=3797-3803&issue=10&author=M.+J.+Higginsauthor=J.+Baselga&title=Targeted+therapies+for+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHiggins%26aufirst%3DM.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DTargeted%2520therapies%2520for%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26issue%3D10%26spage%3D3797%26epage%3D3803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">von Minckwitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span> </span><span class="NLM_article-title">Neoadjuvant treatments for triple-negative breast cancer (TNBC)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">vi35</span><span class="NLM_x">–</span> <span class="NLM_lpage">vi39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1093%2Fannonc%2Fmds193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=23012300" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=vi35-vi39&issue=Suppl.+6&author=G.+von+Minckwitzauthor=M.+Martin&title=Neoadjuvant+treatments+for+triple-negative+breast+cancer+%28TNBC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds193%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DNeoadjuvant%2520treatments%2520for%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26issue%3DSuppl.%25206%26spage%3Dvi35%26epage%3Dvi39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Mayer, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">New strategies for triple-negative breast cancer—deciphering the heterogeneity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">782</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1078-0432.CCR-13-0583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=24536073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=782-790&issue=4&author=I.+A.+Mayerauthor=V.+G.+Abramsonauthor=B.+D.+Lehmannauthor=J.+A.+Pietenpol&title=New+strategies+for+triple-negative+breast+cancer%E2%80%94deciphering+the+heterogeneity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity</span></div><div class="casAuthors">Mayer, Ingrid A.; Abramson, Vandana G.; Lehmann, Brian D.; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">782-790</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biol.  Exploring novel approaches to treatment of these subtypes is crit. because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy.  To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the std. treatment.  We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.  Clin Cancer Res; 20(4); 782-90. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdvsR_JjXMyLVg90H21EOLACvtfcHk0lj8bgrEUh8S9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D&md5=4ce0876cb914096f913a7a637d7b63d5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0583%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DNew%2520strategies%2520for%2520triple-negative%2520breast%2520cancer%25E2%2580%2594deciphering%2520the%2520heterogeneity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D4%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Craig, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shaughnessy, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moses, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christoforides, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aitelli, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izatt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurdoglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacioru, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakarya, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De La Vega, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billings, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salhia, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mousses, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpten, J. D.</span><span> </span><span class="NLM_article-title">Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1535-7163.MCT-12-0781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=23171949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVamug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=104-116&issue=1&author=D.+W.+Craigauthor=J.+A.+O%E2%80%99Shaughnessyauthor=J.+A.+Kieferauthor=J.+Aldrichauthor=S.+Sinariauthor=T.+M.+Mosesauthor=S.+Wongauthor=J.+Dinhauthor=A.+Christoforidesauthor=J.+L.+Blumauthor=C.+L.+Aitelliauthor=C.+R.+Osborneauthor=T.+Izattauthor=A.+Kurdogluauthor=A.+Bakerauthor=J.+Koemanauthor=C.+Barbacioruauthor=O.+Sakaryaauthor=F.+M.+De+La+Vegaauthor=A.+Siddiquiauthor=L.+Hoangauthor=P.+R.+Billingsauthor=B.+Salhiaauthor=A.+W.+Tolcherauthor=J.+M.+Trentauthor=S.+Moussesauthor=D.+Von+Hoffauthor=J.+D.+Carpten&title=Genome+and+transcriptome+sequencing+in+prospective+metastatic+triple-negative+breast+cancer+uncovers+therapeutic+vulnerabilities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities</span></div><div class="casAuthors">Craig, David W.; O'Shaughnessy, Joyce A.; Kiefer, Jeffrey A.; Aldrich, Jessica; Sinari, Shripad; Moses, Tracy M.; Wong, Shukmei; Dinh, Jennifer; Christoforides, Alexis; Blum, Joanne L.; Aitelli, Cristi L.; Osborne, Cynthia R.; Izatt, Tyler; Kurdoglu, Ahmet; Baker, Angela; Koeman, Julie; Barbacioru, Catalin; Sakarya, Onur; De La Vega, Francisco M.; Siddiqui, Asim; Hoang, Linh; Billings, Paul R.; Salhia, Bodour; Tolcher, Anthony W.; Trent, Jeffrey M.; Mousses, Spyro; Von Hoff, Daniel; Carpten, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-116</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2.  Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor prognosis with median survival of one year.  Here, we present initial analyses of whole genome and transcriptome sequencing data from 14 prospective mTNBC.  We have cataloged the collection of somatic genomic alterations in these advanced tumors, particularly those that may inform targeted therapies.  Genes mutated in multiple tumors included TP53, LRP1B, HERC1, CDH5, RB1, and NF1.  Notable genes involved in focal structural events were CTNNA1, PTEN, FBXW7, BRCA2, WT1, FGFR1, KRAS, HRAS, ARAF, BRAF, and PGCP.  Homozygous deletion of CTNNA1 was detected in 2 of 6 African Americans.  RNA sequencing revealed consistent overexpression of the FOXM1 gene when tumor gene expression was compared with nonmalignant breast samples.  Using an outlier anal. of gene expression comparing one cancer with all the others, we detected expression patterns unique to each patient's tumor.  Integrative DNA/RNA anal. provided evidence for deregulation of mutated genes, including the monoallelic expression of TP53 mutations.  Finally, mol. alterations in several cancers supported targeted therapeutic intervention on clin. trials with known inhibitors, particularly for alterations in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways.  In conclusion, whole genome and transcriptome profiling of mTNBC have provided insights into somatic events occurring in this difficult to treat cancer.  These genomic data have guided patients to investigational treatment trials and provide hypotheses for future trials in this irremediable cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-JLQZ9xmALVg90H21EOLACvtfcHk0lj8bgrEUh8S9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVamug%253D%253D&md5=0cc86f6a13750602c4663ad034e9ff71</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0781%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DD.%2BW.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%2BA.%26aulast%3DKiefer%26aufirst%3DJ.%2BA.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DSinari%26aufirst%3DS.%26aulast%3DMoses%26aufirst%3DT.%2BM.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DDinh%26aufirst%3DJ.%26aulast%3DChristoforides%26aufirst%3DA.%26aulast%3DBlum%26aufirst%3DJ.%2BL.%26aulast%3DAitelli%26aufirst%3DC.%2BL.%26aulast%3DOsborne%26aufirst%3DC.%2BR.%26aulast%3DIzatt%26aufirst%3DT.%26aulast%3DKurdoglu%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DA.%26aulast%3DKoeman%26aufirst%3DJ.%26aulast%3DBarbacioru%26aufirst%3DC.%26aulast%3DSakarya%26aufirst%3DO.%26aulast%3DDe%2BLa%2BVega%26aufirst%3DF.%2BM.%26aulast%3DSiddiqui%26aufirst%3DA.%26aulast%3DHoang%26aufirst%3DL.%26aulast%3DBillings%26aufirst%3DP.%2BR.%26aulast%3DSalhia%26aufirst%3DB.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DTrent%26aufirst%3DJ.%2BM.%26aulast%3DMousses%26aufirst%3DS.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26atitle%3DGenome%2520and%2520transcriptome%2520sequencing%2520in%2520prospective%2520metastatic%2520triple-negative%2520breast%2520cancer%2520uncovers%2520therapeutic%2520vulnerabilities%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26issue%3D1%26spage%3D104%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Shah, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oloumi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turashvili, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bashashati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prentice, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khattra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burleigh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shumansky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crisan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliany, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heravi-Moussavi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birol, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varhol, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhalla, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moradian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelmon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueda, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pharoah, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damaraju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harkins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadigotla, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigaroudinia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tlsty, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaves, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserman, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntsman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marra, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparicio, S.</span><span> </span><span class="NLM_article-title">The clonal and mutational evolution spectrum of primary triple-negative breast cancers</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x"> (</span><span class="NLM_issue">7403</span><span class="NLM_x">) </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=395-399&issue=7403&author=S.+P.+Shahauthor=A.+Rothauthor=R.+Goyaauthor=A.+Oloumiauthor=G.+Haauthor=Y.+Zhaoauthor=G.+Turashviliauthor=J.+Dingauthor=K.+Tseauthor=G.+Haffariauthor=A.+Bashashatiauthor=L.+M.+Prenticeauthor=J.+Khattraauthor=A.+Burleighauthor=D.+Yapauthor=V.+Bernardauthor=A.+McPhersonauthor=K.+Shumanskyauthor=A.+Crisanauthor=R.+Giulianyauthor=A.+Heravi-Moussaviauthor=J.+Rosnerauthor=D.+Laiauthor=I.+Birolauthor=R.+Varholauthor=A.+Tamauthor=N.+Dhallaauthor=T.+Zengauthor=K.+Maauthor=S.+K.+Chanauthor=M.+Griffithauthor=A.+Moradianauthor=S.+W.+Chengauthor=G.+B.+Morinauthor=P.+Watsonauthor=K.+Gelmonauthor=S.+Chiaauthor=S.+F.+Chinauthor=C.+Curtisauthor=O.+M.+Ruedaauthor=P.+D.+Pharoahauthor=S.+Damarajuauthor=J.+Mackeyauthor=K.+Hoonauthor=T.+Harkinsauthor=V.+Tadigotlaauthor=M.+Sigaroudiniaauthor=P.+Gascardauthor=T.+Tlstyauthor=J.+F.+Costelloauthor=I.+M.+Meyerauthor=C.+J.+Eavesauthor=W.+W.+Wassermanauthor=S.+Jonesauthor=D.+Huntsmanauthor=M.+Hirstauthor=C.+Caldasauthor=M.+A.+Marraauthor=S.+Aparicio&title=The+clonal+and+mutational+evolution+spectrum+of+primary+triple-negative+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DS.%2BP.%26aulast%3DRoth%26aufirst%3DA.%26aulast%3DGoya%26aufirst%3DR.%26aulast%3DOloumi%26aufirst%3DA.%26aulast%3DHa%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DTurashvili%26aufirst%3DG.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DTse%26aufirst%3DK.%26aulast%3DHaffari%26aufirst%3DG.%26aulast%3DBashashati%26aufirst%3DA.%26aulast%3DPrentice%26aufirst%3DL.%2BM.%26aulast%3DKhattra%26aufirst%3DJ.%26aulast%3DBurleigh%26aufirst%3DA.%26aulast%3DYap%26aufirst%3DD.%26aulast%3DBernard%26aufirst%3DV.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DShumansky%26aufirst%3DK.%26aulast%3DCrisan%26aufirst%3DA.%26aulast%3DGiuliany%26aufirst%3DR.%26aulast%3DHeravi-Moussavi%26aufirst%3DA.%26aulast%3DRosner%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DD.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DVarhol%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DDhalla%26aufirst%3DN.%26aulast%3DZeng%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGriffith%26aufirst%3DM.%26aulast%3DMoradian%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DS.%2BW.%26aulast%3DMorin%26aufirst%3DG.%2BB.%26aulast%3DWatson%26aufirst%3DP.%26aulast%3DGelmon%26aufirst%3DK.%26aulast%3DChia%26aufirst%3DS.%26aulast%3DChin%26aufirst%3DS.%2BF.%26aulast%3DCurtis%26aufirst%3DC.%26aulast%3DRueda%26aufirst%3DO.%2BM.%26aulast%3DPharoah%26aufirst%3DP.%2BD.%26aulast%3DDamaraju%26aufirst%3DS.%26aulast%3DMackey%26aufirst%3DJ.%26aulast%3DHoon%26aufirst%3DK.%26aulast%3DHarkins%26aufirst%3DT.%26aulast%3DTadigotla%26aufirst%3DV.%26aulast%3DSigaroudinia%26aufirst%3DM.%26aulast%3DGascard%26aufirst%3DP.%26aulast%3DTlsty%26aufirst%3DT.%26aulast%3DCostello%26aufirst%3DJ.%2BF.%26aulast%3DMeyer%26aufirst%3DI.%2BM.%26aulast%3DEaves%26aufirst%3DC.%2BJ.%26aulast%3DWasserman%26aufirst%3DW.%2BW.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DHuntsman%26aufirst%3DD.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26aulast%3DAparicio%26aufirst%3DS.%26atitle%3DThe%2520clonal%2520and%2520mutational%2520evolution%2520spectrum%2520of%2520primary%2520triple-negative%2520breast%2520cancers%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7403%26spage%3D395%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span> </span><span class="NLM_article-title">Tackling the diversity of triple-negative breast cancer</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">6380</span><span class="NLM_x">–</span> <span class="NLM_lpage">6388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1078-0432.CCR-13-0915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=24298068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOitb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6380-6388&issue=23&author=N.+C.+Turnerauthor=J.+S.+Reis-Filho&title=Tackling+the+diversity+of+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tackling the Diversity of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Turner, Nicholas C.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6380-6388</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) comprises a highly diverse collection of cancers.  Here, we review this diversity both in terms of gene expression subtypes and the repertoire of genetic events.  Transcriptomic analyses of TNBC have revealed at least six subtypes, with the luminal androgen receptor (luminal AR) or mol. apocrine cancers forming a distinct group within triple-neg. disease.  Distinct from the gene expression subtypes, a diverse set of genetic events have been described in TNBC, with a no. of potentially targetable genetic events found although all at relatively low frequency.  Clin. trials to define the clin. utility of therapies targeting these low-frequency events will require substantial screening efforts to identify sufficient patients.  Set against the diversity of TNBC, clin. studies of patients with triple-neg. disease will need to be either focused on molecularly defined subsets with upfront mol. stratification, or powered for a secondary endpoint anal. of a molecularly defined subset.  Such approaches will be crucial to realize the potential of precision medicine for patients with TNBCs.  Clin Cancer Res; 19(23); 6380-8. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBocxyXfUNR7Vg90H21EOLACvtfcHk0ljRa1YgM_y21A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOitb7K&md5=c04fa1217cdcbef4d75f6ec845cbe401</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0915%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTackling%2520the%2520diversity%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2013%26volume%3D19%26issue%3D23%26spage%3D6380%26epage%3D6388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Tryfonopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corkery, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, M. J.</span><span> </span><span class="NLM_article-title">Src: a potential target for the treatment of triple-negative breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2234</span><span class="NLM_x">–</span> <span class="NLM_lpage">2240</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1093%2Fannonc%2Fmdq757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21357651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A280%3ADC%252BC3MflvFCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2234-2240&issue=10&author=D.+Tryfonopoulosauthor=S.+Walshauthor=D.+M.+Collinsauthor=L.+Flanaganauthor=C.+Quinnauthor=B.+Corkeryauthor=E.+W.+McDermottauthor=D.+Evoyauthor=A.+Pierceauthor=N.+O%E2%80%99Donovanauthor=J.+Crownauthor=M.+J.+Duffy&title=Src%3A+a+potential+target+for+the+treatment+of+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Src: a potential target for the treatment of triple-negative breast cancer</span></div><div class="casAuthors">Tryfonopoulos D; Walsh S; Collins D M; Flanagan L; Quinn C; Corkery B; McDermott E W; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy M J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2234-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancers lack expression of estrogen and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2).  Unlike other subgroups of patients with breast cancer, targeted therapy is currently unavailable for these patients.  The aim of this study was to investigate v-src sarcoma viral oncogene homolog (Src) as a potential target for the treatment of triple-negative breast cancer.  METHODS:  Expression of Src was measured in 87 triple-negative and 93 non-triple-negative breast cancers.  Dasatinib (an inhibitor of Src) was tested in a panel of breast cancer cell lines.  RESULTS:  Cytoplasmic expression of Src was detected in 83 (95%) triple-negative samples versus 78 (84%) non-triple-negative samples (P = 0.012), while membrane Src was detected in 78% triple-negative compared with 38% of non-triple-negative specimens (P < 0.0001).  Dasatinib inhibited growth in three of five triple-negative cell lines (IC(50) < 1 μM).  Dasatinib combined with cisplatin was synergistic in the three dasatinib-sensitive cell lines (combination index < 0.9).  Dasatinib, in combination with 5'-deoxy-5'-fluoruridine, displayed synergy or additivity.  Moderate synergy was observed with docetaxel (Taxotere) in two cell lines but the combination was antagonistic in HCC-1143 cells.  CONCLUSIONS:  We conclude that dasatinib with cisplatin is a rational drug combination for testing in triple-negative breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRLX-5M5TiggxyojvcjibhfW6udTcc2ebEwGs9x_D_Cbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MflvFCqsQ%253D%253D&md5=f91860cdb5da0f86ff6e0ef46eb3ff2f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq757%26sid%3Dliteratum%253Aachs%26aulast%3DTryfonopoulos%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DS.%26aulast%3DCollins%26aufirst%3DD.%2BM.%26aulast%3DFlanagan%26aufirst%3DL.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DCorkery%26aufirst%3DB.%26aulast%3DMcDermott%26aufirst%3DE.%2BW.%26aulast%3DEvoy%26aufirst%3DD.%26aulast%3DPierce%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26atitle%3DSrc%253A%2520a%2520potential%2520target%2520for%2520the%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26issue%3D10%26spage%3D2234%26epage%3D2240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span> </span><span class="NLM_article-title">Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnm.2309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21399647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVGntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=461-469&issue=4&author=S.+Zhangauthor=W.+C.+Huangauthor=P.+Liauthor=H.+Guoauthor=S.+B.+Pohauthor=S.+W.+Bradyauthor=Y.+Xiongauthor=L.+M.+Tsengauthor=S.+H.+Liauthor=Z.+Dingauthor=A.+A.+Sahinauthor=F.+J.+Estevaauthor=G.+N.+Hortobagyiauthor=D.+Yu&title=Combating+trastuzumab+resistance+by+targeting+SRC%2C+a+common+node+downstream+of+multiple+resistance+pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways</span></div><div class="casAuthors">Zhang, Siyuan; Huang, Wen-Chien; Li, Ping; Guo, Hua; Poh, Say-Bee; Brady, Samuel W.; Xiong, Yan; Tseng, Ling-Ming; Li, Shau-Hsuan; Ding, Zhaoxi; Sahin, Aysegul A.; Esteva, Francisco J.; Hortobagyi, Gabriel N.; Yu, Dihua</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">461-469</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Trastuzumab is a successful rationally designed ERBB2-targeted therapy.  However, about half of individuals with ERBB2-overexpressing breast cancer do not respond to trastuzumab-based therapies, owing to various resistance mechanisms.  Clin. applicable regimens for overcoming trastuzumab resistance of different mechanisms are not yet available.  We show that the nonreceptor tyrosine kinase c-SRC (SRC) is a key modulator of trastuzumab response and a common node downstream of multiple trastuzumab resistance pathways.  We find that SRC is activated in both acquired and de novo trastuzumab-resistant cells and uncover a novel mechanism of SRC regulation involving dephosphorylation by PTEN.  Increased SRC activation conferred considerable trastuzumab resistance in breast cancer cells and correlated with trastuzumab resistance in patients.  Targeting SRC in combination with trastuzumab sensitized multiple lines of trastuzumab-resistant cells to trastuzumab and eliminated trastuzumab-resistant tumors in vivo, suggesting the potential clin. application of this strategy to overcome trastuzumab resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAglfHbddvf7Vg90H21EOLACvtfcHk0liME3J9XBd0Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVGntb8%253D&md5=e316dee0106724d2c593358dae9c7801</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnm.2309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2309%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DPoh%26aufirst%3DS.%2BB.%26aulast%3DBrady%26aufirst%3DS.%2BW.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DTseng%26aufirst%3DL.%2BM.%26aulast%3DLi%26aufirst%3DS.%2BH.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DCombating%2520trastuzumab%2520resistance%2520by%2520targeting%2520SRC%252C%2520a%2520common%2520node%2520downstream%2520of%2520multiple%2520resistance%2520pathways%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26issue%3D4%26spage%3D461%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kim, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haura, E. B.</span><span> </span><span class="NLM_article-title">Src kinases as therapeutic targets for cancer</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">595</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnrclinonc.2009.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=19787002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=587-595&issue=10&author=L.+C.+Kimauthor=L.+Songauthor=E.+B.+Haura&title=Src+kinases+as+therapeutic+targets+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Src kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Kim, Lori C.; Song, Lanxi; Haura, Eric B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">587-595</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Src family kinases have been extensively studied and found to be central mediators in multiple signaling pathways that are important in oncogenesis.  Preclin. studies have shown that SFK inhibitors can suppress tumor growth and metastases.  The authors of this Review discuss the potential use of these agents to target cancer in humans.  Src family kinases (SFKs) have a crit. role in cell adhesion, invasion, proliferation, survival, and angiogenesis during tumor development.  SFKs comprise nine family members that share similar structure and function.  Overexpression or high activation of SFKs occurs frequently in tumor tissues and they are central mediators in multiple signaling pathways that are important in oncogenesis.  SFKs can interact with tyrosine kinase receptors, such as EGFR and the VEGF receptor.  SFKs can affect cell proliferation via the Ras/ERK/MAPK pathway and can regulate gene expression via transcription factors such as STAT mols.  SFKs can also affect cell adhesion and migration via interaction with integrins, actins, GTPase-activating proteins, scaffold proteins, such as p130CAS and paxillin, and kinases such as focal adhesion kinases.  Furthermore, SFKs can regulate angiogenesis via gene expression of angiogenic growth factors, such as fibroblast growth factor, VEGF, and interleukin 8.  On the basis of these important findings, small-mol. SFK inhibitors have been developed and are undergoing early phase clin. testing.  In preclin. studies these agents can suppress tumor growth and metastases.  The agents seem to be safe in humans and could add to the therapeutic arsenal against subsets of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mbcbDFh577Vg90H21EOLACvtfcHk0liME3J9XBd0Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbP&md5=5e9e587e835265d1c83857be11411dba</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2009.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2009.129%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DL.%2BC.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26atitle%3DSrc%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D6%26issue%3D10%26spage%3D587%26epage%3D595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Wheeler, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, E. F.</span><span> </span><span class="NLM_article-title">The role of Src in solid tumors</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">678</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=667-678&issue=7&author=D.+L.+Wheelerauthor=M.+Iidaauthor=E.+F.+Dunn&title=The+role+of+Src+in+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DDunn%26aufirst%3DE.%2BF.%26atitle%3DThe%2520role%2520of%2520Src%2520in%2520solid%2520tumors%26jtitle%3DOncologist%26date%3D2009%26volume%3D14%26issue%3D7%26spage%3D667%26epage%3D678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Targeting Src in breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1379</span><span class="NLM_x">–</span> <span class="NLM_lpage">1386</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1093%2Fannonc%2Fmdn291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=18487549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A280%3ADC%252BD1cvotV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1379-1386&issue=8&author=R.+S.+Finn&title=Targeting+Src+in+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src in breast cancer</span></div><div class="casAuthors">Finn R S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1379-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The clinical benefit of blocking oncogenic pathways in breast cancer and other malignancies has validated this approach and ushered in the era of molecularly targeted therapeutics.  Src and its family members make up the largest group of nonreceptor tyrosine kinases.  In laboratory models, these proteins have been shown to play a critical role in cellular growth and proliferation, angiogenesis, and invasion and metastasis.  In addition, Src plays an important role in osteoclast activation and bone resorption, which are often aberrantly activated in the setting of bone metastases.  Given its role in these functions, blocking Src kinase would be predicted to have a broad therapeutic benefit in patients with Src-dependent cancers.  In this review, we highlight the rationale for targeting Src in breast cancer, including laboratory and clinical data implicating it in these signaling pathways, and review small-molecule tyrosine kinase inhibitors currently in clinical development.  Identifying which patients should be selected for Src-directed therapies will be important to the clinical success of these agents.  Importantly, recent preclinical data support a role for this class of inhibitors in basal-type/triple-negative breast cancer, which represents a group of patients with limited effective treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSq3-Zi9cm6LUNHe_gFldTbfW6udTcc2ebbc8XapZv7qrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvotV2rsw%253D%253D&md5=b4f29b2ada4dcb6c89c0301a8440c617</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdn291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdn291%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DTargeting%2520Src%2520in%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2008%26volume%3D19%26issue%3D8%26spage%3D1379%26epage%3D1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Shields, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiede, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurzov, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiganis, T.</span><span> </span><span class="NLM_article-title">TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1128%2FMCB.01016-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=23166300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=557-570&issue=3&author=B.+J.+Shieldsauthor=F.+Wiedeauthor=E.+N.+Gurzovauthor=K.+Weeauthor=C.+Hauserauthor=H.+J.+Zhuauthor=T.+J.+Molloyauthor=S.+A.+O%E2%80%99Tooleauthor=R.+J.+Dalyauthor=R.+L.+Sutherlandauthor=C.+A.+Mitchellauthor=C.+A.+McLeanauthor=T.+Tiganis&title=TCPTP+regulates+SFK+and+STAT3+signaling+and+is+lost+in+triple-negative+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers</span></div><div class="casAuthors">Shields, Benjamin J.; Wiede, Florian; Gurzov, Esteban N.; Wee, Kenneth; Hauser, Christine; Zhu, Hong-Jian; Molloy, Timothy J.; O'Toole, Sandra A.; Daly, Roger J.; Sutherland, Robert L.; Mitchell, Christina A.; McLean, Catriona A.; Tiganis, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">557-570</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tyrosine phosphorylation-dependent signaling, as mediated by members of the epidermal growth factor receptor (EGFR) family (ErbB1 to -4) of protein tyrosine kinases (PTKs), Src family PTKs (SFKs), and cytokines such as interleukin-6 (IL-6) that signal via signal transducer and activator of transcription 3 (STAT3), is crit. to the development and progression of many human breast cancers.  EGFR, SFKs, and STAT3 can serve as substrates for the protein tyrosine phosphatase TCPTP (PTPN2).  Here we report that TCPTP protein levels are decreased in a subset of breast cancer cell lines in vitro and that TCPTP protein is absent in a large proportion of "triple-neg." primary human breast cancers.  Homozygous TCPTP deficiency in murine mammary fat pads in vivo is assocd. with elevated SFK and STAT3 signaling, whereas TCPTP deficiency in human breast cancer cell lines enhances SFK and STAT3 signaling.  On the other hand, TCPTP reconstitution in human breast cancer cell lines severely impaired cell proliferation and suppressed anchorage-independent growth in vitro and xenograft growth in vivo.  These studies establish TCPTP's potential to serve as a tumor suppressor in human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKrzpgI9BYrVg90H21EOLACvtfcHk0lgpAu_5BkPgzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOitL0%253D&md5=82593972a2f8ee8979199c2d10903114</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FMCB.01016-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01016-12%26sid%3Dliteratum%253Aachs%26aulast%3DShields%26aufirst%3DB.%2BJ.%26aulast%3DWiede%26aufirst%3DF.%26aulast%3DGurzov%26aufirst%3DE.%2BN.%26aulast%3DWee%26aufirst%3DK.%26aulast%3DHauser%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DH.%2BJ.%26aulast%3DMolloy%26aufirst%3DT.%2BJ.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DS.%2BA.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DMitchell%26aufirst%3DC.%2BA.%26aulast%3DMcLean%26aufirst%3DC.%2BA.%26aulast%3DTiganis%26aufirst%3DT.%26atitle%3DTCPTP%2520regulates%2520SFK%2520and%2520STAT3%2520signaling%2520and%2520is%2520lost%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2013%26volume%3D33%26issue%3D3%26spage%3D557%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hochgrafe, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browne, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta Cubas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehrbach, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croucher, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickwood, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulghourjian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shearer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swarbrick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faratian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biankin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raftery, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span> </span><span class="NLM_article-title">Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">9391</span><span class="NLM_x">–</span> <span class="NLM_lpage">9401</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=9391-9401&issue=22&author=F.+Hochgrafeauthor=L.+Zhangauthor=S.+A.+O%E2%80%99Tooleauthor=B.+C.+Browneauthor=M.+Pineseauthor=A.+Porta+Cubasauthor=G.+M.+Lehrbachauthor=D.+R.+Croucherauthor=D.+Rickwoodauthor=A.+Boulghourjianauthor=R.+Shearerauthor=R.+Nairauthor=A.+Swarbrickauthor=D.+Faratianauthor=P.+Mullenauthor=D.+J.+Harrisonauthor=A.+V.+Biankinauthor=R.+L.+Sutherlandauthor=M.+J.+Rafteryauthor=R.+J.+Daly&title=Tyrosine+phosphorylation+profiling+reveals+the+signaling+network+characteristics+of+Basal+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHochgrafe%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DS.%2BA.%26aulast%3DBrowne%26aufirst%3DB.%2BC.%26aulast%3DPinese%26aufirst%3DM.%26aulast%3DPorta%2BCubas%26aufirst%3DA.%26aulast%3DLehrbach%26aufirst%3DG.%2BM.%26aulast%3DCroucher%26aufirst%3DD.%2BR.%26aulast%3DRickwood%26aufirst%3DD.%26aulast%3DBoulghourjian%26aufirst%3DA.%26aulast%3DShearer%26aufirst%3DR.%26aulast%3DNair%26aufirst%3DR.%26aulast%3DSwarbrick%26aufirst%3DA.%26aulast%3DFaratian%26aufirst%3DD.%26aulast%3DMullen%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DD.%2BJ.%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DRaftery%26aufirst%3DM.%2BJ.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DTyrosine%2520phosphorylation%2520profiling%2520reveals%2520the%2520signaling%2520network%2520characteristics%2520of%2520Basal%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26issue%3D22%26spage%3D9391%26epage%3D9401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowery, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span> </span><span class="NLM_article-title">SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">5764</span><span class="NLM_x">–</span> <span class="NLM_lpage">5774</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=5764-5774&issue=18&author=S.+Zhangauthor=W.+C.+Huangauthor=L.+Zhangauthor=C.+Zhangauthor=F.+J.+Loweryauthor=Z.+Dingauthor=H.+Guoauthor=H.+Wangauthor=S.+Huangauthor=A.+A.+Sahinauthor=K.+D.+Aldapeauthor=P.+S.+Steegauthor=D.+Yu&title=SRC+family+kinases+as+novel+therapeutic+targets+to+treat+breast+cancer+brain+metastases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLowery%26aufirst%3DF.%2BJ.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DSRC%2520family%2520kinases%2520as%2520novel%2520therapeutic%2520targets%2520to%2520treat%2520breast%2520cancer%2520brain%2520metastases%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D18%26spage%3D5764%26epage%3D5774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Park, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whichard, Z. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, S. J.</span><span> </span><span class="NLM_article-title">Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines—Lessons for design of combination targeted therapy</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1016%2Fj.canlet.2012.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22306341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFKntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2012&pages=104-110&issue=1&author=B.+J.+Parkauthor=Z.+L.+Whichardauthor=S.+J.+Corey&title=Dasatinib+synergizes+with+both+cytotoxic+and+signal+transduction+inhibitors+in+heterogeneous+breast+cancer+cell+lines%E2%80%94Lessons+for+design+of+combination+targeted+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines - Lessons for design of combination targeted therapy</span></div><div class="casAuthors">Park, Brian J.; Whichard, Zakary L.; Corey, Seth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-110</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics.  Multi-cytotoxic drug regimens have been highly successful, yet many studies in targeted therapeutics have centered on a single agent.  We investigated whether the Src/Abl kinase inhibitor dasatinib displays synergy with other agents in molecularly heterogeneous breast cancer cell lines.  MCF-7, SKBR-3, and MDA-MB-231 display different signaling and gene signatures profiles due to expression of the estrogen receptor, ErbB2, or neither.  Cell proliferation was measured following treatment with dasatinib ± cytotoxic (paclitaxel, ixabepilone) or molecularly targeted agents (tamoxifen, rapamycin, sorafenib, pan PI3K inhibitor LY294002, and MEK/ERK inhibitor U0126).  Dose-responses for single or combination drugs were calcd. and analyzed by the Chou-Talalay method.  The drugs with the greatest level of synergy with dasatinib were rapamycin, ixabepilone, and sorafenib, for the MDA-MB-231, MCF-7, and SK-BR-3 cell lines resp.  However, dasatinib synergized with both cytotoxic and molecularly targeted agents in all three molecularly heterogeneous breast cancer cell lines.  These results suggest that effectiveness of rationally designed therapies may not entirely rest on precise identification of gene signatures or mol. profiling.  Since a systems anal. that reveals emergent properties cannot be easily performed for each cancer case, multi-drug regimens in the near future will still involve empirical design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzrsz8f_BOQrVg90H21EOLACvtfcHk0ljxjef0eshx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFKntLw%253D&md5=6c054ce2f8e86d62408010357619be71</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BJ.%26aulast%3DWhichard%26aufirst%3DZ.%2BL.%26aulast%3DCorey%26aufirst%3DS.%2BJ.%26atitle%3DDasatinib%2520synergizes%2520with%2520both%2520cytotoxic%2520and%2520signal%2520transduction%2520inhibitors%2520in%2520heterogeneous%2520breast%2520cancer%2520cell%2520lines%25E2%2580%2594Lessons%2520for%2520design%2520of%2520combination%2520targeted%2520therapy%26jtitle%3DCancer%2520Lett.%26date%3D2012%26volume%3D320%26issue%3D1%26spage%3D104%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Duffy, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span> </span><span class="NLM_article-title">Targeted therapy for triple-negative breast cancer: Where are we?</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2471</span><span class="NLM_x">–</span> <span class="NLM_lpage">2477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1002%2Fijc.27632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22581656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFKmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2012&pages=2471-2477&issue=11&author=M.+J.+Duffyauthor=P.+M.+McGowanauthor=J.+Crown&title=Targeted+therapy+for+triple-negative+breast+cancer%3A+Where+are+we%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for triple-negative breast cancer: Where are we?</span></div><div class="casAuthors">Duffy, Michael J.; McGowan, Patricia M.; Crown, John</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2471-2477</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Breast cancers that are neg. for estrogen receptor (ER), progesterone receptors (PR) and HER2, using std. clin. assays, have been dubbed triple-neg. (TN).  Unlike other mol. subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer.  Preclin. studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2).  Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer.  The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnmJkW7zwQsbVg90H21EOLACvtfcHk0ljxjef0eshx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFKmurg%253D&md5=3e09cb2672f68bc17b80bbc17253f039</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fijc.27632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27632%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DMcGowan%26aufirst%3DP.%2BM.%26aulast%3DCrown%26aufirst%3DJ.%26atitle%3DTargeted%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%253A%2520Where%2520are%2520we%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D131%26issue%3D11%26spage%3D2471%26epage%3D2477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaspy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchekmedyian, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1007%2Fs10549-006-9463-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=17268817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSlsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2007&pages=319-326&issue=3&author=R.+S.+Finnauthor=J.+Deringauthor=C.+Gintherauthor=C.+A.+Wilsonauthor=P.+Glaspyauthor=N.+Tchekmedyianauthor=D.+J.+Slamon&title=Dasatinib%2C+an+orally+active+small+molecule+inhibitor+of+both+the+src+and+abl+kinases%2C+selectively+inhibits+growth+of+basal-type%2F%E2%80%9Ctriple-negative%E2%80%9D+breast+cancer+cell+lines+growing+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro</span></div><div class="casAuthors">Finn, Richard S.; Dering, Judy; Ginther, Charles; Wilson, Cindy A.; Glaspy, Padraic; Tchekmedyian, Nishan; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Dasatinib is an orally active small mol. kinase inhibitor of both the src and abl proteins.  To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer cell lines that have been mol. profiled using Agilent Microarrays.  They represent both luminal and basal breast cancer subtypes based on the relative gene expression of cytokeratin (CK) 8/CK18 and CK5/CK17, resp., and those that have undergone an epithelial-to-mesenchymal transition (post-EMT) based on their expression of vimentin and the loss of CKs.  When treated with 1 μM dasatinib in vitro 8 of them were highly sensitive (>60% growth inhibition), 10 of them were moderately sensitive (40-59% growth inhibition), and 21 were resistant to dasatinib.  A highly significant relationship between breast cancer subtype and sensitivity to dasatinib was obsd. (χ2 = 9.66 and P = 0.008).  Specifically, basal-type and post-EMT breast cancer cell lines were most sensitive to growth inhibition by dasatinib.  In an attempt to identify potential predictive markers of dasatinib response other than breast cancer subtype we analyzed the baseline gene expression profiles for differentially expressed genes.  We identified a set of three biol. relevant genes whose elevated expression is assocd. with dasatinib inhibition including moesin, caveolin-1, and yes-assocd. protein-1 with a sensitivity and specificity of 88 and 86%, resp.  Importantly, these data provide scientific rationale for the clin. development of dasatinib in the treatment of women with "triple-neg." breast cancer, a subtype that is categorized as being aggressive and lacking effective treatments (i.e. hormonal manipulation or trastuzumab).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuiY_J2m5UELVg90H21EOLACvtfcHk0ljxjef0eshx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSlsr3N&md5=82beaf55532a0440f64e215ec57df02e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs10549-006-9463-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-006-9463-x%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DC.%2BA.%26aulast%3DGlaspy%26aufirst%3DP.%26aulast%3DTchekmedyian%26aufirst%3DN.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DDasatinib%252C%2520an%2520orally%2520active%2520small%2520molecule%2520inhibitor%2520of%2520both%2520the%2520src%2520and%2520abl%2520kinases%252C%2520selectively%2520inhibits%2520growth%2520of%2520basal-type%252F%25E2%2580%259Ctriple-negative%25E2%2580%259D%2520breast%2520cancer%2520cell%2520lines%2520growing%2520in%2520vitro%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2007%26volume%3D105%26issue%3D3%26spage%3D319%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">El Touny, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenerhoff, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J. E.</span><span> </span><span class="NLM_article-title">Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=156-168&issue=1&author=L.+H.+El+Tounyauthor=A.+Vieiraauthor=A.+Mendozaauthor=C.+Khannaauthor=M.+J.+Hoenerhoffauthor=J.+E.+Green&title=Combined+SFK%2FMEK+inhibition+prevents+metastatic+outgrowth+of+dormant+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BTouny%26aufirst%3DL.%2BH.%26aulast%3DVieira%26aufirst%3DA.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DKhanna%26aufirst%3DC.%26aulast%3DHoenerhoff%26aufirst%3DM.%2BJ.%26aulast%3DGreen%26aufirst%3DJ.%2BE.%26atitle%3DCombined%2520SFK%252FMEK%2520inhibition%2520prevents%2520metastatic%2520outgrowth%2520of%2520dormant%2520tumor%2520cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26issue%3D1%26spage%3D156%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Bianchi-Smiraglia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paesante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakin, A. V.</span><span> </span><span class="NLM_article-title">Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">25</span><span class="NLM_x">) </span> <span class="NLM_fpage">3049</span><span class="NLM_x">–</span> <span class="NLM_lpage">3058</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=3049-3058&issue=25&author=A.+Bianchi-Smiragliaauthor=S.+Paesanteauthor=A.+V.+Bakin&title=Integrin+beta5+contributes+to+the+tumorigenic+potential+of+breast+cancer+cells+through+the+Src-FAK+and+MEK-ERK+signaling+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi-Smiraglia%26aufirst%3DA.%26aulast%3DPaesante%26aufirst%3DS.%26aulast%3DBakin%26aufirst%3DA.%2BV.%26atitle%3DIntegrin%2520beta5%2520contributes%2520to%2520the%2520tumorigenic%2520potential%2520of%2520breast%2520cancer%2520cells%2520through%2520the%2520Src-FAK%2520and%2520MEK-ERK%2520signaling%2520pathways%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26issue%3D25%26spage%3D3049%26epage%3D3058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&issue=23&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26issue%3D23%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterbein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plé, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, G.</span><span> </span><span class="NLM_article-title"><i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">6465</span><span class="NLM_x">–</span> <span class="NLM_lpage">6488</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060434q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6465-6488&issue=22&author=L.+F.+Hennequinauthor=J.+Allenauthor=J.+Breedauthor=J.+Curwenauthor=M.+Fennellauthor=T.+P.+Greenauthor=C.+Lambert-van+der+Bremptauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Olivierauthor=L.+Otterbeinauthor=P.+A.+Pl%C3%A9author=N.+Warinauthor=G.+Costello&title=N-%285-Chloro-1%2C3-benzodioxol-4-yl%29-7-%5B2-%284-methylpiperazin-1-yl%29ethoxy%5D-5-%28tetrahydro-2H-pyran-4-yloxy%29quinazolin-4-amine%2C+a+novel%2C+highly+selective%2C+orally+available%2C+dual-specific+c-Src%2FAbl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm060434q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060434q%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DOtterbein%26aufirst%3DL.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%2BA.%26aulast%3DWarin%26aufirst%3DN.%26aulast%3DCostello%26aufirst%3DG.%26atitle%3DN-%25285-Chloro-1%252C3-benzodioxol-4-yl%2529-7-%255B2-%25284-methylpiperazin-1-yl%2529ethoxy%255D-5-%2528tetrahydro-2H-pyran-4-yloxy%2529quinazolin-4-amine%252C%2520a%2520novel%252C%2520highly%2520selective%252C%2520orally%2520available%252C%2520dual-specific%2520c-Src%252FAbl%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D22%26spage%3D6465%26epage%3D6488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Ma, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L. H.</span><span> </span><span class="NLM_article-title">PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1007%2Fs10549-010-1302-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21181437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Giu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=85-96&issue=1&author=J.+G.+Maauthor=H.+Huangauthor=S.+M.+Chenauthor=Y.+Chenauthor=X.+L.+Xinauthor=L.+P.+Linauthor=J.+Dingauthor=H.+Liuauthor=L.+H.+Meng&title=PH006%2C+a+novel+and+selective+Src+kinase+inhibitor%2C+suppresses+human+breast+cancer+growth+and+metastasis+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo</span></div><div class="casAuthors">Ma, Jin-gui; Huang, He; Chen, Si-meng; Chen, Yi; Xin, Xian-liang; Lin, Li-ping; Ding, Jian; Liu, Hong; Meng, Ling-hua</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-96</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The central role of Src in tumor progression and metastasis has validated it as an attractive therapeutic target for the treatment of human breast cancer.  The aim of this study was to identify potential Src kinase inhibitor, explore its activity, and mechanism of action in human breast cancer.  A strategy integrating focused combinatorial library design, virtual screening, chem. synthesis, and high-throughput screening was adopted and a novel 6-hydrazinopurine-based inhibitor of c-Src kinase PH006 was obtained.  The kinase enzymic activities were measured by ELISA.  The binding mode between PH006 and Src was profiled by surface plasmon resonance approach and mol. simulation.  The anti-proliferative activity was evaluated by Sulforhodamin B (SRB) and Colony formation.  The anti-invasion and anti-migration activities were assessed by trans-well and wound healing assay.  Results indicated that PH006 was an ATP-competitive Src inhibitor, which selectively inhibited c-Src with an IC50 of 0.38 μM among a panel of 14 diverse tyrosine kinases.  PH006 potently inhibited c-Src phosphorylation and c-Src-dependent signal transduction, resulting in inhibition of cell proliferation, migration, and invasion in human breast cancer MDA-MB-231 cells.  Further study demonstrated that the anti-proliferative activity of PH006 was ascribed to its capability to arrest cells in G1 phase, while its anti-motility activity was related to suppression of MMP2/9 and HGF secretion.  Moreover, PH006 exhibited potent activity against tumor growth as well as metastasis of human breast cancer MDA-MB-435 xenograft beard in nude mice, which was accompanied with reduced Src/FAK signaling in tumor tissue.  Taken together, PH006 is a novel selective inhibitor of c-Src and possesses potent activity against breast cancer growth and metastasis, which could be potentially developed as a lead candidate against breast cancers with elevated Src tyrosine kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM46C77SEoerVg90H21EOLACvtfcHk0li7xY4lD0BXlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Giu7zF&md5=a63e1fa2dea525912df79df32fd93243</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs10549-010-1302-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-010-1302-4%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%2BG.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXin%26aufirst%3DX.%2BL.%26aulast%3DLin%26aufirst%3DL.%2BP.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMeng%26aufirst%3DL.%2BH.%26atitle%3DPH006%252C%2520a%2520novel%2520and%2520selective%2520Src%2520kinase%2520inhibitor%252C%2520suppresses%2520human%2520breast%2520cancer%2520growth%2520and%2520metastasis%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D130%26issue%3D1%26spage%3D85%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kwarcinski, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffey, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soellner, M. B.</span><span> </span><span class="NLM_article-title">Irreversible Inhibitors of c-Src kinase that target a nonconserved cysteine</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1910</span><span class="NLM_x">–</span> <span class="NLM_lpage">1917</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb300337u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1910-1917&issue=11&author=F.+E.+Kwarcinskiauthor=C.+C.+Foxauthor=M.+E.+Steffeyauthor=M.+B.+Soellner&title=Irreversible+Inhibitors+of+c-Src+kinase+that+target+a+nonconserved+cysteine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb300337u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300337u%26sid%3Dliteratum%253Aachs%26aulast%3DKwarcinski%26aufirst%3DF.%2BE.%26aulast%3DFox%26aufirst%3DC.%2BC.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DIrreversible%2520Inhibitors%2520of%2520c-Src%2520kinase%2520that%2520target%2520a%2520nonconserved%2520cysteine%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26issue%3D11%26spage%3D1910%26epage%3D1917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Gushwa, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Selective targeting of distinct active site nucleophiles by irreversible Src-family kinase inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x"> (</span><span class="NLM_issue">50</span><span class="NLM_x">) </span> <span class="NLM_fpage">20214</span><span class="NLM_x">–</span> <span class="NLM_lpage">20217</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja310659j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=20214-20217&issue=50&author=N.+N.+Gushwaauthor=S.+Kangauthor=J.+Chenauthor=J.+Taunton&title=Selective+targeting+of+distinct+active+site+nucleophiles+by+irreversible+Src-family+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja310659j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja310659j%26sid%3Dliteratum%253Aachs%26aulast%3DGushwa%26aufirst%3DN.%2BN.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DSelective%2520targeting%2520of%2520distinct%2520active%2520site%2520nucleophiles%2520by%2520irreversible%2520Src-family%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26issue%3D50%26spage%3D20214%26epage%3D20217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Anbalagan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glodowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hangauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, B.</span><span> </span><span class="NLM_article-title">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1007%2Fs10549-011-1513-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=21509526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=391-409&issue=2&author=M.+Anbalaganauthor=L.+Carrierauthor=S.+Glodowskiauthor=D.+Hangauerauthor=B.+Shanauthor=B.+Rowan&title=KX-01%2C+a+novel+Src+kinase+inhibitor+directed+toward+the+peptide+substrate+site%2C+synergizes+with+tamoxifen+in+estrogen+receptor+%CE%B1+positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span></div><div class="casAuthors">Anbalagan, Muralidharan; Carrier, Latonya; Glodowski, Seth; Hangauer, David; Shan, Bin; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-409</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX-01 is the first clin. Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward Src kinase.  The present study was designed to evaluate the effects of KX-01 as a single agent and in combination with tamoxifen (TAM) on cell growth and apoptosis of ERα pos. breast cancer in vitro and in vivo.  Flow cytometry demonstrated that KX-01 induced cell cycle arrest in G2/M phase.  Immunofluorescent staining for mitotic phase markers and TUNEL staining indicated that cells had arrested in the mitotic phase and mitotic arrested cells were undergoing apoptosis.  KX-01 induced nuclear accumulation of cyclin B1, and activation of CDK1, MPM2, and Cdc25C that is required for progression past the G2/M checkpoint.  Apoptosis resulted from activation of caspases 6, 7, 8, and 9.  Combinational index anal. revealed that combinations of KX-01 with TAM resulted in synergistic growth inhibition of breast cancer cell lines.  KX-01 combined with TAM resulted in decreased ERα phosphorylation at Src-regulated phosphorylation sites serines 118 and 167 that were assocd. with reduced ERα transcriptional activity.  Orally administered KX-01 resulted in a dose dependent growth inhibition of MCF-7 tumor xenografts, and in combination with TAM exhibited synergistic growth inhibition.  Immunohistochem. anal. revealed that combinational treatment reduced angiogenesis, and ERα signaling in tumors compared to either drug alone that may underlie the synergistic tumor growth inhibition.  Combinations of KX-01 with endocrine therapy present a promising new strategy for clin. management of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDjBSgfh5qJbVg90H21EOLACvtfcHk0lgV3KvcBaMbQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D&md5=e55cc94c076cfd5f38a715c4b55b15dd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1513-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1513-3%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DGlodowski%26aufirst%3DS.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DRowan%26aufirst%3DB.%26atitle%3DKX-01%252C%2520a%2520novel%2520Src%2520kinase%2520inhibitor%2520directed%2520toward%2520the%2520peptide%2520substrate%2520site%252C%2520synergizes%2520with%2520tamoxifen%2520in%2520estrogen%2520receptor%2520%25CE%25B1%2520positive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D132%26issue%3D2%26spage%3D391%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fex, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">2-Aminothiazole as a novel kinase inhibitor template. Structure–activity relationship studies toward the discovery of <i>N</i>-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">6819</span><span class="NLM_x">–</span> <span class="NLM_lpage">6832</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&issue=23&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-Aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure%E2%80%93activity+relationship+studies+toward+the+discovery+of+N-%282-chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-Aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure%25E2%2580%2593activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D23%26spage%3D6819%26epage%3D6832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengala, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sy, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, L. J.</span><span> </span><span class="NLM_article-title">Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">6905</span><span class="NLM_x">–</span> <span class="NLM_lpage">6913</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1078-0432.CCR-11-0288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22028489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6905-6913&issue=21&author=R.+S.+Finnauthor=C.+Bengalaauthor=N.+Ibrahimauthor=H.+Rocheauthor=J.+Sparanoauthor=L.+C.+Straussauthor=J.+Fairchildauthor=O.+Syauthor=L.+J.+Goldstein&title=Dasatinib+as+a+single+agent+in+triple-negative+breast+cancer%3A+results+of+an+open-label+phase+2+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study</span></div><div class="casAuthors">Finn, Richard S.; Bengala, Carmelo; Ibrahim, Nuhad; Roche, Henri; Sparano, Joseph; Strauss, Lewis C.; Fairchild, Justin; Sy, Oumar; Goldstein, Lori J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6905-6913</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclin. antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-neg., or basal-like, breast cancer cell lines.  This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-neg. breast cancer (TNBC).  Exptl. Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID.  Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics.  RESULTS: Of the 44 treated patients, 43 were response evaluable.  ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 wk, resp.  Of 11 patients with stable disease, two continued for more than 16 wk, thus protocol-defined DCR was 9.3%.  Median PFS was 8.3 wk (95% CI: 7.3-15.3).  Five patients discontinued before first tumor assessment.  No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5% of patients were fatigue (9.1%), diarrhea, pleural effusion, and dyspnea (all 6.8%).  Lab. abnormalities were uncommon.  Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose redn., and serious AEs were lower with dasatinib 70 mg BID.  CONCLUSIONS: Single-agent dasatinib has limited activity in unselected patients with TNBC.  Dasatinib 70 mg BID was better tolerated than 100 mg BID.  Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.  Clin Cancer Res; 17(21); 6905-13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1kTbssh-wALVg90H21EOLACvtfcHk0lgV3KvcBaMbQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzE&md5=a9133015486c0f5d61a2b6cc33ab7e53</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0288%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DBengala%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DRoche%26aufirst%3DH.%26aulast%3DSparano%26aufirst%3DJ.%26aulast%3DStrauss%26aufirst%3DL.%2BC.%26aulast%3DFairchild%26aufirst%3DJ.%26aulast%3DSy%26aufirst%3DO.%26aulast%3DGoldstein%26aufirst%3DL.%2BJ.%26atitle%3DDasatinib%2520as%2520a%2520single%2520agent%2520in%2520triple-negative%2520breast%2520cancer%253A%2520results%2520of%2520an%2520open-label%2520phase%25202%2520study%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2011%26volume%3D17%26issue%3D21%26spage%3D6905%26epage%3D6913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">4701</span><span class="NLM_x">–</span> <span class="NLM_lpage">4719</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&issue=12&author=W.+S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-yl%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-Abelson+%28BCR-ABL%29+kinase+including+the+T315I+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-Abelson%2520%2528BCR-ABL%2529%2520kinase%2520including%2520the%2520T315I%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D12%26spage%3D4701%26epage%3D4719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&issue=7&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0ljnoJk4vDnaMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D7%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span>GOLD, version <span class="NLM_edition">5.0</span>; <span class="NLM_publisher-name">Cambridge Crystallographic Data Centre</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=GOLD%2C+version+5.0%3B+Cambridge+Crystallographic+Data+Centre%3A+Cambridge%2C+U.K."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGOLD%26pub%3DCambridge%2520Crystallographic%2520Data%2520Centre" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301581y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=879-894&issue=3&author=X.+Renauthor=X.+Panauthor=Z.+Zhangauthor=D.+Wangauthor=X.+Luauthor=Y.+Liauthor=D.+Wenauthor=H.+Longauthor=J.+Luoauthor=Y.+Fengauthor=X.+Zhuangauthor=F.+Zhangauthor=J.+Liuauthor=F.+Lengauthor=X.+Langauthor=Y.+Baiauthor=M.+Sheauthor=Z.+Tuauthor=J.+Panauthor=K.+Ding&title=Identification+of+GZD824+as+an+orally+bioavailable+inhibitor+that+targets+phosphorylated+and+nonphosphorylated+breakpoint+cluster+region-Abelson+%28Bcr-Abl%29+kinase+and+overcomes+clinically+acquired+mutation-induced+resistance+against+imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm301581y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301581y%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLeng%26aufirst%3DF.%26aulast%3DLang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DShe%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520GZD824%2520as%2520an%2520orally%2520bioavailable%2520inhibitor%2520that%2520targets%2520phosphorylated%2520and%2520nonphosphorylated%2520breakpoint%2520cluster%2520region-Abelson%2520%2528Bcr-Abl%2529%2520kinase%2520and%2520overcomes%2520clinically%2520acquired%2520mutation-induced%2520resistance%2520against%2520imatinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D3%26spage%3D879%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Balko, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaught, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuba, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhola, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granja-Ingram, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meszoely, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowsett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemke-Hale, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Angulo, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arteaga, C. L.</span><span> </span><span class="NLM_article-title">Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1052</span><span class="NLM_x">–</span> <span class="NLM_lpage">1059</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1038%2Fnm.2795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22683778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Chu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1052-1059&issue=7&author=J.+M.+Balkoauthor=R.+S.+Cookauthor=D.+B.+Vaughtauthor=M.+G.+Kubaauthor=T.+W.+Millerauthor=N.+E.+Bholaauthor=M.+E.+Sandersauthor=N.+M.+Granja-Ingramauthor=J.+J.+Smithauthor=I.+M.+Meszoelyauthor=J.+Salterauthor=M.+Dowsettauthor=K.+Stemke-Haleauthor=A.+M.+Gonzalez-Anguloauthor=G.+B.+Millsauthor=J.+A.+Pintoauthor=H.+L.+Gomezauthor=C.+L.+Arteaga&title=Profiling+of+residual+breast+cancers+after+neoadjuvant+chemotherapy+identifies+DUSP4+deficiency+as+a+mechanism+of+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance</span></div><div class="casAuthors">Balko, Justin M.; Cook, Rebecca S.; Vaught, David B.; Kuba, Maria G.; Miller, Todd W.; Bhola, Neil E.; Sanders, Melinda E.; Granja-Ingram, Nara M.; Smith, J. Joshua; Meszoely, Ingrid M.; Salter, Janine; Dowsett, Mitch; Stemke-Hale, Katherine; Gonzalez-Angulo, Ana M.; Mills, Gordon B.; Pinto, Joseph A.; Gomez, Henry L.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1052-1059</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neoadjuvant chemotherapy (NAC) induces a pathol. complete response (pCR) in ∼30% of patients with breast cancer.  However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR.  We hypothesized that mol. profiling of tumors after NAC would identify genes assocd. with drug resistance.  Digital transcript counting was used to profile surgically resected breast cancers after NAC.  Low concns. of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status.  BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes.  DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy.  Reduced DUSP4 expression in primary tumors after NAC was assocd. with treatment-refractory high Ki-67 scores and shorter recurrence-free survival.  Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts.  Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6dt_kLh8G67Vg90H21EOLACvtfcHk0lhoZJKG45YwYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Chu70%253D&md5=8e547efaba292ce2cddafd8345038374</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnm.2795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2795%26sid%3Dliteratum%253Aachs%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DCook%26aufirst%3DR.%2BS.%26aulast%3DVaught%26aufirst%3DD.%2BB.%26aulast%3DKuba%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DT.%2BW.%26aulast%3DBhola%26aufirst%3DN.%2BE.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DGranja-Ingram%26aufirst%3DN.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DMeszoely%26aufirst%3DI.%2BM.%26aulast%3DSalter%26aufirst%3DJ.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DStemke-Hale%26aufirst%3DK.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DPinto%26aufirst%3DJ.%2BA.%26aulast%3DGomez%26aufirst%3DH.%2BL.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DProfiling%2520of%2520residual%2520breast%2520cancers%2520after%2520neoadjuvant%2520chemotherapy%2520identifies%2520DUSP4%2520deficiency%2520as%2520a%2520mechanism%2520of%2520drug%2520resistance%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26issue%3D7%26spage%3D1052%26epage%3D1059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Giltnane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balko, J. M.</span><span> </span><span class="NLM_article-title">Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer</span> <span class="citation_source-journal">Discovery Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">95</span><span class="NLM_x">) </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=275-283&issue=95&author=J.+M.+Giltnaneauthor=J.+M.+Balko&title=Rationale+for+targeting+the+Ras%2FMAPK+pathway+in+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26atitle%3DRationale%2520for%2520targeting%2520the%2520Ras%252FMAPK%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DDiscovery%2520Med.%26date%3D2014%26volume%3D17%26issue%3D95%26spage%3D275%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">952</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=10.1158%2F1535-7163.MCT-11-0679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=22319204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=952-962&issue=4&author=Y.+Panauthor=Y.+Xuauthor=S.+Fengauthor=S.+Luoauthor=R.+Zhengauthor=J.+Yangauthor=L.+Wangauthor=L.+Zhongauthor=H.+Y.+Yangauthor=B.+L.+Wangauthor=Y.+Yuauthor=J.+Liuauthor=Z.+Caoauthor=X.+Wangauthor=P.+Jiauthor=Z.+Wangauthor=X.+Chenauthor=S.+Zhangauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=SKLB1206%2C+a+novel+orally+available+multikinase+inhibitor+targeting+EGFR+activating+and+T790M+mutants%2C+ErbB2%2C+ErbB4%2C+and+VEGFR2%2C+displays+potent+antitumor+activity+both+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo</span></div><div class="casAuthors">Pan, Youli; Xu, Yong; Feng, Shan; Luo, Shidong; Zheng, Renlin; Yang, Jiao; Wang, Lijiao; Zhong, Lei; Yang, Han-Yu; Wang, Bing-Lin; Yu, Yang; Liu, Jingjing; Cao, Zhixing; Wang, Xiaoyan; Ji, Pan; Wang, Zerong; Chen, Xin; Zhang, Shuang; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">952-962</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-epidermal growth factor receptor (EGFR) treatment has been successfully applied in clin. cancer therapy.  However, the clin. efficacy of first-generation reversible EGFR inhibitors, such as gefitinib and erlotinib, is limited by the development of drug-resistant mutations, including the gatekeeper T790M mutation and upregulation of alternative signaling pathways.  Second-generation irreversible EGFR inhibitors that were designed to overcome the drug resistance due to the T790M mutation have thus far had limited success.  Here, we report a novel reversible EGFR inhibitor, SKLB1206, which has potent activity against EGFR with gefitinib-sensitive and -resistant (T790M) mutations.  In addn., SKLB1206 has also considerable inhibition potency against some other related oncokinases, including ErbB2, ErbB4, and VEGF receptor 2 (VEGFR2).  SKLB1206 exhibited highly antiproliferative activity against a range of EGFR-mutant cell lines, including gefitinib-sensitive and -resistant cell lines, and EGFR or ErbB2-overexpressing cell lines.  SKLB1206 also showed a potent antiangiogenesis effect in vitro, in a zebrafish embryonic angiogenesis assay, and in an alginate-encapsulate tumor cell assay.  In vivo, oral administration of SKLB1206 showed complete tumor regression in gefitinib-sensitive HCC827 and PC-9 xenograft models and showed a considerable antitumor effect on the gefitinib-resistant H1975 model as well as other EGFR/ErbB2-overexpressing or -dependent tumor models including A431, LoVo, and N87 established in athymic mice.  SKLB1206 also showed a very good oral bioavailability (50.1%).  Collectively, these preclin. evaluations may support clin. development of SKLB1206 for cancers with EGFR-activating/resistance mutations or EGFR/ErbB2 overexpressed.  Mol Cancer Ther; 11(4); 952-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohH2DvdBSqXrVg90H21EOLACvtfcHk0lhoZJKG45YwYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2nurw%253D&md5=a920e9291f2fd615abb65de95f9a192a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0679%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DSKLB1206%252C%2520a%2520novel%2520orally%2520available%2520multikinase%2520inhibitor%2520targeting%2520EGFR%2520activating%2520and%2520T790M%2520mutants%252C%2520ErbB2%252C%2520ErbB4%252C%2520and%2520VEGFR2%252C%2520displays%2520potent%2520antitumor%2520activity%2520both%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D4%26spage%3D952%26epage%3D962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00270">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_54822"></div></div></div></div></div><hr /></hr><p class="last">Chemical structures of top 100 compounds, a full description of the scaffold hopping and molecular docking, and a csv file of molecular formula strings. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00270/suppl_file/jm5b00270_si_001.pdf">jm5b00270_si_001.pdf (591.4 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00270/suppl_file/jm5b00270_si_002.csv">jm5b00270_si_002.csv (3.13 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-9%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00270%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00270" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994c75df2ed1a3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
